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Abstract 
The European Union (EU) Cosmetics Regulation established the ban on animal testing for 
cosmetics ingredients. This ban does not assume that all cosmetics ingredients are safe, but that the 
non-testing procedures (in vitro and in silico) have to be applied for their safety assessment. To this 
end, the SEURAT-1 cluster was funded by EU 7th Framework Programme and Cosmetics Europe. The 
COSMOS (Integrated In Silico Models for the Prediction of Human Repeated Dose Toxicity of 
COSMetics to Optimise Safety) project was initiated as one of the seven consortia of the cluster, with 
the purpose of facilitating the prediction of human repeated dose toxicity associated with exposure 
to cosmetics-related compounds through in silico approaches.  
A critical objective of COSMOS was to address the paucity of publicly available data for 
cosmetics ingredients and related chemicals. Therefore a database was established containing (i) an 
inventory of cosmetics ingredients and related structures; (ii) skin permeability/absorption data 
(route of exposure relevant to cosmetics); and (iii) repeated dose toxicity data. This thesis describes 
the process of “knowledge discovery from the data”, including collation of the content of the 
COSMOS database and its subsequent application for developing tools to support the prediction of 
repeated dose toxicity of cosmetics and related compounds. 
A rigorous strategy of curation and quality control of chemical records was applied in 
developing the database (as documented in the Standard Operating Procedure, chapter 2). The 
chemical space of the cosmetics-related compounds was compared to food-related compounds from 
the U.S. FDA CFSAN PAFA database using the novel approach combining the analysis of structural 
features (ToxPrint chemotypes) and physicochemical properties. The cosmetics- and food- specific 
structural classes related to particular use functions and manifested by distinct physicochemical 
properties were identified (chapter 3). 
The novel COSMOS Skin Permeability Database containing in vivo and in vitro skin 
permeability/absorption data was developed by integrating existing databases and enriching them 
with new data for cosmetics harvested from regulatory documents and scientific literature (chapter 
4). Compounds with available data on human in vitro maximal flux (JMAX) were subsequently 
extracted from the developed database and analysed in terms of their structural features (ToxPrint 
chemotypes) and physicochemical properties. The profile of compounds exhibiting low or high skin 
permeability potential was determined. The results of this analysis can support rapid screening and 
classification of the compounds without experimental data (chapter 5). 
The new COSMOS oral repeated dose toxicity database was established through 
consolidation of existing data sources and harvesting new regulatory documents and scientific 
literature. The unique data structure of the COSMOS oRepeatToxDB allows capturing all toxicological 
effects observed at particular dose levels and sites, which are hierarchically differentiated as organs, 
tissues, and cells (chapter 6). Such design of this database enabled the development of liver toxicity 
ontology, followed by mechanistic mining of in vivo data (chapter 7). As a result, compounds 
associated with liver steatosis, steatohepatitis and fibrosis phenotypic effects were identified and 
further analysed. The probable mechanistic reasoning for toxicity (Peroxisome Proliferator-Activated 
Receptor gamma (PPAR𝛾) activation) was formulated for two hepatotoxicants, namely 1,3-bis-(2,4-
diaminophenoxy)-propane and piperonyl butoxide. 
Key outcomes of this thesis include an extensive curated database, Standard Operating 
Procedures, skin permeability potential classification rules, and the set of structural features 
associated with liver steatosis. Such knowledge is particularly important in the light of the 21st 
Century Toxicology (NRC, 2007) and the ongoing need to move away from animal toxicity testing to 
non-testing alternatives.  
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Chapter 1 
Introduction 
1.1. The EU COSMOS project as a response to the current European Cosmetics Regulation 
Since the beginning of time, humans have applied various substances to the skin for 
multiple reasons: medicinal, religious, and to enhance beauty. Nowadays, the term 
“cosmetics” refers to a range of everyday hygiene and luxury products. According to the 
official definition of the European Union (EU), a cosmetic is “any substance or preparation 
intended to be placed in contact with the various external parts of the human body (…) or 
with the teeth and the mucous membranes of the oral cavity with a view exclusively or 
mainly to cleaning them, perfuming them, changing their appearance and/or correcting 
body odours and/or protecting them or keeping them in good condition”. The term 
“cosmetic product” refers to any cosmetic or mixture of cosmetics, as defined above. The 
final formulation of the cosmetic product, which is placed on the market and made available 
to the consumer, is named the “finished cosmetic product” (EC, 2003).  
Cosmetics and cosmetic products are regulated at the EU level. The Cosmetics 
Regulation (which replaced the Cosmetics Directive as of 11 July 2013) established two bans 
on animal testing for cosmetics purposes, namely: the testing ban (referring to the testing of 
the finished cosmetic products and cosmetic ingredients on animals, completed as of 11 
March 2009), and the marketing ban (related to the marketing in the EU of the finished 
cosmetic products and ingredients which have been tested on animals, completed as of 11 
March 2013) (EC, 2003; EC, 2009). The ban on testing does not assume that all cosmetics 
ingredients are safe, but that non-testing procedures (in vitro and in silico) may have to be 
applied to assess their safety.  
An EU cluster of seven projects, brought together under a Research Cluster entitled 
“Safety Evaluation Ultimately Replacing Animal Testing” (SEURAT-1), was formed as a direct 
response to this legislation, with the vision of the replacement of traditional animal-based 
experiments with predictive toxicology tools. Starting in January 2011, the five-year project 
“Integrated In Silico Models for the Prediction of Human Repeated Dose Toxicity of 
Cosmetics to Optimise Safety” (COSMOS) was launched within the framework of SEURAT-1, 
as a collaboration between major international agencies (the European Commission (EC) 
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Joint Research Centre (JRC) and the U.S. Food and Drug Administration (FDA)), and a range 
of partners from industry and academia (including Altamira LLC, Columbus, OH, USA; 
Bulgarian Academy of Science (BAS), Sofia, Bulgaria; Molecular Networks GmbH, 
Nüremberg, Germany; Soluzioni Informatiche (S-IN), Vicenza, Italy), and was coordinated by 
Prof. M. Cronin from Liverpool John Moores University (LJMU, Liverpool, UK). The COSMOS 
project was funded jointly by the EC 7th Framework Programme and Cosmetics Europe (the 
industry’s trade association for cosmetics, toiletries and perfumes, formerly Colipa), and 
was completed as of December 2015. 
The main focus of the COSMOS project was the development of innovative non-
testing (computational) tools and their subsequent integration into publicly available, 
transparent workflows to facilitate the complex process of predicting human repeated dose 
toxicity associated with exposure to cosmetics and related compounds. At that time, and 
still today, the SEURAT-1 cluster was the largest EU initiative undertaken to develop 
alternatives to animal-based toxicity testing for the safety assessment of chemicals. The 
current PhD program, conducted within the frame of the COSMOS project, supported these 
general efforts. 
1.2. Computational alternatives to animal-based toxicity testing 
In the field of predictive toxicology a range of diverse computational methods is 
applied in order to identify, characterise, and evaluate the hazards and risks posed by 
chemicals to human health and the environment (Yang et al., 2008; Yang et al., 2009; Hardy 
et al., 2012). These methods can be divided into two general categories, namely: prediction 
systems (statistical or knowledgebase expert ones) and data mining (Matthews & Contrera, 
1998; Johnson et al., 2001; Greene, 2002; Benigni & Zito, 2004; Helma et al., 2004; Yang et 
al., 2006). The general principles of the methods relevant to the current thesis are 
introduced in the present section1. 
Generally, prediction systems are based on the premise that the physicochemical 
properties and biological activities of a chemical depend on its intrinsic nature and can be 
                                                      
1 The provided description of the computational methods has been limited to those related to the research 
conducted within the current PhD program and does not cover all approaches utilised in the COSMOS project 
(e.g. Threshold of Toxicological Concerns, Physiologically Based Pharmacokinetic Modelling, etc.)  
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predicted directly from molecular structure or inferred from similar compounds whose 
properties and activities are known (Mostrag-Szlichtyng et al., 2010; Worth & Mostrag-
Szlichtyng, 2010). These methods include a range of approaches, such as Structure-Activity 
Relationships (SARs), Quantitative Structure-Activity Relationships (QSARs), or chemical 
grouping and read-across. 
The SAR-based approaches refer to the qualitative identification of the relationship 
between molecular structure (or a fragment thereof, i.e. an atom, or group of adjacently 
connected atoms in a molecule) and the presence of a particular biological activity, which 
may subsequently lead to the determination of structural alerts. SAR can also refer to the 
determination of the combination of steric and electronic features of the chemical 
compound considered necessary to ensure its intermolecular interaction with a specific 
biological target molecule, which results in the manifestation of a particular biological 
effect. In this case, SAR may be referred to as a “3-dimensional (3D) SAR” or 
“pharmacophore” (Worth & Mostrag-Szlichtyng, 2010). 
QSAR-based methods express the relationship quantitatively (frequently in a form of 
a regression model) between a biological activity (which may be categorical or continuous) 
and one or more molecular descriptor(s), which describe chemical structure in numerical 
terms and serve as biological endpoint predictors (Worth & Mostrag-Szlichtyng, 2010; 
Todeschini & Consonni, 2009). The principles of the validation of QSAR models were 
published by the Organisation for Economic Co-operation and Development (OECD) (OECD, 
2005). Guidance on the regulatory application of QSARs were published by the OECD and 
European Chemicals Agency (ECHA) providing a framework for using the data derived from 
the models as opposed to those derived experimentally (OECD, 2007a; ECHA, 2008).  
It has to be highlighted that, traditionally, a range of statistically-based QSAR models 
were developed to describe the chemical information for the compounds investigated by 
employing a range of molecular descriptors representing relevant structural features. 
However, QSAR methods limit the information relating to the associated complex biology by 
collapsing it into a single value representing the predicted endpoint which, very often, 
imprecisely defines, or covers several different, mechanisms of action. As a consequence, 
the association between chemistry and biology, being the basis of the predictive toxicology, 
remains unclear and makes the resulting predictions difficult to interpret. 
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In order to overcome the limitations of traditional, chemistry-oriented QSAR 
modelling, identification of groups of chemicals with similar or related biological modes of 
action (MoA) can be performed, e.g. through chemical grouping/read-across, or systematic 
data-mining of the available biological data (both approaches have been discussed below). 
QSAR modelling within MoA-based categories of compounds (MoA QSAR) allows the linkage 
of the biological attributes underlying toxicity pathways with chemical structure 
frameworks, and addresses, in part at least, the limitations of statistical models. 
 In order to support the results of QSAR analysis, or to generate estimated data in 
the absence of suitable models, the chemical grouping and read-across approaches can be 
used. Guidance documents on the application of this method have been published by the 
OECD (OECD, 2007b) and ECHA (ECHA, 2008; ECHA, 2010). The term “read-across” refers to 
the use of endpoint information for (“source”) chemical(s) to make a prediction of the same 
endpoint for another (“target”) chemical, for which no, or inadequate, data may exist. With 
respect to the essential concept underlying predictive toxicology, i.e. that similar 
compounds (analogues) are expected to yield similar biological activity (Johnson & 
Maggiora, 1990), the source and target chemicals have to be considered similar according to 
(a set of) relevant characteristic(s) (e.g. structural, mechanistic, metabolic). Depending on 
the general data availability for a given endpoint, it may be possible that only a few suitable 
analogues can be identified, or, conversely, that a larger group of compounds can be found 
and used for a “chemical category” formation. The physicochemical properties and 
biological activities of the chemical category constituents are likely to be similar or follow a 
regular pattern as a result of relevant similarity characteristics and a common underlying 
mechanism or mode-of-action. In general, the application of read-across between analogues 
in a mechanistically supported, MoA-based chemical category is considered to be more 
reliable than the application of read-across in a smaller group of structural analogues based 
on a homologous series (Worth & Mostrag-Szlichtyng, 2010).  
MoA-based predictive toxicology supports, and is supported by, the general Adverse 
Outcome Pathway (AOP) framework (OECD, 2013). AOPs are a predictive paradigm based on 
the upstream sequence of biological events that are determinants of the apical adverse 
outcome. An AOP typically starts from the Molecular Initiating Event (MIE), which triggers 
the progression of the pathway towards the higher level responses (Key Events, KEs), and 
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leads to the perturbations observed at the whole organism level. The MoA/AOP approach is 
increasingly applied to understand adverse health effects caused by repeated exposure to 
chemicals. The MIE delivers mechanistic information on chemical-biological interactions at 
the molecular level that can be further associated with structural and physicochemical 
characteristics of the chemical compound (Ankley et al., 2010). 
The successful application of meaningful MoA-based tools, including chemical 
grouping, read-across, and QSAR models, is related to (and heavily relies on) systematic 
data-mining of the available biological data. Data mining (also termed “data/pattern 
analysis”, “data archaeology” or “data dredging”) can be regarded as a process of 
discovering patterns and retrieving knowledge from massive amounts of raw data, or 
“knowledge discovery from data” (KDD). This interdisciplinary process is situated at the 
crossroads of database technology, statistics, and artificial intelligence and is an iterative 
sequence of the following steps (Bramer, 2007; Han et al., 2012): 
 Data preprocessing – preparation of the raw data for the actual data mining, 
involving: 
o Data cleaning – identification and removal of inconsistent data, 
o Data integration – merging multiple data sources, 
o Data selection – retrieval of the data relevant to the scientific question in hand, 
o Data transformation – data aggregation and summarisation; 
 Data patterns discovery – actual data mining involving application of artificial 
intelligence techniques to uncover and extract hidden patterns in the data; 
 Data patterns evaluation – identification of the patterns truly relevant to the 
investigated issue; 
 Presentation of the knowledge developed by utilising visualisation and knowledge 
representation techniques. 
Data mining allows for the identification of the concealed relationships and patterns 
in the data. Thus, it can be utilised as a predictive technique facilitating the objectives of 
computational toxicology (Yang et al., 2006).  
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The usefulness of QSAR- and predictive data mining- based tools to support 
regulatory safety assessments has been evaluated and demonstrated over the past decade 
(Yang et al., 2006; Yang et al., 2008; Benz, 2007; Mayer et al., 2008). Regardless of the 
method applied (i.e. predictive system or data mining), any computational technique relies 
to a great extent on the size, quality and availability of the biological data (Yang et al., 2006; 
Yang et al., 2009). 
1.3. The role of a database in reaching the goals of predictive toxicology 
In general, the term “database” refers to the collection of interrelated data. 
Together with a set of software programs for data access, management, organisation 
(defining the logical structure of the data, i.e. the data model), and update, it forms a 
database management system (DBMS) (Han et al., 2012). With respect to the database 
design, the commonly used data model is a relational model invented by Edgar F. Codd 
(Codd, 1970). The relational database can be defined as a collection of uniquely named, 
interrelated tables (relations), consisting of a set of attributes (columns, fields) and storing a 
set of tuples (rows, records). Each record (described by a set of field values) represents a 
database object identified by a unique key. Frequently, for relational databases semantic 
data models are also developed, e.g. the entity-relationship (ER) data model representing 
the database as a set of entities and their relationships (Chen, 2002; Han et al., 2012). The 
data in the relational database can be accessed via the database queries. 
From a predictive toxicology standpoint, a database with a relational structure, 
capable of storing chemical structures and toxicity information which can be searched and 
retrieved, is a fundamental form of data for mining applications, computational model 
development, and read-across of diverse sources and endpoints. Connecting biological 
effects and chemicals involved in toxicity pathways can be performed exclusively after 
systematic data mining. This requires a database to be equipped with specifically designed 
ontologies and controlled vocabularies. 
The term ontology refers to the explicit formal representation of a set of concepts 
and their relationships within particular domain, linking facts to the related terms in a causal 
order (Sowa, 1999; Noy & McGuiness, 2001). The iterative process of ontology development 
involves (and leads to) formulating and extending the domain knowledge by interactive 
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integration of knowledge from diverse domains. It requires (and allows for) abstracting and 
generalising information, extracting and formulating rules, and identifying associations with 
fundamental principles. An example of a successful mature ontology covering the cell 
biology area is the Gene Ontology (GO), widely used in biological databases, annotation 
projects, computational analyses for annotating newly sequenced genomes, text mining and 
modelling (Hardy et al., 2012).  
A mature chemical-toxicological ontology is necessary for the KDD process in 
predictive toxicology. The toxic effects and underlying mechanisms can be identified 
through precisely categorised terms, which provide the rationale and the basis for further 
toxicity prediction (by chemical grouping and MoA QSAR modelling, for instance). Chemical-
toxicological ontology supports existing knowledge applications (by sharing the common 
understanding of the information in the scientific community) and extensions (by providing 
a well-structured framework).  
A chemical-toxicological database meeting the outlined requirements is a pre-
requisite to achieve any of the objectives of predictive toxicology in terms of modelling, 
knowledge creation and data management (Yang et al., 2006; Yang et al., 2008; Yang et al., 
2009; Han et al., 2012; Hardy et al., 2012).  
1.4. COSMOS database 
One of the most critical considerations in reaching the objectives of the COSMOS 
project was the paucity of publicly available data for cosmetics and related chemicals. As 
such, the construction of a new, high quality chemical-toxicological database with a 
cosmetics-oriented domain was crucial.  
The majority of publicly available repeated-dose toxicity data refer to the oral route 
of exposure and thus do not include cosmetics (and rarely cover cosmetics-related 
compounds), which are usually applied topically. However, since the scientific community 
has sufficient understanding of oral absorption and skin permeability processes, an 
approach using extrapolation (referred to as “oral-to-dermal extrapolation”) utilising this 
knowledge and oral repeated-dose toxicity data has been applied to realise the goals of the 
COSMOS project. There is an identifiable need to expand knowledge to cosmetics 
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ingredients and related substances. The content requirements for constructing the COSMOS 
database can therefore be summarised as follows2:  
 An inventory of cosmetics and cosmetics-related compounds populated with high 
quality chemical structures and available regulatory information, such as daily intake 
estimates or regulation history; 
 Skin permeability/absorption data for cosmetics and related compounds; 
 Oral repeated dose toxicity data for cosmetics and related compounds. 
The process of collating the required COSMOS database content, as well as the 
strategy of dealing with the difficulties and challenges associated with particular information 
types, are presented in the current thesis. 
In order to serve as a foundation to develop computational tools to predict the 
repeated dose toxicity of cosmetics and related chemicals, the COSMOS database had to 
accommodate various types of biological data. The data model, capable of handling such a 
diverse information types, has been inherited from the risk assessment database of the 
Chemical Evaluation and Risk Estimation (CERES) project at the United States Food and Drug 
Administration (U.S. FDA) Center for Food Safety and Applied Nutrition (CFSAN). The CERES 
database houses the internal regulatory information of the CFSAN, as well as other toxicity 
databases, including the chemical records and toxicity data from the legacy U.S. FDA 
Priority-based Assessment of Food Additives (PAFA) database (Benz & Irausquin, 1991). The 
COSMOS and CERES databases share the same data model, technology, software programs, 
and a very similar user interface.  
The COSMOS database data model consists of two interconnected data domains 
(Figure 1.1): a chemical domain and a biological domain. A very high-level overview of the 
main entities is provided in this section.  
The central entity of the COSMOS database chemical domain is “Compound”, 
meaning that all other entities stored in this part of the database are Compound-related. An 
entity “Compound” (a chemical compound or substance) is identified by a unique system 
identifier, CMS ID, and represents a chemical composition which may consist of one or more 
                                                      
2 The outlined data needs are limited to the data relevant for the presented PhD program, and do not 
exhaustively coverthe requirements of the entire COSMOS project 
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molecules, i.e. “Structure” entities, referring to the molecular structures. Compound may 
thus be formed of multiple Structure entities, and, at the same time, a single Structure may 
appear in multiple Compounds (many-to-many relationship). Depending on its chemical 
composition, Compound may not be related to any Structure (this is discussed more in-
depth in chapter 2). Regardless of the association of the Compound with Structure entities, 
multiple Compound-related information items can be stored in the COSMOS database, 
including Names, Identifiers, Use Functions, along with attributes further defining their 
source, type, etc. 
The toxicological part of the data model reflects the diverse and heterogeneous 
layout of the COSMOS database content. At the very high level it defines the entity “Study”, 
corresponding to a toxicological study, which may consist of a various number of “Test” 
instances, representing a series of experiments applied to a “Test System” (which might be a 
series of animals, tissues, etc.). The Test System instances reflect all the peculiarities of the 
recorded Tests. Each Test entity references a Test Result, reporting the outcomes of the 
relevant toxicity experimental series. Finally, a Study references its own Study Result, 
aggregating the Test Results. The Study Result is a final outcome of the toxicity endpoint, 
which is based on all Test outcomes within a study. Such fine data granularity allows for the 
storage of the information regarding each single experimental series and observed 
toxicological effects on the one hand, and the summarised, higher-level information (final 
Study conclusion, e.g. compiled by the human expert) on the other. It also supports the 
development of the ontology sets facilitating the mechanistic data mining of the COSMOS 
database (which is discussed more in-depth in chapters 6 and 7). 
 
Figure 1 .1 
Simplified schematic diagram of the COSMOS database data model 
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The first version of the COSMOS database (COSMOS DB v1.0) was made publicly 
available in December 2013 and its dump is currently downloadable from 
http://cosmosspace.cosmostox.eu. The final version of the COSMOS database (COSMOS DB 
v2.0) was released in April 2016 and can be accessed at: 
https://cosmosdb.eu/cosmosdb.v2/.  
1.5. The present PhD program and its association with the COSMOS project 
The main aim of the present PhD program, conducted in conjunction with the 
COSMOS project, was the collation of the content, in terms of chemical structures, skin 
permeability and toxicological data, within a relational chemical-toxicological database, 
and its subsequent application for the development of knowledge to support the 
prediction of repeated dose toxicity of cosmetics and related compounds.  
This multi-faceted goal has been broken down into the following objectives, realised 
in collaboration with other COSMOS partners (please refer to Annex 1 for the detailed 
contribution of the author of present thesis), and discussed in depth in the subsequent 
chapters of the thesis:  
Objective 1: The quality control of the COSMOS database chemical domain, with 
particular emphasis on cosmetics ingredients and related compounds 
This objective (discussed in chapter 2) has been realised through: 
 Development of the sets of controlled vocabularies for chemical compounds and 
structures annotations, with a specific goal to address the problematic issues related to 
the representation and identification of cosmetics related substances. It was a dynamic 
process associated with curation of part of the COSMOS database chemical domain (U.S. 
EPA DSSTox inventory); 
 Preparation of the Standard Operating Procedure (SOP) for conducting the Quality 
Control/Quality Assurance (QC/QA) process of the COSMOS database chemical domain; 
 Conducting the QC/QA process. 
Objective 2: Characterising the chemical space occupied by cosmetics ingredients 
and related chemicals 
This objective (discussed in chapter 3) was realised through: 
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 Performing structural features (ToxPrint chemotypes) and physicochemical 
properties space analysis of the COSMOS Cosmetics Inventory profiled for the most 
abundant use functions within cosmetics domain; 
 Comparing the chemical space occupied by the cosmetics-related compounds with 
the food-related compounds from the U.S. FDA CFSAN PAFA database. 
Objective 3: The development of a high quality COSMOS Skin Permeability 
Database enriched with cosmetics ingredients and related compounds 
This objective (discussed in chapter 4) was realised through: 
 Curation and integration of existing skin permeability/absorption data sources, 
namely the EDETOX and University of Kent databases; 
 Development of the SOP for harvesting new data; 
 Harvesting new skin permeability data for cosmetics ingredients and related 
compounds from the regulatory and literature sources according to the SOP developed; 
 Integration of the newly harvested data with the EDETOX and University of Kent 
content; 
 Preparation of a data entry tool for QC of the COSMOS Skin Permeability Database. 
Objective 4: Classification of skin permeability potential following dermal exposure 
to chemicals to support the safety assessment of cosmetics related chemicals 
This objective (discussed in chapter 5) was realised through: 
 Data mining of the Skin Permeability Database that was constructed, leading to the 
collation of the set of compounds with available experimental data on maximal flux (JMAX); 
 Structural (with ToxPrint chemotypes) profiling of the collated dataset combined 
with the analysis of the physicochemical properties of its compounds; 
  Determination of a set of rules classifying a chemical compound into the category of 
low or high skin permeability potential. 
 Objective 5: Construction of a high quality database for oral repeated dose toxicity 
with dose/concentration level information for cosmetics and related compounds 
This objective (discussed in chapter 6) was realised through: 
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 Harvesting new oral repeated dose toxicity data for cosmetics and related 
compounds from regulatory and literature sources according to the predefined SOP; 
 Conducting the QC/QA process on the resultant COSMOS oRepeatToxDB that was 
constructed. 
Objective 6: Mechanistic (ontology-based) liver toxicity data mining of the 
COSMOS oRepeatToxDB on the basis of the ontology developed from the collated data 
This objective (discussed in chapter 7) was realised through: 
 Validation of a liver toxicity ontology developed on the basis of the data collated 
when the COSMOS oRepeatToxDB was constructed; 
 Ontology-based liver toxicity (steatosis) data mining of the COSMOS oRepeatToxDB; 
 Structural (ToxPrint chemotype) analysis of the sets of chemical compounds 
obtained and identification of the structural fragments associated with the investigated 
endpoint; 
 Formulation of the mechanistic reasoning for the toxicity of selected compounds on 
the basis of an evaluation of the published literature and the results of molecular 
modelling analysis (supplied by the collaborating COSMOS project partners from BAS). 
As the current PhD program was undertaken within the auspices of the COSMOS 
project, it supported the general objectives of the Project to develop alternative (non-
testing) tools to facilitate the safety assessment of cosmetics ingredients and related 
chemicals within the European Union. The outcomes of the current PhD program provide a 
solid foundation for further knowledge discovery. 
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Chapter 2 
Quality Control of the COSMOS Database Chemical Domain 
2.1. Background 
2.1.1. General aspects of the quality of chemical information and structures 
The COSMOS database is a chemo-centric system integrating data from various 
sources into a unified data model (please refer to chapter 1.4). For the development of a 
chemistry-aware database, the correct, unambiguous representation of chemical 
compounds encoded in a way enabling convenient storing, searching and integrating with 
other systems, is of major significance. The power of any cheminformatics tool depends 
greatly on the accuracy of the representation of molecular structures and related data, so 
that they can be understood by both human scientists and machines. The importance of the 
accurate identification of chemical structures for in silico modeling has been also recognised 
(Young et al., 2008; Fourches et al., 2010). It has been demonstrated that QSAR models 
developed with incorrect structures, or with the structures incorrectly handled by the 
computational tools, yield significantly poorer predictive accuracies when compared to the 
models developed on the basis of training sets with high quality structures. 
 Currently, several approaches aiming to address chemical identification and 
representation issues are utilised in the chemoinformatics field. Their advantages and 
limitations are discussed below. 
2.1.1.1. Chemical nomenclature 
Chemical nomenclature refers to the set of formalised rules consistently applied to 
generate the names of chemical compounds within a particular convention, e.g. 
International Union of Pure and Applied Chemistry (IUPAC) names (IUPAC, 2016), or 
International Nomenclature of Cosmetic Ingredients (INCI) names (CIRS, 2016). In principle, 
chemical nomenclature should ensure unambiguous identification of a chemical compound, 
meaning that one chemical name should refer to a single substance. In practice, however, 
applying the nomenclature-imposed rules usually leads to very complex names, which 
cannot be commonly recognised or used to infer structural information without expertise. 
Thus, a variety of other names (trivial, trade, etc.) commonly recognised by the scientific 
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community is widely used. As they do not conform to any formal rules or system, they 
cannot directly serve as unambiguous identifiers of chemical compounds (Brecher, 1999; 
Fourches et al., 2010).  
2.1.1.2. Chemical identification codes 
 Chemical identification codes are source-specific identifiers (e.g. digital), without 
any chemical significance per se, which may be utilised at a very local scale (e.g. within the 
laboratory or a corporate database to identify the compounds tested), or may be recognised 
more broadly. An example of internationally used compound identification numbers (albeit 
proprietary in their nature) are Registry Numbers (RNs), assigned by American Chemical 
Society (ACS) Chemical Abstract Services (CAS) (CAS, 2016). CAS RNs are intended to be 
unique numeric identifiers designating only one specific chemical substance and linking 
information to it (e.g. references, names, structures). They constitute from up to ten digits, 
divided by hyphens into three parts. The right-most digit is a “check digit” used to confirm 
the legitimacy and uniqueness of the entire identifier. CAS RNs are not related to any 
system of chemical nomenclature, and, as such, can provide a common link between various 
nomenclatures used to describe substances. However, it should be noted that a single 
chemical compound can be associated with multiple CAS RNs, as several types of CAS RNs 
are currently in use. They include alternate, deleted, and generic RNs. An Alternate Registry 
Number refers to the second RN generated for a less preferred structural representation of 
a substance. A deleted Registry Number is a RN once assigned to a substance, but later 
changed to another RN. Such cases may refer to the compounds that once appeared in the 
literature with a trade name, but without associated structural information, and which are 
later associated with a substance that has been already registered (Stanford University 
Libraries, 2016). A generic Registry Number is a RN representing the whole class of 
compounds (e.g. CAS RN “1330-20-7” for “xylene”) rather than pointing to the individual 
structure (e.g. 1,2-xylene (CAS RN “95-47-6”), or 1,3-xylene (CAS RN “108-38-3”).  
2.1.1.3. Line notations 
Line notations refer to the representation of chemical structures as linear strings of 
characters. The simplest example of a line notation would be the empirical molecular 
formula.  
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The most commonly used line notation system, the Simplified Molecular Line Input 
Entry System (SMILES) (Weininger, 1988), is based on a set of rules for converting the 
chemical structures into SMILES strings, which are accepted as an input format by the 
majority of chemistry software tools. The conversion process is fully automated. Both, 
stereochemistry and double bond geometry of molecular structures can be correctly 
handled by SMILES, however there are many errors involved in this format, due to the 
reality that some tools do not process SMILES correctly, or that many users are not 
sufficiently experienced to use them correctly. The other drawback of the SMILES 
representation is that multiple strings can be written for a single chemical. This limitation 
can be addressed by applying an algorithm for canonical atoms numbering, however it is 
successful only when used consistently as a single algorithm. In reality, different software 
tools utilise different canonical numbering algorithms, thus, the SMILES strings generated by 
them cannot be considered unique. 
Another line notation system is the IUPAC International Chemical Identifier (InChI) 
codes, developed to provide a standardised format for a formalised version of IUPAC names, 
which could be interpreted by humans and conveniently used for searching the chemical 
databases. In order to represent a chemical compound, an InChI code contains layers of 
information on the atoms, bonds, connectivity, tautomeric forms, isotopes, stereochemistry 
and charge (as appropriate to individual chemicals). InChI codes provide truly unique string 
identifiers of chemicals. However, interpretation of InChI codes by human scientists requires 
a lot of expertise, and InChI codes are currently not accepted by the majority of software 
tools. InChIKeys are a version of InChI codes hashed into keys, i.e. strings of characters, in 
order to further support the storage and searching in large chemical databases. InChIKeys 
comprise of 27 characters, and are not interpretable by humans (Heller et al., 2013). For 
InChIKeys, there is a theoretical (albeit statistically unlikely) possibility of duplicates. 
2.1.1.4. Coding constitutions 
Coding constitutions represent the constitutions of chemical structures explicitly. 
The atom-bond connection table (CTAB) is one of the forms of chemical structure 
representation, describing the structural relationships and properties of a collection of 
atoms. Molecular structure is presented as a topological graph with nodes representing the 
atoms linked by edges representing bonds. The atoms in the CTAB may be wholly or partially 
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connected by bonds. The atom block of the CTAB specifies the atom coordinates (2- or 3-
dimensional), atomic symbols, any mass difference (from mass in periodic table), charge 
(including radical state), stereochemistry and associated hydrogens. The bond block 
specifies the two atoms connected by the bond, the bond type (single, double, triple, 
aromatic), any bond stereochemistry and topology (chain or ring properties). The 
connection table is a fundamental part of the Molecular Design Limited (MDL) file format for 
the representation and communication of chemical information, including the Molecule 
(MOL) and Structure-Data (SD) files (MDL, 2005).  
Chemical Mark-up Language (CML) provides a general means to represent chemical 
compounds using the Extensible Mark-up Language (XML) schema, allowing for the storage 
of the annotations and properties for the chemical compound (CMLC, 2016). 
Of the various representation methods, the SD file is one of the most accurate and 
reliable for storing tautomer and stereochemistry information. In addition, the 3D chemical 
structures required to specify certain preferred conformations can be represented only by 
the xyz-coordinates in the connection table of the SD file or in CML atom blocks. 
2.1.2. Compilation of the COSMOS database chemical domain 
As described in section 1.4, the COSMOS database includes two interconnected 
parts: a “Compound”-centred part, referred to herein as “chemical domain”, and “Study”-
centred biological/toxicological part. The chemical domain of the COSMOS database can be 
therefore regarded as a collection of compounds (CMS IDs) with specific attributes: registry 
numbers, names, structures (and their attributes) and use functions. 
2.1.2.1.  Chemical structure sources in COSMOS database 
The chemistry part of the COSMOS database has been built through integration of 
several inventories of compounds (Table 2.1), donated for the COSMOS project by the U.S. 
FDA CFSAN CERES, the U.S. EPA DSSTox (ca. 12,000 records), and businesses related to the 
COSMOS project (e.g. Procter and Gamble contributed ca. 25,000 structures as a result of its 
membership of the Scientific Advisory Board). Multiple structures have been also retrieved 
manually by COSMOS consortium partners. At the time of data integration, each available 
connection table was assigned a “quality score” with respect to its origin. The values of the 
quality scores ranged from 100 (for the highest quality structures from respectable, curated 
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sources, e.g. the U.S. FDA CFSAN) to 5 (for the structures retrieved from publicly available, 
non-curated sources, e.g. the internet). The CAS structures donated from the U.S. FDA 
CFSAN CERES have been considered a “gold standard”. 
Table 2.1 
The source inventories of the COSMOS database chemical domain 
Inventory (Owner, Name, 
Reference) 
Inventory content 
The U.S. FDA CFSAN CERES, 
including the Priority-
Based Assessment of Food 
Additives Database (PAFA) 
(Benz & Irausquin, 1991) 
The U.S. FDA donation of about 70,000 public records from CERES, including 
the chemical part of the PAFA database.  
PAFA is a legacy database of regulatory-relevant chemical records, containing 
administrative, chemical and toxicological information on direct and indirect 
food additives, colour additives, and Generally Recognised As Safe (GRAS) and 
prior-sanctioned substances, as well as over 3,000 substances in an inventory 
called Everything Added to Food in the United States (EAFUS), being the list of 
ingredients added directly to food (FDA-approved as food additives), or listed 
or affirmed as GRAS.  
It is noteworthy that the PAFA Chemical Information includes historical data 
on: population exposure to chemicals, human consumption of the chemical, 
Acceptable Daily Intake (ADI) values set by the Joint FAO/WHO Expert 
Committee on Food Additives (JECFA), and a “Technical Effect” descriptor to 
define chemical use categories. 
The U.S. EPA Distributed 
Structure-Searchable 
Toxicity Database (EPA 
DSSTox, 2016)  
Repository of publicly available chemical structures, accurately mapped to the 
associated bioassay and physicochemical property data. About 12,000 DSSTox 
structures were donated to the COSMOS project by the U.S. EPA. 
The U.S. EPA ToxCast 
Inventory (EPA ToxCast, 
2016) 
Toxicology in the 21st Century (Tox21) is a collaborative project among the 
U.S. EPA, NIH and FDA, aiming to develop enhanced methods for toxicity 
assessment. The Toxicity Forecaster (ToxCast) is one of the EPA’s 
contributions to Tox21 and refers to the chemical screening results for over 
2,000 chemicals conducted in two research phases. The ToxCast inventory has 
been donated to the COSMOS project by the U.S. EPA. 
 
2.1.2.2. COSMOS Cosmetics Inventory 
A special emphasis was placed on cosmetics ingredients and cosmetics-related 
chemicals. The repository of them was compiled by merging the EC COSING database 
(COSING, 2016), and the U.S. PCPC list (Bailey, 2011) (Table 2.2) and is referred to as the 
“COSMOS Cosmetics Inventory”, a fundamental part of the COSMOS database. 
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Table 2.2 
The source inventories of the COSMOS Cosmetics Inventory. The specified counts refer to the 
status of original, not curated inventories 
Inventory (Owner, 
Name, Reference) 
Inventory content 
The European 
Commission COSING 
Database  
Database of information on cosmetic substances and ingredients contained in the 
EC Cosmetics Regulation (EC, 2009), Cosmetics Directive (EC, 2003), and Inventory 
of Cosmetic Ingredients (EC, 2006), as well as covered by the opinions on cosmetic 
ingredients of the Scientific Committee for Consumer Safety, SCCS (SCCS, 2016).  
The COSING database was downloaded in April 2011 from the EC COSING database 
website. The inventory file included:  
o 19,391 COSING identifiers (REFNUMs), encoding the chemical compound 
together with its use functions (the single compound with multiple use 
functions has been represented by multiple REFNUMs) 
o 9,286 CAS RNs 
o 19,397 INCI names used in the EU 
The International Nomenclature of Cosmetic Ingredients (INCI) system was 
established in the early 1970s by the PCPC. The INCI names are assigned according 
to the defined standards by the PCPC and are used in the USA, the EU, China, 
Japan, and many other countries for listing ingredients on cosmetic product labels. 
With few exceptions, the INCI labeling names in all countries should remain the 
same. The current (as of April 2016) list of INCI names is maintained by the PCPC, 
and includes over 16,000 ingredients (CIRS, 2016). 
o 66 chemical use functions 
The extensive list of possible functions of ingredients used in cosmetic products 
and their definitions from the COSING database has been provided in Annex 1. 
The U.S. Personal Care 
Products Council 
(PCPC) List 
The U.S. PCPC inventory has been compiled from a book (Bailey, 2011) published 
from the PCPC containing a list of cosmetics ingredients available in U.S. market. 
The inventory contained:  
o 3,713 CAS RNs 
o 3,512 INCI names used in the U.S 
 
2.1.2.3. Curation needs and integration of the source inventories 
The integration of chemical inventories (Tables 2.1 and 2.2) required curating 
original records (and chemical structures), identifying and removing duplicate ones, and 
joining the inventories on the basis of the common identifier(s). Any of the chemical 
representation methods outlined in section 2.1.1 can potentially become a source of errors. 
With respect to the chemical structures, the errors may occur either due to the implicit 
limitations of line notations and coded constitutions, or due to their incorrect handling by 
the software tools, or humans lacking sufficient expertise.  
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For the COSMOS database, a range of additional quality-related issues had to be 
considered. The Cosmetics Inventory largely comprises botanical extracts, oils, mixtures, 
dyes, etc., which translate chemically into macromolecules (polymers, peptides), inorganic 
compounds, coordination and transition metal complexes, etc. Such compounds frequently 
require the Markush type of representation, which is not handled well by currently available 
cheminformatics tools. Particularly challenging (if not impossible) is assigning structures to 
Unknown or Variable Compositions, Complex Reaction Products and Biological Materials 
(UVCB) (EPA, 2016a). A number of such substances could not be represented by CTABs (or 
other line notations), and were considered “non-structurable”. Frequently, many of these 
types of compounds have not been yet registered in the CAS Registry Database, making the 
task of their accurate representation and identification even more complicated.  
Due to the reasons outlined, the curation of records from the source inventories was 
demanding and required various types of processing. For instance, in case of the U.S. EPA 
DSSTox inventory (please refer to Annex 1), the main focus was placed on adopting the 
original annotations to the controlled vocabulary of the COSMOS database (dynamically 
developed during the curation efforts, please refer to sections 2.3.1 and 2.4.1). 
Considering the COSING and PCPC lists contributing to the COSMOS Cosmetics 
Inventory, additional processing was necessary. For instance, both INCI names and CAS RNs 
should, in principle, uniquely identify the chemical compounds between (and within) the 
COSING and PCPC. In practice, due to the generic representations (please refer to section 
2.1.1.2) of cosmetics ingredients and related chemicals, single compounds have been 
frequently associated with multiple CAS RNs, and conversely, single CAS RNs have been 
related to multiple compounds. Actual examples of many-to-many relationships between 
CAS RNs and INCI names in original records are presented in Table 2.3. Also, other 
nomenclature-related issues were commonly found, e.g. the lack of conformance between 
INCI names from COSING or PCPC lists with CAS Index Names, or differences between INCI 
names used in the U.S. and EU e.g. both INCI names “oryza sativa bran cera” (COSING) and 
“oryza sativa (rice) bran wax” (PCPC) refer to the same botanical compound. 
Whilst some inventories (e.g. the U.S. FDA CFSAN CERES, or EPA DSSTox) were 
processed into the COSMOS database in a relatively straightforward manner, the COSMOS 
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Cosmetics Inventory required the development of a specific integration procedure, 
presented schematically in Figure 2.1.  
 
 
Figure 2.1 
Integration of the EC COSING and the U.S. PCPC inventories leading to the construction of the 
COSMOS Cosmetics Inventory. The two lists were combined by two indices: INCI Names and CAS 
Registry Numbers. The compounds with common INCI Names were assigned a CMS ID in a fully 
automated process. For the compounds without common INCI Names, CAS RNs were analysed and 
used to text-mine the name nests. The INCI Names of these nests have been further examined and 
controlled. Due to many-to-many relationships, abundant between INCI Names and CAS RNs from 
the source lists, detections of duplicates in overlaps between the two inventories have been 
performed by direct comparison of InChIKeys for the compounds with available connection tables 
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Table 2.3 
An example of many-to-many relationships between CAS registry numbers and INCI Names found for the compounds from the surfactants class in 
unprocessed COSING and PCPC inventories*  
Source 
inventory 
INCI Name (from 
source inventory) 
CAS RN (from source 
inventory) 
Molecular formula 
(from source 
inventory) 
 
CAS index name (for CAS reported in the 
source inventory) 
CAS molecular formula (for CAS 
reported in the source inventory) 
COSING 
Sodium laureth-12 
sulfate 
9004-82-4 Not given 
Poly(oxy-1,2-ethanediyl), α-sulfo-ω-
(dodecyloxy)-, sodium salt (1:1) 
(C2H4O)nC12H26O4S.Na 
PCPC 
Sodium laureth-12 
sulfate 
66161-57-7 C36H74O16S.Na 
3,6,9,12,15,18,21,24,27,30,33,36-
Dodecaoxaoctatetracontan-1-ol, 1-(hydrogen 
sulfate), sodium salt (1:1) 
C36H74O16S.Na 
PCPC 
Sodium laureth-12 
sulfate 
9004-82-4 (generic) C36H74O16S.Na 
Poly(oxy-1,2-ethanediyl), α-sulfo-ω-
(dodecyloxy)-, sodium salt (1:1) 
(C2H4O)nC12H26O4S.Na 
COSING 
Sodium laureth-7 
sulfate 
9004-82-4 Not given 
Poly(oxy-1,2-ethanediyl), α-sulfo-ω-
(dodecyloxy)-, sodium salt (1:1) 
(C2H4O)nC12H26O4S.Na 
PCPC 
Sodium laureth-7 
sulfate 
9004-82-4 (generic) 
C26H54O11S.Na Poly(oxy-1,2-ethanediyl), α-sulfo-ω-
(dodecyloxy)-, sodium salt (1:1) 
(C2H4O)nC12H26O4S.Na 
*Inspecting the three records available for sodium laureth-12 sulfate, CAS RN “9004-82-4” (provided in both, COSING and PCPC inventories) is a generic 
CAS, representing the whole class of polymeric surfactants with dodecyl or C10-C16 range of alkyl chain length with varying number of ethoxy ether groups. 
This “generic representation” is clearly indicated in the CAS molecular formula by ill-defined number of repeating units (n), and in the CAS index name. On 
the contrary, CAS RN “66161-57-7” is a specific registry number, referring to the polymeric surfactant with dodecyl alkyl chain and 12 ethoxy ether groups, 
i.e. sodium laureth-12 sulfate. Whilst a compound with varying composition (such as a polymeric material having a distribution of chain lengths) can be 
represented by a generic CAS, a compound with specific composition/configuration within such a class should be associated with a specific CAS RN. 
Considering the example of sodium laureth-7 sulfate with the defined molecular formula: “C26H54O11S.Na”, the specific CAS would be: “66197-75-9” and the 
corresponding CAS index name: “3,6,9,12,15,18,21-Heptaoxatritriacontan-1-ol, 1-(hydrogen sulfate), sodium salt (1:1)” 
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2.1.3. Final content of the COSMOS database chemical domain 
As a result of merging the inventories identified in Tables 2.1-2.2, the entire COSMOS 
v.2.0 database (https://cosmosdb.eu/cosmosdb.v2/accounts/login/?next=/cosmosdb.v2/) 
consists of 81,604 chemical records. Connection tables are available for 46,791 (48%) 
compounds. The remaining ones largely consist of natural products (biological 
macromolecules, botanical oils, extracts, mixtures, etc., minerals) and other non-
structurable substances. The InChI Keys analysis performed on 46,791 COSMOS structures 
indicated 44,773 unique CTABs. Structural duplicates in the COSMOS database were allowed 
in multiple cases requiring the use of representative structures (please refer also to Table 
2.4). Over 72% of all available connection tables were assigned the highest quality score of 
100 (section 2.1.2.1). The lowest quality structures, with a score of 5, comprise ca. 8% of all 
COSMOS CTABs. 
2.1.3.1. COSMOS Cosmetics Inventory 
The COSMOS Cosmetics Inventory, compiled from the EU COSING and U.S. PCPC list 
(Table 2.2; Figure 2.2), consists of 17,100 unique chemical records (by CMS IDs), associated 
with 9,278 unique CAS RNs and 16,111 unique INCI Names. The connection tables are 
available for 5,562 Cosmetics Inventory compounds.  
 
Figure 2.2 
Venn Diagrams showing the number of chemical records (by assigned CMS IDs, curated CAS RNs or 
INCI Names) present in both (EU COSING and U.S. PCPC) or only one (EU COSING or U. S. PCPC) of 
the source inventories 
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2.2. The aims of chapter 2 
As outlined, properly identified chemical compounds represented by high quality 
structures are crucial for the successful development of a chemical-biological relational 
database and for facilitating the development of any in silico tool for toxicity prediction.  
The aims of the present chapter realised in collaboration with the COSMOS 
consortium partners (please refer to Annex 1) relate to the objective 1 of the current PhD 
program (section 1.5), and include: 
 Development of the sets of controlled vocabularies for chemical compounds and 
structures annotations, with a specific goal to address the problematic issues related to 
the representation and identification of cosmetics related substances. It was a dynamic 
process associated with curation of part of the COSMOS database chemical domain (U.S. 
EPA DSSTox inventory); 
 Development of a Standard Operating Procedure (SOP) to conduct the Quality 
Control/Quality Assurance (QC/QA) process of the COSMOS database chemical domain; 
 Conducting the QC/QA process. 
2.3. Materials and methods 
2.3.1. Development of a controlled vocabulary for compounds and structures 
annotations 
In every case of information exchange and integration, it is fundamental to have a 
set of common standards with respect to both the format and content of the data. 
According to the COSMOS database data model (chapter 1.4), the chemical compounds 
registered in the COSMOS database (uniquely identified with CMS IDs) can be associated 
with no (for non-structurable compounds), or one or more (for structurable compounds) 
connection tables. For each unique CMS ID multiple, non-unique information items may be 
stored (e.g. names, use functions, external identifiers). The many-to-many relationships 
between compounds and structures have been allowed, e.g. between parent and related 
compounds, such as components of mixtures, monomers of polymers, representative 
structures, etc. Controlled vocabularies were designed as an integral part of the COSMOS 
database data model, providing the terminology and foundation to correctly organise and 
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handle the complex relationships within the content of the COSMOS database chemical 
domain, as well as to deal with a range of problematic cosmetics-related compounds, e.g. 
those that are non-structurable and could not be represented by empirical molecular 
formulae, other line notations, or connection tables (section 2.1.2.3). 
The process of the development of a controlled vocabulary was dynamic. The 
preliminary terminology was designed in collaboration with the U.S. FDA, the U.S. EPA, and 
Altamira LLC (please refer to Annex 1) at the initial stage of curating and integrating the 
source inventories. As the chemistry content curation progressed, the controlled 
vocabularies were refined and updated, as needed. The sets of the controlled vocabularies 
have been designed for the following compound- and structure-related elements: 
stereochemistry, double bond geometry, material type and composition type. 
2.3.2. Development of the Standard Operating Procedure for the Quality Control (QC) 
of the COSMOS database chemical domain 
In order to perform the Quality Control of the COSMOS database by several COSMOS 
partners with maintained consistency, it was necessary to develop a Standard Operating 
Procedure (SOP). It was compiled by Altamira LLC (Annex 1), and covered all the tasks 
planned to be conducted during the QC process (including the verification of correctness of 
chemical names, registry numbers, structures, and compound and structures annotations). 
The initial SOP was systematically updated during the ongoing QC procedure to cover newly 
identified issues. 
2.3.3. Conducting the Quality Control (QC) and Quality Assurance (QA) Processes of the 
COSMOS database chemical domain 
The Quality Control (QC) process can be defined as the verification of the accuracy of 
the database content with respect to the predefined standards, resolving the eventual 
deviations and modifying the process as needed. The QC of the COSMOS v.1.0 database 
chemistry content was led by LJMU, and has been completed with the effort of five 
COSMOS partners (Annex 1). Approximately 1% of structurable (i.e. containing connection 
tables) compounds included in the COSMOS database were sampled randomly and evenly 
distributed between the QC participants. QC was performed via the COSMOS database Data 
Entry System (DES), according to the previously developed SOP (section 2.3.2). 
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The Quality Assurance (QA) process maintains the quality standards of the database 
by sampling the observations at a given confidence level, such that the relevant statistics 
(error rates, i.e. the ratios of incorrect records to the total number of sampled records) can 
be reported. During the Quality Control process, the main emphasis was placed on assuring 
the connection tables, registry numbers and names correctness, as these elements were 
subsequently used for the calculation of the QA statistics. The QA statistics have been 
derived from the COSMOS DB DES audit trail and by comparing all the QC-ed records to the 
original, not QC-ed ones.  
2.4. Results 
2.4.1. Controlled vocabularies for chemical compounds and structures annotation 
Sets of controlled vocabularies were developed to annotate the following 
compound- and structure- related elements: stereochemistry, double bond geometry, 
material type and composition type. 
2.4.1.1.  Stereochemistry 
Stereochemistry annotations refer to the isomerism of the structure resulting from 
the differences in the spatial arrangement of atoms without accompanying differences in 
connectivity or bond multiplicity (IUPAC, 2016). The following controlled vocabulary was 
designed for the COSMOS database: 
 Absolute stereochemistry, referring to the chemical structures for which the 
absolute configuration of the chiral centre(s) is provided. The structures with a known, 
specific, single configuration have the direction of rotation specified, i.e. they were 
annotated as “Absolute stereochemistry, rotation (-)”, or “Absolute stereochemistry, 
rotation (+)”. 
 Relative stereochemistry, applicable to the structures for which the relative 
configuration of two or more chiral centres was provided (i.e. the relationship to two or 
more centres was specified), but the absolute value in their relationship is unknown. 
 Relative stereochemistry, racemic mixture: The compound is a racemic mixture of 
the structure as drawn, and its identical mirror image. 
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 No stereochemistry, meaning that no stereochemistry is associated with the 
compound (i.e. the sterochemistry annotation was not applicable). 
2.4.1.2.  Double bond geometry 
Double bond geometry annotations include: 
 Double bond geometry (E-), referring to structures with single or multiple double 
bonds(s), all with trans- geometry. 
 Double bond geometry (Z-), referring to structures with single or multiple double 
bonds(s), all with cis- geometry. 
 Double bond geometry (E-,Z-), referring to structures with multiple double bonds(s) 
representing both (trans-, cis-) types of geometric isomerism. 
 Double bond geometry unspecified, referring to structures with double bond(s), but 
without geometric isomerism specified. 
 No double bond geometry, relevant for structures that are not associated with any 
double bond geometry (i.e. the double bond geometry annotation is not applicable). 
2.4.1.3.  Material type 
Material type refers to the chemical nature of the compound. The following material 
types have been recognised in the COSMOS database: 
 Biological, referring to macromolecules of biological importance, e.g. protein or 
nucleic acid sequences, lipids, enzymes, etc. for which it is (usually) difficult to define a 
structure, or they are non-structurable. 
 Botanical, referring to compounds of natural/plant origin, largely comprising of 
complex, structurally difficult to define (or non-structurable) mixtures, extracts, oils, etc. 
 IOM, denoting the entire category of compounds including: 
o Inorganic: Chemical structures without organic carbon atoms; elements including 
metal atoms and metalloid atoms (boron (B), silicon (Si), germanium (Ge), arsenic 
(As), antimony (Sb), tellurium (Te)); ions (e.g. borate, chromate); minerals. 
o Organometallic: Chemical structures containing organic carbon(s) directly bonded 
to any metal atom other than alkali (I) or alkaline earth (II) metals. 
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o Organometalloid: Chemical structures containing organic carbon directly bonded 
to any metalloid atom. 
o Metal complex: Chemical structures containing a central metallic atom covalently 
bonded to the total number of ligands, either larger or smaller than indicated by 
the central metal atom’s oxidation state. 
o Metalloid complex: Chemical structures containing a central metalloid atom 
covalently bonded to the total number of ligands, either larger or smaller than 
indicated by the central metalloid atom’s oxidation state. 
 Organic, to annotate the chemical compounds containing organic carbon atom(s) 
(i.e. not carbon monoxide, carbon dioxide, carbonates and cyanides), but not being 
classified as organometallics or organometalloids. 
 Polymer, referring to the chemical compounds with polydispersed composition, i.e. 
constituted by regularly or irregularly repeated units. 
 Unspecified, relevant in cases when little or no information was available for a 
compound (e.g. exhaust gases, complex reaction products obtained in industrial 
processess). 
2.4.1.4. Composition type 
Composition type corresponds to the chemical constitution of the compound, i.e. the 
elements listed in its molecular formula. In the majority of cases, the composition type can 
be inferred solely from the molecular formula. However, the information on the 
configuration of the chemical compound (e.g. geometric or positional isomers, 
stereoisomers) cannot be derived from the molecular formula and has to be inferred from 
the compound name or connection table, if applicable. The composition type has been 
controlled by the following vocabulary: 
 Defined formula, referring to chemical compounds with chemical structure fully 
represented in the molecular formula (except configuration information, please refer to 
the descripton above and to the annotation ”varying isomers” below) 
 Ill-defined formula, relevant in many cases when chemical structure is only partially 
represented in the molecular formula. This composition type can include varying 
compositions and/or varying number of repeating units (polydispersion) 
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o Varying composition, refers to chemical structures in which one or more 
components are unknown (unspecified), or the stoichiometric ratios (e.g. in salts) 
are unknown.  
o Polydispersion, refers to the varying number of repeating units. This term is 
relevant for polymers and is usually reflected in the molecular formula (()n), 
and/or in the name of the compound (poly-). For instance: C8H8 is a molecular 
formula of styrene, whereas (C8H8)n represents polystyrene.  
 Formulation, for annotating well-defined (usually commercial, possibly proprietary) 
compositions of two or more substances. 
 Unspecified, applicable in cases when little or nothing is known about the 
composition of the chemical and, as such, no molecular formula can be derived (e.g. 
complex reaction products). 
 Varying isomers, referring to any type of relevant isomerism (may be geometric, 
positional, or stereoisomerism) and is applicable to both, defined and ill-defined 
compositions. The information on the isomerism cannot be inferred from the molecular 
formula and has to be decided upon after inspection of the name or the structure of the 
chemical compound. 
2.4.1.5. Application of the annotations scheme 
Examples of application of the above controlled vocabularies in the COSMOS 
database are presented in Table 2.4. The COSMOS annotations facilitate the compilation of 
computational datasets (i.e. the datasets that can be used for the computational analysis; 
described in more details in chapter 3). 
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Table 2.4 
An example of application of composition and material type annotations in the COSMOS database. The records 1-2 and 3-5 refer to cases where the 
composition type of the compound cannot be inferred from the molecular formula  alone and the positional isomerism has to be inferred from the 
compound name. Record 6 demonstrates the case when annotations can be assigned from the molecular formula alone. Cases where the 
representative structures have been used are also presented 
Rec # 
Molecular 
Formula 
CAS RN CAS Index Name Composition Type Material Type Structure Image Structure note 
1 (C2H4O)nC15H24O 26027-38-3 
Poly(oxy-1,2-ethanediyl), α-(4-
nonylphenyl)-ω-hydroxy- 
Ill-defined formula – 
polydispersed 
Organic - 
polymer  
Representative structure 
for polymer (n=1) 
2 (C2H4O)nC15H24O 9016-45-9 
Poly(oxy-1,2-ethanediyl), α-
(nonylphenyl)-ω-hydroxy- 
Ill-defined formula – 
polydispersed – varying 
isomers 
Organic - 
polymer  
Representative structure 
for polymer (n=1) and 
positional isomer (as 4-
nonylphenyl) 
3 C8H10 1330-20-7  Benzene, dimethyl- 
Defined formula – varying 
isomers 
Organic 
 
Representative structure 
for positional isomer (as 
1,3-dimethyl) 
4 C8H10 108-38-3 Benzene, 1,3-dimethyl- Defined formula Organic 
 
Actual structure 
5 C8H10 95-47-6 Benzene, 1,2-dimethyl- Defined formula Organic 
 
Actual structure 
6 (C8H17N5)n.xClH 32289-58-0 
Poly[iminocarbonimidoyliminocar
bonimidoylimino-1,6-hexanediyl], 
hydrochloride 
Ill-defined formula – 
polydispersed – varying 
composition 
Organic - 
polymer 
 
Representative structure 
for polymer (n=1) and 
composition (x=1) 
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2.4.2. Standard Operating Procedure for the Quality Control (QC) process 
The final SOP (updated and finalised after the QC) is provided in Annex 2. The entire 
QC procedure consisted of several steps, as presented in Figure 2.3.  
 
Figure 2.3 
An overview of the Quality Control procedure conducted of the COSMOS database chemical domain 
through Data Entry System. The QC procedure consisted of the following steps:  
(1) Logging-in to the COSMOS database Data Entry System with the personal access credentials; 
(2) Accessing the Data Entry System; 
(3) Selecting the “Review and QC Existing Structures and Data” option under the “Chemistry” 
section of Data Entry System; 
(4) Searching for the query compound (i.e. the one subjected to the QC) in the COSMOS 
database chemical domain; 
(5) Selecting the compound for QC from the search results list (the outmost right “QC-ed” box is 
not checked yet); 
(6) Selecting the tab corresponding to the QC-ed element: “Structure Annotation”, “Compound 
Annotation”, “Registry Numbers and IDs”, or “Names”, and performing the actual quality 
control tasks. Subsequently saving the results; 
(7) Receiving the confirmation of the successful completion of the QC process on the final 
screen (the outmost right “QC-ed” box is now marked) 
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The actual tasks performed during the QC of particular elements are discussed in the 
following paragraphs. 
2.4.2.1.  Structure annotation 
The Quality Control of “Structure Annotation” (Figure 2.4A) covered the verification 
(and correction, if needed) of the following elements: 
 Connection table (and depiction of the structure’s image). For each connection table 
the COSMOS database automatically calculates the InChIKey using the RDKit 
chemoinformatics library (RDKit, 2016). For the purpose of the QC process, the “corrected 
connection table” has been defined as a connection table which has been sufficiently 
modified in the QC process, as to result the creation of a new InChIKey; 
 Stereochemistry annotation (with respect to the developed controlled vocabularies); 
 Double bond geometry annotation (with respect to the developed controlled 
vocabularies); 
 The source provided for each structure. This element was subject to correction in 
addition to making any changes in the connection table during the QC procedure. 
2.4.2.2.  Compound annotation 
The Quality Control of the “Compound Annotation” (Figure 2.4B) focused on 
checking of the correctness of the following elements: 
 Molecular formula; 
 Material type annotation (with respect to the developed controlled vocabularies); 
 Composition type annotation (with respect to the developed controlled 
vocabularies). 
 2.4.2.3. Registry numbers and IDs 
The QC of “Registry Numbers and IDs” (Figure 2.4C) focused on the verification (and 
resolving any conflicts, if necessary) of: 
 The correctness of Registry Number(s) assigned to the compound (structure/name 
pair correctness); 
 The correctness of specified RN types (active, alternate, deleted, generic, etc.) 
(please refer to section 2.1.1.2); 
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 The correctness of other (external) identifiers, e.g. the EC COSING REFNUMs, the 
DSSTox CIDs, etc., by querying them in the source inventories. 
2.4.2.4.  Names 
The Quality Control of the “Names” (Figure 2.4D) covered the verification (and 
correction, if needed) of:  
 The correctness of the chemical names provided for the query compound (also with 
respect to the structure, Registry Numbers, identifiers); 
 The correctness of “Name Type”, as specified, e.g. INCI Name. The “Preferred Name” 
in the COSMOS database was not subjected to any changes; 
 The correctness of “Name Source”, as specified. The “Name Source” should correctly 
correspond to the “Name Type”, e.g. for the INCI Name type, the correct sources could 
include “COSING” or “PCPC”. 
 
Figure 2.4 
Quality Control of the COSMOS database chemical domain though the COSMOS DES: (A) Structure 
Annotation; (B) Compound Annotation; (C) Registry Numbers and IDs; (D) Names 
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2.4.3. Results of the QC/QA of the COSMOS database chemical domain 
The QC/QA process of the COSMOS v.1.0 database chemistry content was performed 
for ca. 1% of structurable (i.e. containing connection tables) compounds randomly sampled 
from the database, giving a total number of 442 structures subjected to the QC. The QC 
tasks were accomplished through the COSMOS DB Data Entry System (DES), with particular 
emphasis placed on the QC of connection tables, Registry Numbers, and compound names, 
as these elements were used for the QA statistics determination. 
2.4.3.1. Connection tables quality control 
The QC of the 442 structures led to the correction of a total of 43 connection tables, 
giving an overall error rate of 9.7%. Three specific types of corrections were performed: 
 Correction of the connectivity and stereochemistry, or protonation state, of the 
structure; 
 Correction of the stereochemistry and protonation state (connectivity unchanged); 
 Correction of the protonation state (connectivity and stereochemistry unchanged). 
Overall, 16 connectivity changes have been made (giving the connectivity error rate 
of 3.6%), 24 stereochemistry changes (the error rate of 5.4%) and 3 changes for protonation 
states (the error rate of 0.7%).  
2.4.3.2. Registry numbers quality control 
During the QC cycle only two (out of 442) CAS RNs were identified as being 
incorrectly assigned and were thus corrected, giving an error rate of 0.45%. Additionally, 
151 new CAS RNs were added to the compounds inspected. 
2.4.3.3. Chemical names quality control 
The QC process has resulted in correcting ten (out of 442) chemical names, giving an 
error rate of 2.2%. Additionally, 732 new names were added to the databases. 
Based on the results of the QA on chemical structures, the approximate percentage 
of inaccurate structures in COSMOS v.1.0 is 4.3% (if stereochemistry is ignored), and 9.7% (if 
stereochemistry is considered). Approximately 2.2% of the names may contain errors and 
0.5% of the records may have incorrect registry numbers. The COSMOS database is, by far, 
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the only publically available database, which chemistry content has been carefully QC-ed 
and for which the QA statistics are available. 
2.5. Discussion 
This chapter describes the process of collation of the COSMOS database chemistry 
content, including the COSMOS Cosmetics Inventory. It involved integration of several 
chemical inventories into a unified data model, and systematic curation and quality control 
of chemical records.  
The need for a strategy addressing concerns over the quality of chemical information 
and structures was clearly demonstrated. As such, a novel set of controlled vocabularies was 
developed with respect to the specific features of cosmetics and related compounds. It 
provides the unified terminology systematising the complex relationships within the 
cosmetics domain and the framework to deal with a range of non-structurable (or difficult 
to structure) compounds. The designed COSMOS annotations may facilitate the compilation 
of computational datasets (i.e. the datasets that can be used for the computational analysis) 
by enabling fast and convenient identification of non-structurable compounds (e.g. 
unspecified compositions or material types), or compounds that are not handled well by the 
computational tools (inorganics, metal complexes, organometalloids, polymers, mixtures, 
etc.).  
The systematic quality control procedure established during the COSMOS database 
development was captured as the Standard Operating Procedure (SOP) document (Annex 
2), which can serve as a point of reference during future efforts of chemical structures 
collation. 
The precise identification of chemical compounds within COSMOS Database 
supports the populating of the associated toxicological content by enabling accurate 
referencing of chemical and biological records. This, in turn, supports the development of 
meaningful in silico tools, as their performance is dependent on the accuracy of the 
representation of molecular structures and related data. 
The COSMOS Database contains 81,604 chemical records. The COSMOS Cosmetics 
Inventory is particularly important part of the COSMOS database. It consists of 17,100 
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unique chemical records, associated with 5,567 chemical structures and is, by far, the 
largest publicly available inventory of cosmetics and related compounds. During the 
COSMOS project it served as a foundation to realise multiple objectives. After the COSMOS 
project, it still has numerous scientific and regulatory applications. As a publicly available, 
ready-to-use repository of cosmetics-related compounds with associated toxicological data 
it can support data mining, in silico methods development, risk assessment and read-across 
tasks (by, for example, enabling identification of structural analogs within cosmetics 
domain). The COSMOS Cosmetics Inventory was used in the analysis described in chapter 3, 
including the determination of structural features and physicochemical properties 
associated with different types of cosmetics and comparison of these characteristics with 
food-related compounds.  
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Chapter 3 
Chemical Space Analysis of the COSMOS Cosmetics Inventory 
3.1. Background 
The chemical space of an inventory of chemicals (or a toxicity database) can be 
regarded as the ranges of physicochemical properties and structural features covered by its 
constituents. It is an important piece of information for many reasons (Yang et al., 2008; 
Worth & Mostrag-Szlichtyng, 2010):  
 Analysis of chemical space may be a first step towards the development of 
meaningful computational methods accurately predicting toxicity by verifying and assuring 
sufficient coverage of the relevant chemical space. Utilising relevant means of describing 
the physicochemical and structural characteristics of the chemicals across various 
inventories ensures that the basic concept underlying predictive chemistry and toxicology 
that similar molecules are expected to exhibit similar properties and biological activities is 
fulfilled (Johnson and Maggiora, 1990); 
 The structural and physicochemical properties space of a dataset, analysed together 
with the biological activity of its members, may provide insights improving the 
understanding of complex toxicological phenomena. It may lead to the identification of the 
chemistry-biology associations and facilitate the discovery of structural features linked to 
toxicity. Thus, it supports the development of mode-of-action knowledge from the data; 
 Information on the chemical space covered by the inventory or a dataset is also 
particularly important for the successful application of existing computational tools. In 
silico models should be applied only to the chemical compounds situated within their 
applicability domains, since outside this they are unlikely to give reliable predictions. When 
the predictive performance of model is assessed by challenging it with an independent 
(external) validation (test) set, it is useful to compare the chemical space of the test set 
with that of the training set. When the predictive performance of a model is assessed 
against a limited test set, and the conclusions are generalised to a wider dataset (or 
chemical inventory), it is important to compare the chemical space of the test set with that 
of the wider inventory;  
Chapter 3 
37 
 
 The comparison of the chemical space occupied by diverse inventories representing 
various types of compounds (e.g. cosmetics- vs food-related, as in the research discussed 
in the present chapter) enables the investigation of the physicochemical and structural 
features of the molecules with respect to their specific use types in specific environments. 
It allows for the context of where and how the particular molecular characteristics have 
been manifested to be investigated.  
Performing computational analysis of the chemical space of an inventory of 
compounds or a dataset requires the following steps: (i) preparing molecular structures for 
the purpose of computational analysis; (ii) calculating relevant molecular descriptors; (iii) 
applying appropriate statistical techniques to make the results of calculations interpretable. 
Each of these steps is discussed below. 
3.1.1. Curation of chemical structures 
The importance of appropriate preparation of molecular structures for 
computational analysis, so that they can be correctly interpreted and handled by the 
software used to compute molecular descriptors, has been widely recognised (Young et al., 
2008; Fourches et al., 2010; Waldman et al., 2015) and outlined in chapter 2. No 
standardised sets of procedures that should be applied to curate structures have so far been 
formulated, as the computational generation of structures should be always performed with 
regard to the aim of the analysis. For instance, the investigation of general structural classes 
represented in a given inventory or a dataset requires a different approach than the 
calculation of quantum mechanical descriptors for individual compounds. In the first case, 
2D structures may be sufficient, whereas in the second one, 3D coordinates of the 
investigated molecules have to be provided. General aspects related to the preparation of 
computational datasets are listed and discussed in depth in Table 3.1. 
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Table 3.1 
General aspects associated with preparation of molecular structures for computational analysis 
(Young et al., 2008; Fourches et al., 2010) 
Task Description 
Identification of IOM 
compounds (please refer 
to chapter 2) 
The majority of molecular descriptors were designed for organic compounds for 
which valence-bond structures can be formulated and, as such, cannot be 
calculated for inorganics. For organometallics and organometalloids, 
calculations may be also not possible, due to the common lack of necessary 
calibration for rare earth metals. 
Identification of salts The majority of software tools cannot process organic salts, which contain 
metal counter ions. The properties of salts can vary from the properties of 
parent compounds. However, in cases when the organic part of the molecule is 
responsible for its biological activity, the metal counter ions should be removed 
and the remaining carbo- cations or anions should be neutralised. 
Identification and 
processing of mixtures 
Although some approaches to deal with mixtures have been suggested, the 
majority of available software tools are not capable of handling these types of 
compounds (consisting of multiple structures) in a transparent and appropriate 
way. The most common approach is based on automated removal of the 
mixture constituent(s) with the lowest molecular weights or the smallest 
number of atoms. However, in cases when the entire mixture has been tested 
for toxicity, the associated data do not necessarily correspond to the toxicity of 
individual components. The “smallest fragment” should be therefore removed 
only in cases when it is clear that the “largest fragment” is responsible for the 
biological activity of the whole mixture. Such cases refer, for example, to 
hydrates and hydrochlorides consisting of a large biologically active organic 
molecule and small inorganic one(s). In case of mixtures consisting of several 
organic constituents with similar molecular weight, the decision on the 
fragment removal should be made after careful review. 
Validation of chemical 
structures with respect to 
the representation of 
mesomeric (resonance) 
forms, tautomeric forms 
and aromatic rings 
Resonance structure and aromaticity should be represented in a consistent way 
as any differences in representation may significantly change the values of 
calculated properties. For tautomers, the mechanism of action (if known) 
should be considered prior deciding on the appropriate representation of the 
compound. 
Detection and removal (if 
desired) of duplicates 
Due to nomenclatures, digital identifiers, or SMILES strings limitations 
repetitions of the same compound (and hence the same structure) in large 
inventories are relatively common (chapter 2). To detect duplicate structures, 
InChIKeys comparison can be successfully applied (section2.1.1.3). However, it 
should be stressed that duplicate structures may also appear as a result of 
performing some of the above mentioned structure processing steps. For 
instance, counter ion(s) removal, and subsequent neutralisation of the 
remaining organic part of the molecule, or small fragments removal, may both 
lead to a single “computational” structure, represented by a single InChIKey, 
which actually is a (neutralised) part or a substructure of several tested 
compounds. On occasions, the experimental results for those records may vary. 
This could mean that the structure curation procedure had led to the removal 
of a significant molecular fragment which may be responsible for the activity of 
the compound tested. Such cases should be reviewed manually by human 
experts. Generally, the process of the removal of duplicates should be 
controlled and it should be always possible to relate the resulting 
computational structure back to the original compound tested. 
Chapter 3 
39 
 
3.1.2. Calculation of molecular descriptors 
“The molecular descriptor is the final result of a logic and mathematical procedure 
which transforms chemical information encoded within a symbolic representation of a 
molecule into a useful number or the result of some standardised experiment” (Todeschini & 
Consonni, 2009).  
The selection of relevant molecular descriptors with regard to the aim(s) of the 
analysis is essential. In case of chemical space analysis, the selected molecular descriptors 
should be capable of capturing the variability of investigated compounds in as broad as 
possible manner. As such, several types of descriptors should, ideally, be utilised. Various 
descriptors generated by different computational algorithms are, in principle, expected to 
derive diverse types of information for the compared sets of molecules. The selected 
descriptors should be also transparent and easy to interpret.  
Molecular descriptors can be categorised in a range of different ways, for example 
with regard to the molecular representation used for the calculations (into zero- to three- 
dimensional descriptors), or to the nature (and complexity) of the calculations (into 
constitutional, topological, geometrical, electronic, or quantum-mechanical approaches) 
(Fara & Oprea, 2016). The example of generic categories of molecular descriptors is 
provided in Table 3.2.  
Table 3.2 
General categories of molecular descriptors 
Molecular descriptor category Description 
Zero-Dimensional (0D) Descriptors derived directly from the molecular formula of the compound 
(e.g. molecular weight, number of atoms in the molecule, etc.) 
One-Dimensional (1D) Fragment counts (e.g. number of H-bond donor and acceptor atoms) 
Two-Dimensional (2D) Topological descriptors, referring to the manner in which the atoms are 
connected in the molecule and calculated from mathematical graph theory 
(e.g. topological polar surface area) 
Three-Dimensional (3D) Geometrical, electronic and quantum-mechanical descriptors derived from 
the results of empirical schemes or molecular orbital calculations requiring 
the 3D structure of the molecule (e.g. dipole moment) 
 
Structural fingerprints comprise another type of descriptors, encoding the molecular 
structure in a form of binary digits (bit-strings) representing the presence or absence of 
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particular substructures in the molecule (Fara & Oprea, 2016). The molecular fragments for 
fingerprints generation are, in principle, designed to encode particular chemical 
information, which can be interpreted by human scientists. The molecules can be thus 
compared through the comparison of their fingerprints. 
The 0- to 3-D molecular descriptors, along with the structural fingerprints, provide a 
large portion of the information about the molecule. They are well-defined by the available 
cheminformatics tools and have been broadly applied throughout the present thesis (in 
chapters 3, 5 and 7).  
3.1.3. Application of relevant statistical methods 
The subsequent step of chemical space analysis requires applying relevant statistical 
method(s) to transform the multidimensional space occupied by the studied inventories into 
a lower dimensional space, and to visualise it, so it can be interpreted by a human scientist. 
Multiple statistical approaches have been successfully applied to this end, including Cluster 
Analysis (Cattell, 1943), Artificial Neural Networks (ANN) (Kohonen, 1982; Zupan & 
Gasteiger, 1999), or Principal Components Analysis (PCA). The technique broadly utilised in 
the present thesis is PCA (this chapter and chapter 5), which is discussed below.  
Principal Components Analysis (Pearson, 1901; Wold et al., 1987; Jolliffe, 2002; 
Begam & Kumar, 2014) is a multivariate method belonging to the group of statistical 
multidimensional factorial methods (Cordella, 2012) that provides a compact view of 
variation in a data matrix by defining the orthogonal directions of maximum variance. The 
Principal Components-based decomposition of the original data matrix is presented 
schematically in Figure 3.1. Briefly, PCA can be performed by eigenvalue decomposition of 
the covariance (or correlation) matrix of the data and the first Principal Component (PC) is 
the eigenvector (showing the “direction” of the highest variance in the data) with the 
highest eigenvalue (specifying the amount of variance in the data in this direction). The 
following Principal Components are the directions maximising variance among all directions 
orthogonal to the previous Principal Components. Frequently, PCA results are interpreted in 
terms of the loadings (the covariance/correlation between the particular Principal 
Components and the original variables, providing information on how much of the variation 
in a variable is explained by the PC) and scores (defining the positions of each observation in 
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the new space of the Principal Components). Generally, a large proportion of the total 
variability in a dataset can be explained by a small number of the Principal Components. 
PCA is one of the most frequently employed techniques for visualising and exploring the 
space occupied by large chemical/toxicological datasets. 
 
Figure 3.1 
Linear decomposition of original data matrix (consisting of n compounds and m variables) by 
Principal Components Analysis. The columns in matrix S correspond to the score vectors of the 
Principal Components (PCs), whereas the columns in the matrix L to the loading vectors of the PCs. 
The matrix R represents any residual information not included in the S and L decomposition. PCA 
orders the loading and score vectors in decreasing order of variance (on the basis of (Burger & 
Gowen, 2011; Begam & Kumar, 2014) 
3.2. The aims of chapter 3 
The process of compiling the chemistry part of the COSMOS database and COSMOS 
Cosmetics Inventory was described in detail in chapter 2. The aims of the present chapter 
are related to the objective 2 of the current PhD program (section 1.5), and include: 
 Analysis of the chemical space covered by the COSMOS Cosmetics Inventory in terms 
of the structural features (ToxPrint chemotypes) and physicochemical properties, with 
particular focus put on the most abundant use functions within the cosmetics domain; 
 Comparison of chemical space occupied by cosmetics- to the food- related 
compounds from the U.S. FDA CFSAN PAFA. 
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3.3. Materials and methods 
3.3.1. Analysed inventories  
The chemical space analysis was performed for the two following inventories:  
 COSMOS Cosmetics Inventory containing 5,562 structures (the collation of the 
COSMOS Cosmetics Inventory was described in chapter 2); 
 Food-related compounds from the U.S. FDA CFSAN PAFA database (Table 2.1) 
including 4,337 structures. 
The structures comprising both inventories were obtained from the COSMOS 
database as 2D SD files (referred to herein as “2D-tested” SDFs). The chemical space analysis 
was performed with respect to both, structural features and physicochemical properties. 
Each part of the analysis was based on a different methodology, thus required a different 
type of original SD files pre-processing. 
3.3.2. Use functions of cosmetics-related compounds 
Prior to the chemical space analysis, the COSMOS Cosmetics Inventory was 
characterised with respect to the 66 chemical use functions associated with cosmetics-
related compounds from the EU COSING database (Table 2.2). The entire list of COSING use 
functions along with their definitions is provided in Annex 3. It was expected that specific 
use functions will be reflected in the structural characteristics and physicochemical 
properties of individual molecules. 
3.3.3. Structural features (chemotypes) analysis 
The analysis of general structural features represented by cosmetics and food 
related compounds was performed using novel approach based on the ToxPrint chemotypes 
(Yang et al., 2015), belonging to the structural fingerprints type of descriptors. The term 
“chemotype” refers to a means of representing the chemical entities as structural fragments 
encoded for connectivity (which may extend beyond a single connected fragment). If 
needed, chemotypes may be also encoded for physicochemical properties of atoms, bonds, 
fragments, electron systems and even whole molecules. The conceptual graph of the 
chemotype is presented in Figure 3.2. 
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Figure 3.2 
Schematic definition of a chemotype 
The ToxPrint chemotypes (Yang et al., 2015), which were developed from over 
100,000 chemicals present in publicly available chemical inventories and toxicity databases, 
cover a range of hierarchically organised structural classes (Table 3.3) and capture broad 
chemical spaces of food ingredients, food direct additives, food-contact substances, 
pharmaceuticals, agrochemicals, cosmetics ingredients and industrial chemicals. The library 
of 729 ToxPrint chemotypes is publicly available at www.toxprint.org and can be 
downloaded as a .csrml (Chemical Subgraphs and Reactions Markup Language) file (Yang et 
al., 2015). 
Table 3.3 
Classes of ToxPrint chemotypes (from Yang et al., 2015) 
Top 
class 
1st level classes 
Total # of 
chemotypes 
Atom 
main group element, metal (group I, II, III, transition metals, metalloid, poor 
metals) 
 
Bond 
C#N, C(∼Z)∼C∼Q, C(=O)N, C(=O)O, C=N, C=O, C=S, CC(=O)C, CN, CNO, COC, COH, 
CS, CX, metal, N(=O), N[!C], N=[N+]=[N−], N=C=O, N=N, N=O, NC=O, NN, NN=N, 
NO, OZ, P(=O)N, P=C, P=O, PC, PO, QQ(Q∼O_S), quaternaryN, quaternaryP, 
quaternaryS, S(=O)N, S(=O)O, S(=O)X, S=O, Se∼Q, X(any), X[(any)_!C], X∼Z 
411 
Chain 
alkaneBranch, alkaneCyclic, alkaneLinear, alkeneBranch, alkeneCyclic, 
alkeneLinear, alkyne, aromaticAlkane, aromaticAlkene, oxy-alkaneBranch, oxy-
alkaneLinear 
95 
Group aminoAcid, carbohydrate, ligand, nucleobase 69 
Ring aromatic, fused, hetero, polycycle 144 
 
In the current analysis, the ToxPrint chemotypes were used to explore and compare 
the structural space occupied by cosmetics- and food- related compounds. For 
comprehensive investigation, it was particularly important to preserve all chemical classes 
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occurring in both inventories, including inorganics, organometallics, organometals and 
metal complexes. Generating the fingerprints using ToxPrint chemotypes in this analysis did 
not require 3D computational structures. The salts and IOM compounds were therefore 
retained, and “2D-tested” SD files were used as input. 
The analysis was performed with the publicly available (www.chemotyper.org) 
software application, ChemoTyper (Altamira LLC, Columbus, OH, USA; Molecular Networks 
GmbH, Nüremberg, Germany). Using the ChemoTyper, the input structures (imported from 
the “2D-tested” SD files) were mapped against the predefined ToxPrint library 
(toxprint_V2.0_r711.xml file downloaded at www.toxprint.org). The features describing the 
query compounds were subsequently exported in the form of a table of binary chemical 
fingerprints. The rows in this data matrix corresponded to particular molecules (structures) 
and the columns to particular ToxPrint chemotypes: a value of 1 indicated that the 
compound contained a given feature, whereas a value of 0 that it did not. 
The frequencies of particular ToxPrint chemotypes (i.e. the number of “matches” 
between ToxPrint chemotypes and the query structures) have been investigated. The 
structural domains of the analysed inventories were presented in terms of distributions of 
the compounds across specified generic structural classes.  
3.3.4. Analysis of physicochemical properties  
The physicochemical properties space covered by the two inventories was 
investigated using diverse types of molecular descriptors. Therefore, this part of the analysis 
required pre-processing of original “2D-tested” files and generating 3D-computational 
structures. All these steps, as well as descriptors calculations, were conducted in the Corina 
Symphony software tool (Molecular Networks GmbH, Nüremberg, Germany). 
The salts and IOM compounds identified through the material type and composition 
type annotations (section 2.4.1) have been excluded from investigation. The input files 
containing only organic compounds were pre-processed with the following options: 
desalting and small fragments removal, neutralising charged compounds, detecting and 
removing duplicate structures. Subsequently, the 3D coordinates have been generated and 
oriented according to their maximal moments of inertia. The resulting SD files (referred to 
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herein as “3D-computational” SD files) were used to calculate the “global molecular” and 
“size and shape” descriptors in Corina Symphony. 
The data matrix containing (n) rows corresponding to the chemical compounds and 
(m) columns corresponding to the calculated descriptors was subsequently used as input in 
the Principal Components Analysis (PCA) performed in the JMP Pro 12.2.0 software tool 
(JMP, SAS Institute Inc.). For m standardised original variables (transformed to have zero 
mean and unit variance), m PCs were calculated. The first PC was the linear combination of 
the standardised original variables that had the greatest possible variance. Each subsequent 
PC was the linear combination of the variables that had the greatest possible variance and 
was uncorrelated with all previously defined components. The PCs explaining the large 
portion of variance in the analysed datasets and having the eigenvalues >1 were considered 
in the final analysis. Their scores were projected into 3D plots to visualise the 
physicochemical properties space. The most influential properties were identified. 
3.4. Results 
3.4.1. COSMOS Cosmetics Inventory – use functions analysis 
The COSMOS Cosmetics Inventory was characterised with respect to the 66 chemical 
use functions from the EU COSING database. The Cosmetics Inventory is very diverse, with 
the majority of its constituents associated with multiple (up to 18) functions (for 72% of 
Cosmetics Inventory compounds up to three functions have been reported). The most 
populated use functions include skin protection and skin conditioning agents, surface-active 
agents (surfactants, emulsifiers, emulsion stabilisers, foaming agents and foam boosters), 
perfuming agents, and hair fixing and conditioning substances (Figure 3.3). The most 
populated use functions in the cosmetics domain have been further characterised with 
respect to their structural features and physicochemical properties in the following sections 
of this chapter. 
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Figure 3.3 
The most populated COSING use functions in the COSMOS Cosmetics Inventory 
3.4.2. Structural (chemotypes) space analysis  
The structural features (ToxPrint chemotypes) analysis was performed for cosmetics 
related compounds from the COSMOS Cosmetics Inventory (5,562 compounds) and food 
related compounds from the U.S. FDA CFSAN PAFA (4,337 compounds). The overlap 
between the two inventories (on the basis of the CMS IDs and InChI Keys generated for “2D-
tested” structures) is presented in Figure 3.4.  
 
Figure 3.4  
Venn Diagrams demonstrating the overlap between the COSMOS Cosmetics Inventory and food 
related compounds from the U.S. FDA CFSAN PAFA:  
(A) The inventories were compared by CMS IDs of compounds with available structures; 1,773 
(out of 8,126) compounds appeared in both inventories; 3,552 was found only in COSMOS 
Cosmetics Inventory; 2,429 – only among PAFA members; 
(B) The original (not processed) 2D structures from both inventories were compared by the 
InChI Keys. A total of 7,509 unique InChI Keys was present in both inventories (the 617 
structural duplicates resulted from using representative structures; please refer also to Table 
2.4); 1,725 InChi Keys were common in both inventories  
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The structural domain of both inventories was covered by a total number of 553 (out 
of 729) ToxPrint chemotypes indicating a very sparse structural space. The overlap between 
structural features identified in each individual inventory (Figure 3.5) is large: 455 out of 553 
ToxPrint chemotypes appeared in both the COSMOS Cosmetics Inventory and PAFA. 
However, due to distinctive use functions of cosmetics- and food-related compounds, 
several features appearing exclusively in only one of the inventories were also observed 
(Figure 3.5). For instance, organotin compounds (appearing in food contact materials) and 
dithiocarbamates (food contact substances, antimicrobials, food direct additives) were 
found only in PAFA, whereas several transition metals (used as preservatives, buffers or 
antimicrobials), metals from group III of periodic table (cosmetics colorants, hair dyes, 
antiperspirants, deodorants, also buffering and chelating agents), certain carbohydrates 
(skin conditioning, surface active agents, antioxidants), purine/adenine (skin conditioning), 
or polyethylene glycols with >10 ethylene oxide (EO) units (surface-active agents) were 
present only in the inventory of cosmetics related compounds. 
 
Figure 3.5 
Venn diagram showing the overlap of ToxPrint chemotypes between the two investigated 
inventories 
Both analysed inventories had similar proportions of acyclic carboxylic esters, 
aromatic carboxylic acids, halides, aromatic aldehydes, aliphatic ketones, benzyl alcohols, 
and heterocyclic rings (Figure 3.6).  
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Figure 3.6 
The structural classes (ToxPrint chemotypes) uniformly distributed between the two investigated 
inventories expressed as ratios of % frequencies (the actual counts of each feature are given on the 
plot’s bars) 
The structural classes appearing more frequently among cosmetics- than food-
related compounds are presented in Figure 3.7. They include: polyethylene glycols, 
quaternary ammonium salts, organosilicons, long chain linear and branched alkanes and 
diethanolamines (i.e. the classes characteristic for surface active agents), primary, 
secondary, and tertiary aromatic amines, nitro- and azo- aromatic compounds (specific for 
cosmetics colorants and hair dyes, i.e. relatively reactive compounds that would not be 
associated with food), cyclic/heterocyclic and fused rings (present predominantly in 
perfuming agents).  
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Figure 3.7  
The general structural classes (presented as ratios of the total frequencies of ToxPrint chemotypes) 
identified more frequently in COSMOS Cosmetics Inventory than in PAFA inventory of food related 
compounds (the actual counts of each feature are given on the plot’s bars) 
The structural features more characteristic of food-related compounds include 
sufides, disulfides, sulfhydrides, thio- carboxylic esters, thiophenes, furans and pyrazines 
(flavoring agents and food direct additives), as well as phosphites, phosphine oxides, acyl 
and alkyl halides, isocyanates and acid anhydrides (food contact materials) (Figure 3.8). 
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Figure 3.8 
The general structural classes (presented as ratios of the total frequencies of ToxPrint chemotypes) 
identified more frequently in PAFA inventory of food related compounds than in the COSMOS 
Cosmetics Inventory (the actual counts of each feature are given on the plot’s bars) 
3.4.3. Physicochemical properties space analysis 
The physicochemical properties space occupied by COSMOS Cosmetics Inventory 
and food-related compounds from PAFA was analysed with 14 (Table 3.4) Corina Symphony 
“global molecular” and “size and shape” descriptors (Molecular Networks, Nüremberg, 
Germany). They were calculated for 5,664 3-dimensional computational structures (3,935 
cosmetics- and 3,022 food-related compounds) generated after:  
 Removing IOM compounds (997 from COSMOS Cosmetics Inventory and 1,068 from 
PAFA);  
 Removing small fragments (in 705 compounds from COSMOS Cosmetics Inventory 
and 309 from PAFA);  
 Neutralising charged fragments (in 343 compounds from COSMOS Cosmetics 
Inventory and 157 from PAFA);  
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 Removing duplicates (630 from COSMOS Cosmetics Inventory and 247 from PAFA).  
The overlap between the two final structure files is presented in Figure 3.9. 
 
Figure 3.9 
Venn Diagram demonstrating the overlap between COSMOS Cosmetics Inventory and food related 
compounds from the U.S. FDA CFSAN PAFA – comparison by unique InChI Keys generated for 3D-
computational structures 
Table 3.4 
CORINA Symphony (Molecular Networks GmbH, Nüremberg, Germany) descriptors utilised in 
chemical space analysis. 
GLOBAL MOLECULAR PROPERTIES 
Number of open-chain, single rotatable bonds (BondsRot) [unitless] 
Number of hydrogen bonding acceptors derived from the sum of nitrogen and oxygen atoms in the molecule 
(H-Acc) [unitless] 
Molecular weight derived from the gross formula (MW) [Da]  
Octanol/water partition coefficient of the molecule following the XlogP approach (Log P) [unitless]  
McGowan molecular volume approximated by fragment contributions (McGowan) [mL/mol] 
Topological polar surface area of the molecule derived from polar 2D fragments (TPSA) [Å2] 
Mean molecular polarisability of the molecule (Polariz) [Å3] 
SHAPE DESCRIPTORS 
Molecular diameter – maximum distance between two atoms in the molecule (Diameter) [Å] 
Molecular eccentricity (Eccentric) [unitless] 
Molecular radius of gyration (Rgyr) [Å] 
Molecular span – radius of the smallest sphere centred at the centre of mass which completely encloses all 
atoms in the molecule (Span) [Å] 
Principal moment of inertia of 1st principal axis (InertiaX) [Da∙Å²] 
Principal moment of inertia of 2nd principal axis (InertiaY) [Da∙Å²] 
Principal moment of inertia of 3rd principal axis (InertiaZ) [Da∙Å²] 
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The Principal Components Analysis reduced the dimensions of 14 molecular 
descriptors to 3 representative PCs. The three PCs described a total of 89.73% of the 
variance in the defined chemical space. The scree plot (i.e. the plot of eigenvalues vs 
number of PCs) and variance explained by each PC are presented in Figure 3.10) 
 
Figure 3.10 
Scree plot and % variance explained by each calculated Principal Component. The PCs with 
eigenvalues >1 were considered. The plot was prepared in JMP Pro 12.2.0 software tool (JMP, SAS 
Institute Inc.) 
The scores of the 3 PCs were used to generate 3D score plots (Figure 3.11) visualising 
the physicochemical properties space occupied by the compounds investigated.  
 
Figure 3.11 
The 3D score plots visualising the physicochemical properties space of COSMOS Cosmetics Inventory 
and the U.S. FDA CFSAN PAFA database covered by the three PCs explaining 89.7% of the cumulative 
variance in both inventories (A). 
Due to the large number of plotted compounds, additional plots were included: (B) Highlighted 
COSMOS Cosmetics Inventory compounds; (C) Highlighted compounds present in both, cosmetics 
inventory and PAFA; (D) Highlighted food-related compounds from the U.S. FDA CFSAN PAFA 
database. The plots were prepared in JMP Pro 12.2.0 software tool (JMP, SAS Institute Inc.) 
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The most influential properties associated with each PC are presented in Figure 3.12. 
The descriptors related to the flexibility of the molecules (BondsRot), their size and shape 
(MW, McGowan Diameter, Inertia, Rgyr, Span), as well as to the hydrophobicity/lipophilicity 
(logP) had the most significant impact on PC1. Topological polar surface area and the 
hydrogen-bonding (H-Acc) related properties had the highest loadings on the PC2. The 
descriptors related to the size and shape of the molecules (Eccentric, InertiaX) were the 
most significant in the PC3 (Figure 3.12). 
 
Figure 3.12 
The loading bar plots for the three Principal Components characterising physicochemical space 
occupied by the cosmetics- and food- related compounds. The properties with loadings above (or 
close to) 0.7 were considered the most influential 
The 3D PCs score plot (Figure 3.11) demonstrates that physicochemical properties 
space covered by cosmetics- and food- related compounds is very sparse and similar in 
shape. It indicates that both inventories cover a broad and similar range of values of utilised 
descriptors. This is not unexpected, considering a diversity of structural classes identified 
(3.4.2). The results of this analysis however suggest that the physicochemical properties 
utilised do not have sufficient power to discriminate between both inventories when 
applied alone and that structural features analysis is necessary to identify the differences 
between cosmetics- and food- related compounds. 
As discussed in sections 3.4.1 and 3.4.2, the COSMOS Cosmetics Inventory is very 
diverse and includes cosmetics ingredients associated with multiple use functions. The most 
Chapter 3 
54 
 
populated use categories were therefore projected in the physicochemical properties space 
defined by PC1-PC3 (Figure 3.13). It became apparent that the compounds representing 
different use functions occupy very distinct regions represented by unique properties and 
are associated with specific structural features (section 3.4.2).  
 
Figure 3.13 
Projection of the most populated COSING use functions on the 3D score plot visualising the 
physicochemical properties space of analysed inventories of compounds. The plots were prepared in 
JMP Pro 12.2.0 software tool (JMP, SAS Institute Inc.) 
 3.5. Discussion 
The chemical space of the COSMOS Cosmetics Inventory was analysed and compared 
with the chemical space of food-related compounds from the U.S. FDA CFSAN PAFA 
database. The novel approach of the ToxPrint chemotypes was used to determine the 
structural domains of each inventory. Subsequently, the associations between structural 
features, physicochemical properties, and use functions (with detailed applications within 
cosmetics domain) were identified. 
It was demonstrated that cosmetics- and food- related chemicals cover sparse, but 
similar in shape, chemical space. The structural domain of both inventories was captured by 
a large number of 553 (out of 729) ToxPrint chemotypes, indicating a large variety of the 
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occurring structural classes. This diversity was reflected also in the broad ranges of the 
values covered by investigated physicochemical properties.  
Both inventories analysed are broadly represented by carboxylic esters, aromatic 
carboxylic acids, halides, aromatic aldehydes, aliphatic ketones, benzyl alcohols, and 
heterocyclic rings. Several differentiating characteristics were also identified. The structural 
classes dominating among cosmetics-related compounds were associated with specific use 
functions and manifested through distinct physicochemical properties. Surfactants, 
emollients (softening and smoothing the skin) and humectants (holding and retaining the 
moisture) were particularly rich in carboxylic esters, polyethylene glycol esters, ethoxylated 
aliphatic alcohols, diethanolamines (DEA) and carboxamides (specific for nonionic 
surfactants), carboxylates and alkyl sulfates (anionic surfactants), quaternary ammonium 
salts (cationic surfactants), carbohydrate-based structures and long, linear and branched 
alkanes and alkenes. Perfuming agents included mostly aliphatic, cyclic and aromatic 
ketones, aldehydes, alcohols, diols, ethers and carboxylic acids, alkanes (aromatic with 
predominantly short C2-C4 chains attached to phenyl rings and aliphatic with short C2-C4 
chains), compounds with polycyclic rings, and heterocyclic compounds with 3- (e.g. 
epoxides), 5- (e.g. oxolanes, pyrroles), 6- (e.g. pyranes) and 7-membered (e.g. oxepins) rings. 
The compounds used as cosmetics colorants and hair dyes were widely represented by 
aromatic and aliphatic amines, azo- compounds, nitro- compounds (multiple nitro- aromatic 
amines and nitro- benzenes), compounds with fused (naphthalene, indane, phenanthren, 
pyrene) and hetero- aromatic rings. The structural features characteristic for the food 
related compounds included sufides, disulfides, sulfhydrides, thio- carboxylic esters, 
thiophenes, furans and pyrazines, occurring mostly in in flavoring agents and food direct 
additives, as well as phosphites, phosphine oxides, acyl and alkyl halides, isocyanates and 
acid anhydrides abundant among food contact substances. 
The results of the present analysis demonstrate the utility and relevance of the novel 
methodology (ToxPrint chemotypes- and physicochemical properties-based) for the analysis 
of the chemical space occupied by large inventories of compounds. It allowed for 
identification of the differences between various use classes in the cosmetics domain, 
suggesting the need to treat them separately during computational modeling (i.e. 
development of different models and/or using different modelling approaches for different 
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groups). The fact that the analysis performed revealed differences between different use 
functions of cosmetics ingredients indicates the usefulness of this approach for chemical 
design and toxicity prediction as well as for read-across and category formation.  
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Chapter 4 
The COSMOS Skin Permeability Database: Harvesting, Curating and Quality Control of the 
Data 
4.1. Background 
4.1.1. Measurement of skin permeability  
Skin permeability is a complex biological and physicochemical process involving the 
transport of chemicals from the outer surface of the skin to the systemic circulation. The 
amount of a chemical penetrating the skin at a given time determines whether the chemical 
can potentially be bioavailable (i.e. absorbed into the systemic circulation) and, as such, 
exert toxicity after topical exposure (it should be noted that systemic absorption can be 
preceded by metabolic transformation(s) of a substance within the deeper layers of the 
viable skin). The mechanistic and physicochemical basis of skin permeability/absorption as 
well as multiple factors influencing its rate is described in more detail in chapter 5. 
Experimental measurement of dermal penetration/absorption can be conducted 
both in vivo and in vitro. It should be noted that since the implementation of recent EU 
legislation (EC, 2009), the testing of new cosmetic ingredients in vivo has been prohibited. 
Historically, no standardised experimental protocols for any type of dermal penetration 
testing were formulated. Early in vitro models were not associated with any formal 
validation program (numerous in-house procedures were used in industry and academia). It 
took several decades to publish formally agreed guidelines, however the documents (Table 
4.1) remain broad in nature and do not endorse specific protocols or protocol components 
(Brain et al., 2005).  
Due to the historical lack of standard testing procedures to measure skin 
permeability, and the plethora of factors influencing the permeability/absorption process 
(e.g. species, sex, application site, dosage regimen, vehicle, occlusion, etc.; please refer also 
to chapter 5), experimental results are highly variable (Brain et al., 1995; Walters et al., 
1997; van de Sandt et al., 2004). This presents a major challenge to the development of 
computational tools, as data variability is related to a decrease in the statistical validity of 
the models developed. The lack of accuracy of the experimental values together with errors 
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across different datasets contributes to the paucity of high quality data for skin 
permeability/absorption modelling. 
Table 4.1 
Overview of the test guidelines and other relevant documents available for the measurement 
of skin permeability/absorption  
Test method Available guidelines and documents 
In vivo 
o EC Test Method B.44: Skin Absorption: In Vivo Method (EC, 2008) 
o OECD Test Guideline 427: Skin Absorption: In Vivo Method (OECD, 2004a) 
o WHO Environmental Health Criteria 235: Dermal Absorption (WHO, 2006) 
o EFSA Guidance on Dermal Absorption (EFSA, 2012) 
In vitro 
o EC Test Method B.45: Skin Absorption: In Vitro Method (EC, 2008) 
o OECD Test Guideline 248: Skin Absorption: In Vitro Method (OECD, 2004b) 
o WHO Environmental Health Criteria 235: Dermal Absorption (WHO, 2006) 
o Basic Criteria for the In Vitro Assessment of Dermal Absorption of Cosmetic 
Ingredients (SCCS, 2010) 
o EFSA Guidance on Dermal Absorption (EFSA, 2012) 
 
4.1.2. The COSMOS Skin Permeability Database 
For over a decade the necessity of construction of an accurate, well-curated skin 
permeability database has been recognised. The European Union project “Evaluations and 
Predictions of Dermal Absorption of Toxic Chemicals” (EDETOX), coordinated by the 
University of Newcastle, UK (Project Number: QLKA-2000-00196) was a three-year initiative 
launched in 2000, which aimed to address the need for a comprehensive database of skin 
permeability values. One of the outcomes of this project was the EDETOX database (publicly 
available at: http://edetox.ncl.ac.uk/), containing in vitro and in vivo percutaneous 
absorption/penetration studies recorded for 320 chemicals from the published literature. 
The EDETOX database provides information on the following skin absorption/permeability 
parameters: percentage of dose absorbed, percentage of dose recovered, maximal flux, 
permeability coefficient, and lag time, wherever available (please refer to chapter 5 for 
definitions of these parameters). Although being a valuable resource of experimental data 
on skin permeability/absorption, the EDETOX database alone did not contain sufficient 
information on cosmetics ingredients and related chemicals to meet the needs of modellers 
in this area (specifically in the COSMOS project). Only about 35% of the substances in the 
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EDETOX database could be considered cosmetics-related, as they have been also found in 
the COSMOS Cosmetics Inventory. 
A database was donated to the current data gathering initiative by Dr Taravat 
Ghafourian from the Medway School of Pharmacy, University of Kent, Chatham, UK, whose 
contribution is gratefully acknowledged. This database is referred to herein simply as “the 
Kent database”. It was compiled as an update of the EDETOX database after the exhaustive 
survey of over 1,800 recent (2001-2010) literature publications (Samaras et al., 2012). 
Although it includes human skin absorption/permeability data from in vitro experiments for 
a total number of 254 compounds, it again lacks information on cosmetics ingredients and 
related compounds, as its focus was placed mostly on pharmaceuticals. 
The COSMOS Skin Permeability Database was therefore developed to address all of 
the above issues (please refer to Annex 1). On one hand, a database consolidation approach 
was applied for existing data i.e. the merging of the EDETOX and Kent databases. On the 
other, new data were harvested from a range of regulatory and literature sources. In 
particular, the main emphasis was placed on harvesting skin permeability data published 
after the completion of the EDETOX database. Concerns over the accuracy of data were 
minimised by establishing a consistent procedure for data curation and quality control. 
4.1.3. General aspects of the quality of biological data 
The quality of any biological data incorporated into a structured database depends 
on many complex aspects, but the most essential are the reliability of the data record and 
the data acceptance, both of which are described below. 
4.1.3.1. The reliability of the data record  
The data reliability refers to the accuracy of database records with respect to the 
original data and to the completeness of the original data with regard to the relevant 
guidelines. Guideline studies, i.e. the studies that have been performed in compliance with 
the protocols specified by internationally accepted documents, e.g. OECD Guidelines for the 
Testing of Chemicals, are usually conducted according to the Good Laboratory Practice (GLP) 
Regulations (e.g. OECD, 1998) (the exceptions are the guideline studies pre-dating the GLP 
regulations). GLP defines a set of principles for planning, performing, monitoring, recording, 
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reporting and archiving laboratory studies. Guideline, GLP-compliant studies are usually 
considered to be of high reliability. 
The reliability of the data record can be assessed algorithmically at the time of the 
data entry. Each toxicity database defines a set of specific study inclusion criteria, i.e. the 
characteristics that the toxicological study must have in order to be included in the database 
(accordingly, the exclusion criteria would be the characteristics disqualifying the study from 
being included in the database, e.g. missing information on the test species). Compliance of 
the data records with the database inclusion criteria can be used to score the data for 
reliability. The study inclusion criteria play a particularly significant role in case of toxicity 
studies which have not followed any formal guideline document(s), i.e. non-guideline 
studies (e.g. old studies preceding the guideline documents). Often, when qualified 
according to the database-specific inclusion criteria (usually less stringent than the formal 
guideline requirements), such studies can be considered as a usable source of information.  
Further, data accuracy can be assessed by the database Quality Control (QC) process 
and evaluated statistically by the Quality Assurance (QA) process (as defined in chapter 2). 
4.1.3.2. Data acceptance 
Data acceptance addresses the issues of the interpretability and relevance of data 
with respect to a particular purpose. The accuracy and completeness of recorded 
information does not implicitly ensure that this information leads to appropriate 
conclusions. Thus, acceptance is a more subjective, and a more difficult to quantify, aspect 
of data quality as it has to be evaluated by toxicologists with regard to a specific scientific 
question. 
4.1.3.3. The Klimisch scoring system for data quality assessment 
An example of a broadly applied (e.g. by ECHA) method of ascertaining the quality of 
biological data is the scoring system devised by Klimisch et al. (Klimisch et al., 1997). The 
Klimisch scheme, originally devised to evaluate the quality of fish acute toxicity data has 
been expanded and is currently applied to all toxicity endpoints. Klimisch and co-workers 
recognise three aspects of biological data quality: reliability, relevance and adequacy. With 
respect to the data reliability, the Klimisch score system has been developed to assign 
toxicity data into one of four categories (Table 4.2). 
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Table 4.2 
The Klimisch score system (from Klimisch et al., 1997) 
Data quality 
aspect 
Definition 
Reliability Evaluating the inherent quality of a test report or publication relating to preferably 
standardised methodology and the way the experimental procedure and results are 
described to give evidence of the clarity and plausibility of the findings. The following 
categories can be distinguished: 
(1) reliable 
without 
restrictions 
“Studies or data from the literature or reports which were carried out 
or generated according to generally valid and/or internationally 
accepted testing guidelines (preferably performed according to GLP) 
or in which the test parameters documented are based on a specific 
(national) testing guideline (preferably performed according to GLP) or 
in which all parameters described are closely related/comparable to a 
method.” 
(2) reliable with 
restrictions 
“Studies or data from the literature, reports (mostly not performed 
according to GLP), in which the test parameters documented do not 
totally comply with the specific testing guideline, but are sufficient to 
accept the data or in which investigations are described which cannot 
be subsumed under a testing guideline, but which are nevertheless 
well documented and scientifically acceptable.” 
(3) not reliable “Studies or data from the literature/reports in which there were 
interferences between the measuring system and the test substance 
or in which organisms/test systems were used which are not relevant 
in relation to the exposure (e.g. unphysiologic pathways of 
application) or which were carried out or generated according to a 
method which is not acceptable, the documentation of which is not 
sufficient for assessment and which is not convincing for an expert 
judgment.” 
(4) not 
assignable 
“Studies or data from the literature, which do not give sufficient 
experimental details and which are only listed in short abstracts or 
secondary literature (books, reviews, etc.).” 
Relevance Covering the extent to which data and/or tests are appropriate for particular hazard 
identification or risk characterisation. 
Adequacy Defining the usefulness of data for hazard/risk assessment purposes. When there is more 
than one set of data for each effect, the greatest weight is attached to the most reliable 
and relevant one. 
 
The controversial point of the Klimisch scoring system is the term “restriction” in the 
categories of data quality, as it mixes the paradigms of data record reliability and 
acceptance by requiring human expert judgements. 
4.1.4. Data record reliability in the COSMOS skin permeability database 
The study inclusion criteria (please refer to section 4.1.3.1 for the definition of the 
term inclusion criteria) of the COSMOS Skin Permeability Database were established with 
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respect to its data model, which was defined by the experimental protocols of the in vitro 
and in vivo dermal permeability/absorption tests available from the EDETOX database and 
described by the OECD test guidelines (OECD, 2004a; OECD, 2004b). The study inclusion 
criteria of the EDETOX database required the following information types to be clearly 
provided in the source publications: chemical concentration (concentration of chemical 
applied), dose volume (volume of chemical applied to the skin), loading (amount of chemical 
added per unit area), area (area of skin to which the chemical was applied), vehicle 
(application medium), species (species of animal used in the study), exposure time (length 
of time the chemical was left on the skin), analytical method (method by which the results 
were determined), receptor fluid (medium that bathes the underside of the skin) and 
temperature (temperature of the receptor fluid/skin/water bath during in vitro 
experiments). 
The COSMOS Skin Permeability Database data model (Figure 4.1) was designed with 
respect to both in vitro and in vivo percutaneous penetration/absorption studies. The 
following information types have been specified for in vitro experiments: 
 The test system details on skin donor (species, strain, sex, age/weight at the time of 
skin harvesting, number of donors) and skin membrane (membrane type, thickness, size 
and storage, site from which the skin was obtained); 
 The test conditions, including the dosage details (vehicle, receptor solutions, dose 
levels, exposure time, etc.) and diffusion parameters (diffusion cell types and size, bath 
and mounted membrane temperature, flow value, etc.); 
 The study results for skin permeability/absorption parameters (lag time, steady-state 
flux, absorption – as total amount and/or % of dose absorbed permeability coefficient) and 
recovery (i.e. amounts and/or % of dose recovered from particular skin layers and receptor 
fluid, also washed from the skin surface and remaining on the diffusion cell material). 
The criteria relevant to in vivo experiments include:  
 The test system details on the test animals (species, strain, sex, age/weight at the 
study initiation, number of animals) and dosed sites (site and site area); 
 The test condition details on dosage regimen (dose application method, dose 
delivery type, e.g. single or repeated dose, vehicle, dose levels, exposure duration, etc.); 
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 The results for skin permeability/absorption parameters (lag times, maximal flux, 
total amount (and %) of test substance absorbed, permeability coefficient), 
distribution/elimination of the test material (i.e. the amount or % of dose identified in 
particular skin layers, blood, excreta, carcass, etc. after euthanising the test animals), and 
recovery (the amount or % of dose recovered).  
The majority of the study parameters have been represented by the controlled 
vocabulary. 
 
Figure 4.1 
The entities and their relationships of the Skin Permeability Database data model 
4.2. The aims of chapter 4 
The biological data needs to achieve the goals of the COSMOS project were 
discussed in 1.4. Skin permeability data were identified as one of the essential elements of 
the COSMOS database. The aims of the present chapter realised in collaboration with the 
partners of the COSMOS project (please refer to Annex 1) are related to the objective 3 of 
the current PhD program (section 1.5) and include: 
 Curation and integration of existing skin permeability/absorption data sources, 
namely the EDETOX and Kent databases; 
 Development of the SOP for the harvesting of new data; 
 Harvesting new skin permeability data for cosmetics ingredients and related 
compounds from regulatory and literature sources according to the developed SOP; 
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 Integration of the newly harvested data with the EDETOX and Kent content; 
 Preparation of data entry tool for QC of the COSMOS Skin Permeability Database. 
4.3. Materials and methods 
4.3.1. Data sources 
New data harvesting was performed by six COSMOS consortium partners (Altamira, 
BAS, U.S. FDA, S-IN, LJMU, and Molecular Networks; Please refer also to Annex 1). The focus 
was placed on high priority compounds from the COSMOS Cosmetics Inventory, i.e. the 
compounds for which oral repeated dose toxicity data had been identified, but for which 
the information on dermal permeability/absorption was missing. The following data sources 
were used: 
 The European Commission Scientific Committee on Consumer Safety (EU SCCS) 
opinions on cosmetic ingredients, available at: 
https://ec.europa.eu/health/scientific_committees/consumer_safety_en; 
 The European Chemicals Agency (ECHA) Registered Substances database: 
https://echa.europa.eu; 
 Other relevant data sources: For cases where ECHA or SCCS opinions referenced an 
unpublished report as the original data source, the information provided in the ECHA or 
SCCS opinion was harvested. However, if the original source of data was a scientific 
publication or a book chapter, the original data source was consulted. 
4.3.2. Curation and integration of existing databases 
The EDETOX content was imported into a Microsoft Access database for further use 
as the COSMOS Skin Permeability Database. In order to merge it with the Kent database, 
curation and quality control of original Kent records was necessary. Curation was performed 
by Altamira/LJMU (Annex 1). 
4.3.3. New data harvesting: data entry tool and data entry process 
The data harvesters were provided with a data entry tool in the form of .xls file with 
several tables corresponding to the COSMOS Skin Permeability Data Model (section 4.1.4), 
prepared by Altamira/LJMU (Annex 1). In order to test the relevance of the .xls data entry 
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tables, two cycles of the pilot data harvesting were conducted prior to the launch of the 
final procedure. The pilot studies were accomplished successfully and provided a plethora of 
valuable information on how to improve the .xls tables to make the data entry process more 
convenient (for instance, the fields for recording specific activity value and unit of 
radiolabeled test substances were added). 
The final data harvesting was performed according to the Standard Operating 
Procedure (SOP) which was prepared by Altamira/LJMU (Annex 1). The data entry tool 
consisted of eleven .xls tables. Controlled vocabularies were distributed in the form of drop-
down pick lists and, along with the full SOP document, are provided in Annex 4. The details 
of the data entry procedure are summarised in Figures 4.2-4.3, using 1,3-phenylenediamine 
(CMS-1149, CAS RN: 108-45-2) as an example. This compound has been tested in vitro (the 
EU ECHA database has been harvested) and in vivo (the data from the scientific publication 
were harvested). 
After finalising the data harvesting process, the results from each participating 
COSMOS partner were combined and integrated with the content of EDETOX and Kent 
databases by Altamira LLC (Annex 1). 
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Figure 4.2 
An illustration of the .xls data entry tables for skin permeability/absorption data harvesting (part 1): 
Chemistry (identification of the compound in the COSMOS database); StudySubstance (information 
on the tested substance, e.g. radiolabeling, tested form); StudyInfo (data quality related 
information), StudyReference (data origin); Metabolites (metabolism information, if available); and 
two tables related to the test system, namely TestAnimal and TestSkin. The fields marked in red 
refer to those controlled by vocabulary that have been not subjected to any changes, whereas the 
fields marked in green are those that were extended during the data harvesting 
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Figure 4.3 
An illustration of the .xls data entry tables for skin permeability/absorption data harvesting (part 2): 
TestDose (dosing conditions for each study – one study may be associated with multiple dose 
groups); TestDiffusion (details about the diffusion system utilised – applicable only for in vitro 
studies); TestResults (permeability/absorption parameters and distribution in blood/excreta/carcass, 
etc., in case of in vivo studies), TestRecovery (dose recovery information). The fields marked in red 
refer to those controlled by vocabulary that have been not subjected to any changes, whereas the 
fields marked in green refer to those that were extended during the data harvesting 
4.3.4. The quality control of COSMOS Skin Permeability Database 
During the data harvesting procedure, the data quality issues were addressed by 
recording the Klimisch scores and information about the compliance of the studies with the 
OECD guidelines (and GLP). This information was retrieved from the original data sources, 
i.e. EU ECHA and SCCS. As a first step, the record reliability and accuracy of the data 
harvested were reviewed manually (without any tools) at the stage of integrating new data 
with the EDETOX/Kent content. 
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Further, the QC of the COSMOS Skin Permeability Database content was performed 
by the COSMOS Expert Group (EG) coordinated by the International Life Sciences Institute-
Europe (ILSI-Europe), including experts in this area: Prof. Mark Cronin (LJMU, Liverpool, UK), 
Dr Chihae Yang (Altamira LLC), Prof. Faith Williams (University of Newcastle, Newcastle, UK), 
Dr Nancy Monteiro-Riviere (Kansas State University, Manhattan, KS), Dr Gordon Barrett 
(Health Canada), Dr Miriam Verwei (TNO), Dr James Plautz (DSM Nutritional Products, Ciba, 
Inc., Switzerland) whose contribution is acknowledged. During this process, the experts also 
contributed additional information relating to skin metabolism to the database. 
Approximately 5% of compounds comprising the COSMOS Skin Permeability Database were 
subjected to the QC. The experts were provided with the .xls QC entry tables prepared by 
Altamira/ LJMU (with collaboration with the U.S. FDA; Please refer to Annex 1). The 
template for the COSMOS Skin Permeability QC tables is presented in Figure 4.4. The QC 
comments from the Expert Group were processed and incorporated into the final database. 
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Figure 4.4 
The template of the COSMOS Skin Permeability QC tables 
4.4. Results 
In order to address the general lack of publically available, good quality skin 
permeability/absorption data for cosmetics and related compounds, the COSMOS Skin 
Permeability Database was developed. Existing data (EDETOX and Kent databases) were 
integrated with newly harvested ones. 
The EDETOX database provided a total number of 1,657 records for in vitro studies 
(244 unique chemicals) and 844 records for in vivo studies (156 unique chemicals) for 297 
unique chemicals (126 cosmetics-related). It was combined with 999 records from the 
curated Kent database containing: 
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 436 updated studies for 156 compounds already present in EDETOX;  
 563 new studies for 128 compounds (88 new compounds and 40 already included in 
EDETOX. Out of those 88 new chemicals, only 16 were cosmetics-related). 
The COSMOS data harvesting effort contributed 268 in vitro studies (for 85 
compounds) and 159 in vivo studies (for 48 compounds) to the Skin Permeability Database. 
In total, 103 cosmetics-related compounds were harvested (99 new compounds and 4 
already present in the database).  
Thus, the final COSMOS Skin Permeability Database contains 484 unique chemical 
compounds for which 2488 in vitro and 1003 in vivo studies have been recorded (Figure 4.5). 
  
Figure 4.5 
COSMOS Skin Permeability Database: Final content with respect to the data origin  
The COSMOS Skin Permeability Database mostly contains defined organic 
compounds (only 24 do not fall into this category, please refer to the Table 4.3). 
Approximately 46% of its content was in common with the COSMOS Cosmetics Inventory. 
With regard to the EU COSING database use functions (Annex 3), the most populated 
cosmetics-related chemicals in the Skin Permeability Database include perfuming agents, 
antimicrobials, preservatives, antioxidants, colorants and hair dyes, skin and hair 
conditioning agents, surfactants and emulsifiers, moisturisers, emollients and humectants, 
and UV filters/absorbers. They cover a broad range of chemical classes, mostly alcohols, 
carboxylic esters, glycol ethers and parabens. 
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Table 4.3 
COSMOS Skin Permeability Database constituents: composition and material types  
Composition type Material type # compounds 
Defined formula IOM 13 
Defined formula Organic 452 
Defined formula – varying isomers IOM 2 
Defined formula – varying isomers Organic 8 
Ill-defined formula Organic 3 
Ill-defined formula – polydispersed Organic - polymer 5 
Ill-defined formula – polydispersed – varying isomers Organic - polymer 1 
TOTAL 484 
 
As far as experimental data content is concerned, a range of species (human, pig, rat, 
mouse, rabbit, minipig, guinea pig, dog, monkey, marmoset, snake), in vitro membrane 
types (dermis, epidermis, stratum corneum, full- and split-thickness skin and artificial 
membranes), in vivo application sites (abdomen, breast, back, scalp, leg, arm, etc.), and 
vehicles were included. The results recorded included flux, absorption, permeability 
coefficient and recovery data. The detailed statistics are presented in Table 4.4 and Figures 
4.6-4.9.  
Information on the distribution (in blood, plasma, carcass, or other organs and 
tissues) and elimination (via urine, faeces, exhaled air, etc.) was retrieved for over 40 
compounds tested in more than 100 in vivo studies. In addition, information regarding skin 
metabolism was captured for 12 cosmetics-related compounds, including information on 
the metabolites identified in skin or eliminated after dermal applications, enzymes and 
probable pathways. 
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Table 4.4 
Statistics of the COSMOS Skin Permeability Database for human, pig, rat and mouse studies 
Species Membrane Type Main Application Site 
Main Vehicle for 
reported species 
In vitro studies (2488) 
Human (1206) 
Epidermis (516) Abdomen; Back; Breast (432) 
Water (264); Neat (149); 
Formulation (68) 
Split-Thickness Skin (404) 
Abdomen; Arm; Breast; Leg 
(302) 
Full-Thickness Skin (223) Abdomen; Breast (194) 
Stratum Corneum (19) Abdomen (18) 
Pig (226) 
Split-Thickness Skin (186) Back (145) Ethanol (69); 
Formulation (25); 
Acetone (20) Full-Thickness Skin (28) Ear (9); Back (5) 
Rat (502) 
Full-Thickness Skin (240) Abdomen; Back (199) 
Acetone (76); Ethanol 
(52); Water (45); 
Hydrocarbon (41) 
Split-Thickness Skin (195) Back (176) 
Epidermis (47) Back (19) 
Mouse (306) Full-Thickness Skin (284) Abdomen; Back (259) 
Saline (115); Saline/ 
Aqueous Alcohol (45); 
Acetone (28) 
In vivo studies (1003) 
Human (300) Not applicable 
Arm/Axilla/Hand/Palm (210); 
Abdomen (21); Back (12) 
Acetone (129); Ethylene 
glycol/Surfactant (57); 
Aqueous Ethanol (34) 
Pig (48) Not applicable Back (27); Abdomen (14) Ethanol (31) 
Rat (394) Not applicable Back (340); Abdomen (13) 
Acetone (120); Aqueous 
Ethanol (79); 
Formulation (38); Water 
(35); Neat (31) 
Mouse (43) Not applicable Back (26) Ethanol (11); Neat (9) 
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Figure 4.6 
The in vitro flux data available in the COSMOS Skin Permeability Database, profiled with respect to 
the species, membrane types, and dominating vehicle types 
 
Figure 4.7 
The in vitro permeability coefficient data available in the COSMOS Skin Permeability Database, 
profiled with respect to the species, membrane types, and dominating vehicle types 
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Figure 4.8 
The in vitro absorption data (including the percentage and amount of the dose absorbed, whichever 
was provided) available the in COSMOS Skin Permeability Database. The data were profiled with 
respect to the species, membrane types and vehicles 
 
 
Figure 4.9 
The in vivo absorption data (including the percentage and amount of the dose absorbed, whichever 
was provided) available in the COSMOS Skin Permeability Database. The data has been profiled with 
respect to the species and vehicles 
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4.5. Discussion 
This chapter demonstrates the current demand for a database containing high 
quality skin permeability/absorption data for cosmetics and related compounds, and 
describes the collation of COSMOS Skin Permeability Database satisfying this need. The 
novel developed database, containing 2488 in vitro and 1003 in vivo studies for 484 
compounds (46% of cosmetics-related ones), can be considered a milestone towards 
estimating the human exposure to chemicals via dermal exposure for several reasons. 
The data curated from the EDETOX and Kent databases were enriched with the 
studies harvested manually from literature and regulatory sources, including SCCS opinions, 
which were not previously used for this purpose. The data harvesting procedure was 
conducted according to rigorous rules, iteratively developed and refined, as part of this 
work, ensuring consistency was maintained across the data harvesters and addressing the 
concerns with regard to data quality. These rules were captured in the SOP document 
(Annex 4), which may be consulted in the future and used to harvest additional data. 
The COSMOS Skin Permeability Database provides information on the test system 
details (skin donors, skin membranes, or test animals) and test conditions (including 
diffusion experiment parameters of in vitro studies). The available results include lag times, 
flux, absorption (total amounts and %), permeability coefficients and recovery or 
distribution/elimination information (for in vivo studies) for the test materials. The unique 
data model of the skin permeability database enables efficient data mining and fast 
identification of the studies available for particular species, membrane types, conducted 
with (or without) certain vehicles, etc. This data structure supports the computational 
modelling activities.  
The COSMOS Skin Permeability database has undergone a QC procedure performed 
by the experts from the COSMOS ILSI Expert Group, who added the information on the skin 
metabolism (pathways/steps/enzymes) for 12 cosmetics-related compounds.  
Overall, the collated COSMOS skin permeability database is the largest database for 
this endpoint, with a range of high quality data for diverse types of chemicals (including 
cosmetics), that may serve as a solid basis for computational modelling and support the 
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development of in silico tools for safety/risk assessment of cosmetics and related 
compounds. It was a foundation of the analysis discussed in the subsequent chapter. 
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Chapter 5 
Classification of Skin Permeability Potential Following Dermal Exposure to Support the 
Prediction of Repeated Dose Toxicity of Cosmetics-Related Compounds 
5.1. Background 
The safety evaluation of chemicals includes hazard characterisation and the 
assessment of potential human exposure. Human exposure to cosmetics and related 
compounds occurs primarily via the topical route. Thus, the rate and extent of the transfer 
of chemicals across the skin are of particular interest for the safety evaluation of cosmetics 
and related compounds.  
The skin is a metabolically active, living organ, which can be penetrated by chemicals 
through complex biological and physicochemical processes. The skin is also the largest organ 
of the body and, as such, may act as a main route of entry of the compound into the 
systemic circulation. The multiple factors which influence the rate of percutaneous 
permeability have been broadly reported in the literature (Elias et al., 1981; Southwell et al., 
1984; Rougier et al., 1987; Williams et al., 1992; Liu et al., 1993; Cua et al., 1995; Tsai et al., 
2003; Otberg et al., 2004; Chilcott et al., 2005; Akomeah et al., 2007). In general, they are 
associated with:  
 The variability of the structure of the skin, including inter-species differences 
(varying lipid content, thickness of the stratum corneum, number of appendageal shunts, 
etc.) and individual variations within species (age, sex, race), as well as anatomical site, 
skin condition, hydration, temperature and blood flow rate; 
 The physicochemical nature of the penetrants, i.e. the compound and its vehicle, 
including the physical state, size (molecular weight), binding properties, etc.; 
 The external conditions (experimental design, dosage regimen, etc., in case of 
laboratory studies). 
5.1.1. The structure of the skin 
The skin consists of several heterogenic structural compartments: epidermis (outer 
layer), dermis (inner layer), basement membrane (the multilayered structure at the junction 
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between epidermis and dermis), subcutis (the layer of fat and connective tissue below the 
dermis) and multiple appendages (sweat glands, hair follicles, etc.). The epidermis 
comprises about 5% of the thickness of the skin. The majority of the epidermal cells 
(keratinocytes) are formed by differentiation from one layer of mitotic basal cells (stratum 
basale). Nevertheless, several layers of epidermis (Figure 5.1) can be distinguished 
according to their cellular characteristics.  
The outermost layer of the epidermis, the stratum corneum, is the actual barrier 
protecting the body against external influences and excessive water loss. It consists of 
multiple layers of non-viable cells, corneocytes, located in the lipid matrix, essential for the 
lipid skin barrier function. The structure of the stratum corneum resembles a “brick and 
mortar system” (Michaels et al., 1975). 
 
Figure 5.1 
The structure of epidermis (adapted from WHO, 2006; Bensouilah & Buck, 2006; Menon et al., 2012; 
Van Smeden et al., 2014) 
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The dermis is a tissue of variable thickness (from 0.6 mm on the eyelids to 3.0 mm 
on the back, soles and palms), providing the nutritional support for the avascular epidermis. 
It consists of a tough, supportive fibrous protein matrix, composed of two layers: papillary 
(connecting with epidermis and build from thin collagen fibres) and reticular (including 
thicker collagen bundles). The dermis is built up from fibroblasts, producing collagen, 
elastin, structural proteoglycans and immunocompetent mast cells and macrophages. The 
blood vessels, sensory nerves (pressure, temperature, and pain) and lymphatic cells are 
located in the dermis, along with the inner segments of the sweat glands and pilosebaceous 
units. The dermis has multiple functions: it provides flexibility, strength, protection from 
infections as well as serving as a water storage organ (Bensouilah & Buck, 2006; Dancik et 
al., 2012). Derivative structures of the skin include hair, nails, sebaceous and sweat glands. 
5.1.2. Transport of chemicals through the skin  
The transport of chemicals through the skin can occur via intra- or inter-cellular 
transepidermal routes (i.e. across the stratum corneum) or through skin appendages. The 
intracellular (transcellular) route refers to the partitioning of chemicals into and out of the 
cell membrane of keratin-rich corneocytes. The intercellular process includes transfer of the 
chemicals through the lipid-rich matrix in which the corneocytes are embedded. The 
appendageal route involves the movements of chemicals through the skin appendages (hair 
follicles, sweat glands, and sebaceous glands), bypassing the corneocytes. Appendageal 
transport may be significant in particular regions of the skin, e.g. the hair-rich scalp, where 
the number of appendageal openings per unit of surface area is relatively large. In addition, 
it has been demonstrated that sebaceous glands may serve as a drug reservoir for some 
substances (Scheuplein, 1967). The transport of a chemical through the epidermis is 
followed by its uptake by the capillary network at the basement membrane 
(dermal/epidermal junction) into the cutaneous blood and lymphatic system (resorption). 
However, the chemicals can be retained in the viable epidermis, dermis, or in the subcutis if 
the blood flow is insufficient (WHO, 2006). 
The permeability of a chemical through the skin is considered to be a process of 
passive diffusion. The rate of permeability is limited by the layer within the skin with the 
highest resistance to diffusion. The stratum corneum is, most commonly, the primary rate-
limiting barrier. However, for very lipophilic substances the diffusion through the 
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hydrophilic epidermis and dermis can be rate limiting. Diffusion of compounds across a 
membrane is described by Fick’s first law (Crank, 1975). For the individual (pseudo-
homogeneous) layers of the skin Fick’s law can be expressed by Equations 5.1-5.7 (WHO, 
2006). 
𝐽 = −𝐷
𝜕𝐶
𝜕𝑥
  
Equation 5.1 
Where:  J Flux (the rate of transfer of a chemical per unit area in particular time) 
D  Diffusion coefficient 
𝜕𝐶
𝜕𝑥
 Concentration gradient 
Over a specific time (the so-called lag time), flux reaches a steady-state value and the 
cumulative amount penetrating the skin increases: 
𝐽𝑠𝑠 =
𝐷(𝐶1−𝐶2)
ℎ
  
Equation 5.2 
Where:  Jss  Flux at steady-state 
h  Membrane thickness 
C1, C2  Chemical concentrations at interface of the two membranes (at x1=0 and 
x2=h, respectively) 
Assuming a local equilibrium with the vehicle and that the stratum corneum controls 
the dermal diffusion process: 
𝐶1 = 𝐾𝑚 ∙ 𝐶𝑣  
Equation 5.3 
Where:  C1  Chemical concentration before the diffusion process (at x1=0) 
Km  Stratum corneum-to-vehicle partition coefficient 
 Cv  Concentration of the vehicle 
Assuming that after passing through the membrane (x=h) the chemical 
concentration is close to zero (so-called sink conditions): 
𝐽𝑠𝑠 =
𝐷∙𝐾𝑚∙𝐶𝑣
ℎ
  
Equation 5.4 
If: 
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𝐾𝑃 =
𝐾𝑚∙𝐷
ℎ
  
Equation 5.5 
Where:  KP  Permeability coefficient 
Then: 
𝐽𝑠𝑠 = 𝐾𝑃 ∙ 𝐶𝑣  
Equation 5.6 
The maximum steady-state flux through the membrane can be thus be expressed as: 
𝐽𝑀𝐴𝑋 =
𝐷∙𝑆𝑆𝐶
ℎ
= 𝐾𝑃𝑉 ∙ 𝑆𝑉  
Equation 5.7 
Where:  JMAX  Maximum steady-state flux 
SSC  The saturated concentration of solute in the stratum corneum 
KPV  The permeability coefficient of a solute in a vehicle 
Sv  The solubility of the solute in that vehicle 
The maximum steady-state flux (JMAX) is a valuable parameter to determine the 
percutaneous penetration/absorption of a chemical.  
5.1.3. Modelling of skin permeability  
5.1.3.1. General overview of the tools and approaches 
The computational modelling of skin permeability has been investigated for over two 
decades resulting in a plethora of in silico models and tools. A number of comprehensive 
reviews have been published in this area (Moss et al., 2002; Geinoz et al., 2004; Degim, 
2006; WHO, 2006; Mitragotri et al., 2011, Jepps et al., 2013; Naegel et al., 2013) along with 
the comparative studies evaluating the available models (Bouwman et al., 2008; Lian et al., 
2008; Farahmand & Maibach, 2009; Brown et al., 2012). 
One of the most significant skin permeability (KP) models was published by Potts and 
Guy (Potts & Guy, 1992) for 93 historical permeability coefficients compiled from the 
literature by Flynn (Flynn, 1990). The Potts and Guy model accounts solely for the size and 
hydrophobicity of the permeant (Eq. 5.8), with a resulting correlation coefficient of 0.67.  
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𝐿𝑜𝑔𝐾𝑃 =
𝐷 ∙ 𝑆𝑆𝐶
ℎ
= 0.71𝐿𝑜𝑔𝑃 − 0.061𝑀𝑊 − 6.3 
Equation 5.8 
Where:  Log KP  Logarithm of the permeability coefficient 
Log P  Logarithm of the n-octanol/water partition coefficient 
MW  Molecular weight  
The main limitation of this model is the over-prediction of the KP for highly lipophilic 
compounds. In order to address this drawback, a modification was proposed (Cleek & 
Bunge, 1993; Bunge & Cleek, 1995) that split components representing the stratum 
corneum partitioning and diffusivity. The Potts and Guy model has also been further 
extended by a number of other workers, e.g. Moss and Cronin used an updated and revised 
set of 116 compounds obtaining a correlation coefficient of 0.82 (Moss & Cronin, 2002). 
Following the Potts and Guy model, a plethora of multi-parameter QSAR models 
have been developed for skin permeability. Diverse types and numbers of descriptors have 
been proposed (e.g. over 1,600 descriptors were used by Baert et al., 2007). The most 
frequently applied include lipid/water partition coefficients, water solubility, melting point, 
molecular size and hydrogen bonding (Abraham et al., 1999; Roberts & Sloan, 1999; Roberts 
& Sloan, 2000; Abraham & Martins, 2004; Zhang et al., 2009). The majority of the models 
developed were based on the assumption that inter-cellular pathway (i.e. through the lipid 
matrix) is the dominant route of transport for a compound and that the corneocytes are not 
permeable. Such models, however, tend to under-predict the skin permeability of 
hydrophilic compounds. 
A further alternative approach to predict skin permeability is based on the use of 
mechanistic models. These are derived from the Fick’s laws of diffusion and mass balance 
equations, taking into account various diffusion pathways, not being limited to the lipid-
based inter-cellular pathway. A four-pathway model considering the aqueous pores in the 
stratum corneum lipid matrix and the appendageal openings as the hydrophilic pathway in 
additional to the impermeable corneocytes has been proposed (Mitragotri, 2003). The 
model yields good results for both hydrophilic and hydrophobic permeants. Another type of 
mechanistic model is based on the “brick and mortar” framework of the stratum corneum. 
The two-dimensional (biphasic) microtransport model was developed by Kasting and co-
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workers (Wang et al., 2006; Wang et al., 2007) and further extended (Dancik et al., 2012). 
This model provides the maximal fluxes, concentrations and distribution details for the 
permeant, as well as the amount of permeant prone to removal/evaporation. 
5.1.3.2. Computational modelling of maximal flux (JMAX) 
As mentioned in section 5.1.2, JMAX is a relevant measure of the skin permeation of 
chemical. Relatively few studies, however, have used JMAX as a dependent variable in the 
QSPR models. Of these studies, predicting the maximal flux on the basis of the molecular 
volume and solubility of the permeant in octanol was proposed for a small dataset of 35 
drugs (Kasting et al., 1987). Molecular weight-based simplistic regression models for JMAX 
prediction have been developed for the aqueous solutes by Magnusson and co-workers 
(Magnusson et al., 2004a). Their model, which used the largest number of compounds (279) 
of any of the models, yielded a correlation coefficient of 0.688: 
𝐽𝑀𝐴𝑋 = 0.041𝑀𝑊 − 4.52 
Equation 5.9 
Where:  MW  Molecular weight  
An alternative approach to predict JMAX is based on the determination of the “rules of 
thumb” to identify compounds exhibiting high or low skin permeability – a type of 
“pass/fail” test for rapid screening of compounds without experimental data (Magnusson et 
al., 2004b). “Rules of thumb” for intestinal absorption have been successfully formulated by 
Lipinski and coworkers (Lipinski et al., 1997). With respect to skin permeability, this 
approach was utilised by Magnusson et al. (Magnusson et al., 2004b). In order to identify 
compounds with extreme (high or low) JMAX values, they analysed the following molecular 
descriptors: molecular weight (MW), melting point (MP), octanol/water partition coefficient 
(Log K), aqueous solubility (Log S) and number of atoms available for hydrogen bonding 
(HB), divided into H-bond donors (HB-d) and acceptors (HB-a). The boundary values 
reported in their study are presented in Table 5.1. The properties with the highest predictive 
power were: MW, HB-a, and Log S. Using the combination of 2 or 3 predictors yielded the 
best results. 
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Table 5.1 
The boundary values for “good” (high JMAX) and “bad” (low JMAX) skin permeants (taken from 
Magnusson et al., 2004b) 
JMAX 
Descriptors 
MW MP HB-d HB-a Log K Log S 
Low (“bad” penetrants) > 213 ≥ 223 ≥ 0 ≥ 3 > 1.2 > -1.6 
High (“good” penetrants) ≤ 152 ≤ 432 ≤ 2 ≤ 3 < 2.6 ≥-2.3 
 
The work of Magnusson et al., was elaborated further by Xu et al. (Xu et al., 2013) 
who reduced the rules to MW and Log P only. The permeants with MW ≥ 400, logP ≤ 1, or 
logP ≥ 4 have been considered “bad” penetrants. 
The method of estimating dermal absorption (when the experimental data are not 
available) on the basis of calculated JMAX values was proposed by Kroes and co-workers 
(Kroes et al., 2007). For JMAX values between 0.1 and 10 μg/cm
2/h, they recommended 
assuming 40% absorption of the applied dose (per 24 hour exposure). For JMAX <0.1, or >10 
μg/cm2/h, the percent dose absorbed was suggested to be 10% or 80%, respectively. For 
non-reactive chemicals with molecular weights greater than 1000, negligible absorption was 
assumed. 
5.2. The aims of chapter 5 
As maximal flux (JMAX) is a significant parameter in the assessment of the dermal 
delivery of the chemical compounds (defining their maximal toxic or systemic effects 
resulting from the topical exposure), it has been selected as the endpoint of the present 
research. The aims of chapter 5 are related to the objective 4 of the current PhD program 
(please refer to section 1.5) and include: 
 Data mining of the Skin Permeability Database (its development was described in 
chapter 4) leading to the collation of a set of compounds with available experimental 
maximal flux (JMAX) data; 
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 Structural (ToxPrint chemotypes) profiling of the collated dataset followed by the 
analysis of the physicochemical properties of its constituents; 
 Determination of a set of rules classifying a chemical as having low or high potential 
to permeate the skin. 
5.3. Materials and methods 
5.3.1. Dataset for analysis 
The final content of the COSMOS Skin Permeability Database was described in 
chapter 4. The database contains measured in vitro JMAX values for over 200 compounds. 
Many chemicals were tested in multiple experiments (e.g. as many as 46 studies are 
available for diethyltoluamide or salicylic acid), resulting in the total number of data points 
for in vitro JMAX exceeding 900. The experiments were performed with a range of skin 
membranes (e.g. whole skin, epidermis, stratum corneum, etc.) obtained from various 
species (human, pig, mouse, rat, rabbit) and sampling sites (abdomen, breast, back, leg, 
neck) using diverse diffusion cells types (static or flow-through) and dose application 
regimes (occluded, non-occluded or semi-occluded conditions).  
As mentioned previously, experimental measures of skin permeability are highly 
variable. The variability of in vitro JMAX measurement results was reported in the scientific 
literature (Howes et al., 1996; Benech-Keiffer et al., 2000; Akomeah et al., 2007). It was 
demonstrated that for some compounds (e.g. methyl paraben) the variability is as high as 
35%, and a difference between the highest and lowest flux values as high as 4-fold can be 
obtained, even when the same experimental protocol was applied (Chilcott et al., 2005; 
Akomeah et al., 2007). The underlying reasons were attributed to a variety of factors 
including human error, differences in experimental design (e.g. receptor chamber volume 
and surface area, the type of diffusion cell used), skin morphology (e.g. samples of variable 
origin) or the physicochemical properties of tested substance (Elias et al., 1981; Southwell et 
al., 1984; Rougier et al., 1987; Williams et al., 1992; Liu et al., 1993; Cua et al., 1995; Tsai et 
al., 2003; Otberg et al., 2004; Chilcott et al., 2005; Akomeah et al., 2007). 
For the purpose of the present analysis the JMAX values measured in vitro with human 
skin samples were utilised. The COSMOS Skin Permeability Database contains a total of 640 
in vitro human studies (for 184 compounds) with JMAX provided. The variability of the data 
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was analysed for all compounds with multiple results from more than a single study. When 
JMAX values were highly variable and it was not feasible to make a conclusion regarding the 
skin permeability category, all the records for a compound were dropped from the analysis. 
For the compounds with multiple studies but low range of JMAX values the means were 
calculated. The IOM compounds and mixtures were excluded from the investigation. It 
should be noted that only in vitro human data were used, but all membrane types 
(epidermis, split-thickness skin, full-thickness skin, etc.) and vehicles were considered.  
Once the set of compounds with low variability of in vitro JMAX values was identified, 
three initial categories, corresponding to low, medium and high skin permeability potential 
were defined using 33.3% and 66.7% quantiles. 
5.3.2. Structural features and physicochemical properties analysis  
The structures of compounds analysed were prepared for computational analysis in 
the Corina Symphony software tool (Molecular Networks GmbH, Nüremberg, Germany) 
following the procedure described in detail in chapter 3. Subsequently, the dataset was 
analysed with respect to the structural features and molecular properties.  
The structural domain of the dataset was characterised by the ToxPrint chemotypes 
calculated in the ChemoTyper software tool (Altamira LLC, Columbus, OH; Molecular 
Networks GmbH, Nüremberg, Germany) and presented in terms of their distributions across 
different skin permeability categories. The in depth description of this methodology is 
provided in chapter 3.  
The physicochemical profile of the dataset was determined with the “global 
molecular” and “size and shape” descriptors calculated in Corina Symphony software tool 
(Molecular Networks GmbH, Nüremberg, Germany). For the purpose of the current analysis, 
fifteen properties were selected a priori on the basis of knowledge available in the scientific 
literature (Table 5.2). The standardised values of the calculated descriptors were used as 
variables in the Principal Component Analysis conducted in JMP Pro 12.2.0 software (SAS 
Institute Inc.). This technique was discussed in-depth in chapter 3. 
 
 
Chapter 5 
87 
 
Table 5.2 
CORINA Symphony (Molecular Networks GmbH, Nüremberg, Germany) descriptors utilized in 
the present analysis  
GLOBAL MOLECULAR PROPERTIES 
Number of open-chain, single rotatable bonds (BondsRot) [unitless] 
Number of hydrogen bonding acceptors derived from the sum of nitrogen and oxygen atoms in the molecule 
(H-Acc) [unitless] 
Number of hydrogen bonding donors derived from the sum of N-H and O-H groups in the molecule (H-Don) 
[unitless] 
Number of tetrahedral stereocentres in the molecule (Stereo) [unitless]  
Solubility of the molecule in water (Log S) [mol/L] 
Mean molecular polarisability of the molecule (Polariz) [Å3] 
Molecular complexity (Complex) [unitless] 
Ring complexity (ComplexRing) [unitless] 
Molecular weight derived from the gross formula (MW) [Da]  
Octanol/water partition coefficient of the molecule following the XlogP approach (Log P) [unitless] 
McGowan molecular volume approximated by fragment contributions (McGowan) [mL/mol] 
Topological polar surface area of the molecule derived from polar 2D fragments (TPSA) [Å2] 
SHAPE DESCRIPTORS 
Molecular diameter – maximum distance between two atoms in the molecule (Diameter) [Å] 
Molecular radius of gyration (Rgyr) [Å] 
Molecular span – radius of the smallest sphere centred at the centre of mass which completely encloses all 
atoms in the molecule (Span) [Å] 
 
5.3.3. Defining the classification rules 
On the basis of the structural and physicochemical profiles of the dataset, sets of 
rules were proposed for skin permeability categories to support the classification of query 
compounds without experimental data. 
5.4. Results 
5.4.1. Dataset for analysis 
The dataset compiled consisted of 112 organic compounds (after removing 
compounds with high variability of reported JMAX values and compounds which are not 
handled well by computational tools used for calculating molecular descriptors). The full 
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dataset is reported in Annex 5. The summary statistics and distribution of experimental JMAX 
values in the entire dataset of 112 compounds analysed are presented in Figure 5.2A. Based 
on the 33.3% and 66.7% quantiles, the dataset was divided into the following skin 
permeability potential categories (the summary statistics and distributions of log JMAX values 
within each category are presented in Figure 5.2B): 
 Low (36 compounds): JMAX < 0.75 µg/cm
2/h (log JMAX < -0.12); 
 Medium (38 compounds): JMAX between 0.75-10 µg /cm
2/h (log JMAX <-0.12, 1>); 
 High (38 compounds): JMAX > 10 µg/cm
2/h (log JMAX > 1). 
 
Figure 5.2 
(A) The summary statistics, quantile analysis estimates (mean confidence interval (1-α) of 0.95) 
and histogram of log JMAX values distribution for the set of 112 compounds subjected into 
analysis; 
(B) The summary statistics and histograms of log JMAX values distribution for the low, medium, 
and high skin permeability categories 
The plots were prepared in JMP Pro 12.2.0 software tool (JMP, SAS Institute Inc.) 
5.4.2. Chemotype analysis 
The structural profile of compounds belonging to the low, medium and high skin 
permeability categories was analysed with the ToxPrint chemotypes (Figure 5.3). Fused rings 
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(e.g. steroids), cyclic alkenes and alkanes (C5 and C6), secondary alkyl alcohols, ketones, 
aliphatic amines, and neopentyl groups were found in abundance in the low skin 
permeability category of compounds. Aliphatic ethers and ethylene oxides were identified 
predominantly in compounds with high skin permeability potential. The medium skin 
permeability compounds were rich in aromatic rings with hetero atoms, aromatic alkanes, 
cyclic alkanes (C3), halides (especially alkyl halides) and halocarbonyls, tertiary alkyl 
alcohols, and carboxylic acids.  
 
Figure 5.3 
The structural profile of compounds from low, medium and high skin permeability categories, 
expressed as % frequency of features. The actual counts of each structural feature are provided on 
the plot’s bars 
5.4.3. Physicochemical properties analysis  
The physicochemical properties space of a dataset of 112 compounds was 
investigated in terms of Principal Components Analysis on the basis of 15 physicochemical 
descriptors (Annex 7) selected a priori (as described in 5.3.3) and calculated in Corina 
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Symphony (Molecular Networks GmbH, Nüremberg, Germany). The scree plot and variance 
explained by each PC are presented in Figure 5.4.  
 
Figure 5.4 
Scree plot and % variance explained by each calculated Principal Component. The PCs with 
eigenvalues >1 were considered. The plot was prepared in JMP Pro 12.2.0 software tool (JMP, SAS 
Institute Inc.) 
The three first Principal Components (with eigenvalues >1) cumulatively explaining 
90.3% variance in the dataset were considered. Their scores (Annex 7) were used to 
generate 3D score plot visualising the physicochemical properties space covered by the 
investigated dataset (Figure 5.5). The empirical categories of low, medium and high skin 
permeability potential were projected onto the PCs score plot.  
The most influential properties associated with each considered PC are presented in 
Figure 5.6. The first Principal Component was most significantly influenced by descriptors 
related to the size, shape, and volume of the molecules (MW, Diameter, Complex, Span, 
Rgyr, McGowan), their hydrophilicity/lipophobicity (Log S, TPSA), mean molecular 
polarizability (Polariz), and the number of hydrogen bond acceptors (H-Acc). The 
octanol/water partition coefficient (Log P) had the highest loading on the PC2. The number 
of rotational bonds reflecting the flexibility of the molecule (BondsRot) and ring complexity 
(ComplexRing) were the most significant in the PC3. 
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Figure 5.5 
The 3D score plot of the three first Principal Components (PC1-PC3) defining the properties space of 
the dataset analysed (cumulatively explaining 90.3% of the variance in the dataset). The plot was 
prepared in JMP Pro 12.2.0 software tool (JMP, SAS Institute Inc.) 
 
Figure 5.6 
The loading bar plots for the three Principal Components characterising physicochemical properties 
of investigated dataset of 112 compounds. The properties with loadings above 0.7 (or close to) were 
considered to be the most influential 
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As presented in Figure 5.5, the regions rich in compounds with high or low skin 
permeability potential could be clearly distinguished in the investigated physicochemical 
properties space, whereas the compounds from the medium skin permeability category 
(evenly distributed across the entire space) did not form a separate cluster. This result 
indicates that the set of molecular descriptors utilised was relevant to identify the 
differences between low and high skin permeability compounds. The separation of the 
medium category compounds was not obtained as they exhibit a range of “mixed” features, 
not sufficiently discriminative to be captured solely by the properties used. Thus, the 
structural characteristics of “medium” category compounds were projected into the 2D 
score plot (PC1 vs PC2) of their physicochemical properties space (Figure 5.7).  
It can be observed that the “medium” category compounds with distinctive 
structural features (identified in section 5.4.3) form individual clusters in the 
physicochemical properties space: a group of naltrexone derivatives, containing fused rings 
and cyclopropane moieties is located in the region richer in low skin permeability 
compounds, while the cluster abundant in halocarbonyls, alkyl halides, aromatic halides and 
medium-length chain aromatic alkanes is situated in the region occupied mostly by high skin 
permeability compounds. Therefore, to characterise medium skin permeability category 
fully, the structural features have to be considered together with physicochemical 
descriptors. The compounds from “low” and “high” skin permeability categories exhibit such 
different structural characteristics that the physicochemical properties alone are able to 
clearly reflect them (Figure 5.8). Complex molecules containing fused rings, cyclic alkenes 
and alkanes (C5 and C6), secondary alkyl alcohols, ketones and aliphatic amines are located` 
on the right-hand side of the PC1 vs PC2 plot (Figure 5.8), whereas polyethylene glycol 
ethers and short chain alkanes are situated on the left-hand side. For these classes of 
compounds, belonging (respectively) to “low” and “high” skin permeability categories, the 
boundary values of descriptors were determined in the next step of the analysis. 
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Figure 5.7 
The 2D PCs score plot demonstrating the location of the compounds from the medium skin permeability potential category in the considered 
physicochemical properties space and their distinctive structural features (grey dots denote the compounds from the “low” and “high” categories). The plot 
was prepared in JMP Pro 12.2.0 software tool (JMP, SAS Institute Inc.) 
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Figure 5.8 
The 2D PCs score plot demonstrating the good separation between low and high skin permeability potential category compounds in the considered 
physicochemical properties space and their distinctive structural features (grey dots denote the compounds from the “medium” category). The plot was 
prepared in JMP Pro 12.2.0 software tool (JMP, SAS Institute Inc.) 
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5.4.4. Defining the classification rules 
The distributions and ranges of values of the most significant physicochemical 
properties (as identified by loadings, Figure 5.6) were analysed for compounds assigned into 
the low and high skin permeability potential categories (Figure 5.9). In general, skin 
permeability decreased with increasing size, volume, and flexibility of molecules (molecular 
weight, diameter, complexity, span, radius of gyration, McGowan volume, the number of 
rotational bonds), as well as with the numbers of hydrogen bond acceptors and donors, 
topological polar surface area and molecular polarisability. The Log P and Log S values 
associated with “low” and “high” permeability categories were also identified.  
The scatterplot matrix of correlations between the 12 physicochemical properties is 
presented in Figure 5.10. It visualises the capability of the descriptors to discriminate 
between low and high skin permeability categories. 
The full set of defined boundaries of physicochemical properties’ values for 
particular structural classes is presented in Table 5.3. The interpretation of these results is 
provided in the following section. 
Table 5.3 
The set of rules for assigning the compounds without experimental data into the low or high 
skin permeability category on the basis of structural features and calculated properties. The 
structural features characteristic for medium skin permeability category compounds are also 
provided 
 
 
 
MW Complex McGowan BondsRot Log P Rgyr H-Acc TPSA Polariz Log S Diameter Span
HIGH
(aliphatic ethers and ethylene oxides)
≤ 213 ≤ 224 < 157 ≤ 10 < -0.5 < 2 ≤ 4 < 47 < 14 > -0.9 < 8.8 < 5
LOW
(fused rings, multiple aromatic rings, cyclic 
alkenes and alkanes (C5 and C6), secondary 
alkyl alcohols, ketones, aliphatic amines 
with long aliphatic chains)
≥ 226 ≥ 245 > 171 > 10 > 4 > 4 > 4 > 47 > 24 < -4 > 12.3 > 7.3
MEDIUM
(halocarbonyls, alkyl halides, aromatic 
halides, medium-length chain aromatic 
alkanes)
MEDIUM
(fused rings, cyclic alkanes (C3))
Properties indicating "high" skin permeability
Properties indicating "low" skin permeability
Skin permeability category
(Structural features)
Physicochemical properties ranges
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Figure 5.9 
Histograms of distribution of 12 individual molecular properties within particular skin permeability potential categories. The boundary values of 
physicochemical properties ranges were defined for the “high” and “low” categories; the histograms of “medium” category were depicted to illustrate that 
the compounds from this group have the “mixed” values of analysed properties. The ranges and mean values for all descriptors are provided in Annex 7. 
The plots were prepared in JMP Pro 12.2.0 software tool (JMP, SAS Institute Inc.) 
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Figure 5.10 
The scatterplot matrix presenting the correlations between individual molecular properties used to 
discriminate the categories of low (green) and high (red) skin permeability potential. The plot was 
prepared in JMP Pro 12.2.0 software tool (JMP, SAS Institute Inc.) 
5.5. Discussion 
The main function of the skin is to act as a physicochemical barrier, and, as such, to 
resist the penetration of chemicals. Many molecules, however, can pass this barrier in a 
passive diffusion process. As outlined above, the permeability of a chemical through the skin 
is limited by the skin layer with the highest resistance to diffusion (stratum corneum, or 
hydrophilic epidermis and dermis for very lipophilic substances). In the current analysis, the 
structural features and physicochemical properties of compounds exhibiting high and low 
skin permeability potential were analysed. The main molecular characteristics determining 
chapter 5 
98 
 
the skin permeability potential identified were associated with the molecular size (including 
volume, dimensions, and complexity of the molecules), hydrophobicity and hydrogen 
bonding ability. These findings remain in agreement with the findings of other researchers 
(e.g. Cronin et al., 1999, Walters, 2002; Magnusson et al., 2004b; Abraham and Martins, 
2004; Zhang et al., 2009; Kupczewska-Dobecka et al., 2010). The molecular size (molecular 
weight and diameter), volume (McGowan), complexity (Complex, ComplexRing), 
dimensions, and spatial arrangement of atoms in the molecules (Span, Rgyr, Stereo) are all 
negatively correlated with the skin permeability potential. Larger and more complex 
molecules have more difficulty in passing the corneal layer. This can be related to the steric 
hindrance – multiple aromatic rings, or fused rings in complex molecules (e.g. steroids) may 
slow diffusion by steric effects. In case of very polar solutes, the polar pathway with a 
defined radius for transport is utilised (Walters, 2002). The increasing molecular weight/size 
is generally positively correlated with a range of other features, e.g. the number of 
rotational bonds, or hydrogen-bonding capabilities of the molecules. High molecular 
flexibility (reflected in the number of rotational bonds) is associated with lower permeability 
potential. Similarly, the large number of hydrogen bond acceptors and/or donors may slow 
diffusion by hydrogen bonding effects. The topological polar surface area (TPSA) (the 
surface of polar fragments present in the molecule), octanol/water partition coefficient (Log 
P), aqueous solubility (Log S), and polarisability (Polariz) provide information on the 
hydrophobicity of the solutes and their partitioning between lipophilic and hydrophilic 
regions of the skin membrane. The compounds with large TPSA and high polarizability tend 
to be poor skin permeants. Poor skin permeability potential was observed for compounds 
with Log P >4 and Log S <-4. 
In summary, in the present analysis it was demonstrated that the complex process of 
skin permeability expressed as the maximal flux, is governed by molecular size-, 
hydrophobicity- and hydrogen bonding-related properties, reflecting the structural features 
of the solutes. For the chemical classes identified with the ToxPrint chemotypes, the 
boundary values of physicochemical properties capable of distinguishing the groups of 
compounds with high and low skin permeability potential was identified (Table 5.3).  
The analysis performed utilises a novel methodology (combination of ToxPrint 
chemotypes with physicochemical properties) and demonstrates its capability for 
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performing a simultaneous analysis for different groups of chemicals (cosmetics, drugs, 
pesticides), exhibiting various properties (e.g. highly lipophilic or highly hydrophilic) and 
structural diversity. The approach proposed can be further elaborated and used for the 
development of computational models utilising both types of descriptors at once. The 
determined profiles of bad and good skin penetrants can be used for rapid screening of 
chemicals without experimental data and support assessment of potential human exposure 
to chemicals via the topical route. This, in the broader scale, can facilitate the process of 
safety evaluation of chemicals, including cosmetics ingredients and related compounds. 
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Chapter 6 
COSMOS Oral Repeated Dose Toxicity Database (oRepeatToxDB): Harvesting, Curating and 
Quality Control of the Data 
6.1. Background 
6.1.1. In vivo oral repeated dose toxicity tests 
Repeated dose toxicity is a broad term referring to the general, adverse toxicological 
effects resulting from the repeated daily exposure to (or dosing with) a substance for a 
specified period of time, up to the expected lifespan of the test species. The main goal of 
repeated dose toxicity studies is the characterisation of the toxicological profile of the test 
substance including the identification of: the potential target organs of toxicity, the dose-
response relationships for each toxicity endpoint (and margin between toxic and non-toxic 
dose), the delayed responses, cumulative effects (and, eventually, their reversibility) and the 
responses to toxic metabolites formed in the organism. The information delivered from 
repeated dose toxicity testing is essential for safety and risk assessment of any substance, 
including industrial chemicals, pharmaceuticals, biocides, and cosmetics ingredients (EMA, 
2010; EURL ECVAM, 2016).  
The major outcomes of a repeated dose toxicity study are: the No Observed 
(Adverse) Effect Level (NO(A)EL) value, referring to the highest dosage of the test substance 
for which no (adverse) treatment-related effects have been observed, and the related 
Lowest Observed (Adverse) Effect Level (LO(A)EL), i.e. the lowest dosage of the test 
substance where (adverse) treatment-related findings have been observed (SCCS, 2012). 
 The NO(A)EL value is used for systemic toxicity safety assessment, including, for 
example, the calculation of the Margin of Safety (MoS)3 for cosmetic substances by the EU 
SCCS. For systemic toxicity risk assessment, particularly significant is the “critical toxic 
effect”, defined as the first adverse effect (or its known precursor), that occurs at the 
                                                      
3 Margin of Safety (MoS) – uncertainty factor applied at the last stage of the safety evaluation of cosmetic 
substance, calculated by dividing the lowest NO(A)EL identified for this substance in repeated dose toxicity 
study by the Systemic Exposure Dosage (SED) value. Generally, minimum MoS value of 100 is necessary to 
conclude that a substance is safe for use (SCCS, 2012) 
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LO(A)EL. It may vary from lethality to a minor toxic effect, but in general is associated with 
the particular “critical” target organ in which it has been observed (EPA, 2016b).  
As far as experimental protocols are concerned, several types of in vivo studies with 
repeated dosage regimen, and an oral route of exposure, can provide the above 
information. They include: short-term studies in rodents (28 days), subchronic studies in 
rodents and non-rodents (90 days), chronic studies in rodents (usually 12 months, however 
either shorter, e.g. 6 or 9 months, or a longer, e.g. 18 or 24 months, study duration is also 
applied) and reproductive/developmental/neurotoxicity studies. The list of the relevant 
guideline documents used in various regulatory agencies is summarised in Table 6.1. The 
guideline documents from the OECD, U.S. FDA and EPA for oral repeated dose toxicity 
studies (including chronic, subchronic, reproductive and developmental tests) require 
similar study parameters of design and result findings.  
Table 6.1 
Types of toxicity studies with oral repeated dosage and corresponding test guidelines 
Test method 
The EC Council 
Regulation Test 
Method 
(EC, 2008) 
The OECD Test Guideline 
(TG) 
The U.S. FDA 
Redbook 2000 
Regulation 
(FDA, 2007) 
The U.S. EPA 
OCSPP (previous 
OPPT) Guideline 
Short-term, rodents B.7 
407 
(OECD, 2008) 
IV.C.3.a 
870.3050 
(EPA, 2000) 
Subchronic, rodents B.26 
408 
(OECD, 1998a) 
IV.C.4.a 
870.3100 
(EPA, 1998a) 
Subchronic, non-
rodents 
B.27 
409 
(OECD, 1998b) 
IV.C.4.b 
870.3150 
(EPA, 1998b) 
Chronic, rodents 
B.30 
452 
(OECD, 2009) 
IV.C.5.a 870.4100 
(EPA, 1998c) Chronic, non-rodents IV.C.5.b 
Developmental 
(prenatal) 
B.31 
414 
(OECD, 2001) 
IV.C.9.b 
870.3700 
(EPA, 1998d) 
Reproductive 
B.34 (1GEN*) 
B.35 (2GEN**) 
415 (1GEN), 416 (2GEN) 
(OECD, 1983; OECD, 2001a) 
IV.C.9.a N/A 
Neurotoxicity B.43 
424 
(OECD, 1997) 
IV.C.10 
OPPTS 870.6200 
(EPA, 1998e) 
* 1GEN: 1-generation study; ** 2GEN: 2-generation study 
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6.1.2. COSMOS oRepeatToxDB 
For the purpose of constructing the COSMOS Oral Repeated Dose Toxicity Database, 
and in order to facilitate the development of in silico tools for target organ toxicity 
prediction, detailed information on critical target organ(s), critical toxic effect(s) and 
associated LO(A)EL values were absolutely essential. Although a plethora of repeated dose 
toxicity databases exist (extensive reviews of these have been published recently, e.g. by 
Madden, 2013), there is a general lack of publicly available databases providing organ level 
toxicity effect data associated with the LO(A)EL values. Moreover there is a lack of 
databases which link this information with accurately identified chemical compounds, and 
fewer or no databases that focus on cosmetics and their ingredients at the same time. There 
is also a general paucity of mature chemical-toxicological ontologies for target organs 
toxicity in the available databases (the importance of the ontologies for data mining has 
been described in chapter 1.3). The COSMOS Oral Repeated Dose Toxicity Database 
(oRepeatToxDB) was constructed to address these issues (the design of ontologies has been 
discussed more in-depth in chapter 7; please refer to Annex 1).  
The process of the database development included consolidation of available data 
sources and harvesting of new ones. As far as the existing data sources are concerned, two 
publicly available databases were found that were relevant for the needs of COSMOS 
oRepeatToxDB, namely the U.S. EPA ToxRefDB (EPA DSSTox, 2016) and the public part of the 
U.S. FDA CFSAN CERES, including the PAFA database (Benz & Irausquin, 1991).  
The majority of ToxRefDB content refers to agrochemicals (pesticides), since the U.S. 
EPA does not regulate cosmetics. However, about 15% of the content of ToxRefDB was 
found to be in common with the COSMOS Cosmetics Inventory. ToxRefDB content, along 
with NOEL/LOEL values, was provided by the U.S. EPA and used as received.  
The U.S. FDA CFSAN PAFA (please refer also to Table 2.1) provides oral repeated-
dose toxicity information for several hundred compounds, referencing (as original data 
sources) internal U.S. FDA documents, U.S. National Toxicology Program (NTP) study reports 
and the scientific literature. Approximately 30% of those chemicals were found to be 
common to the COSMOS Cosmetics Inventory. As the PAFA is the legacy database of the 
U.S. FDA, in many cases (mostly due to the technical limitations existing at the time of its 
construction) it does not provide sufficient level of detail for the toxicity data recorded (e.g. 
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information on the target organs). Thus, PAFA served more as the repository of cosmetics-
related chemicals for which oral repeated dose toxicity studies have been performed. For 
several PAFA compounds the referenced materials have been consulted and either re-
harvested or exchanged with more recent studies.  
The main focus of the COSMOS oRepeatToxDB was placed on cosmetics and 
cosmetics ingredients. The only exception to this rule was the inclusion of Food Contact 
Substances (FCS) and impurities from the U.S. FDA Food Contact Notification program 
through collaboration with the CERES project. This was to enable the consideration of 
compounds which may be unintentionally present in the final cosmetic products (as a result 
of migration from packaging materials, for example). 
The new oral repeated dose toxicity data were harvested for the cosmetics and 
related compounds from a range of regulatory and literature sources. The concerns over the 
accuracy of data incorporated into COSMOS oRepeatToxDB were minimised by establishing 
a consistent procedure for data curation and quality control, as described below. 
6.1.3. Data record reliability in COSMOS oRepeatToxDB 
The general aspects of the quality of biological data in toxicity databases have been 
described in detail in chapter 4.1.3. As far as the existing sources of the oral repeated dose 
toxicity data are concerned, both the U.S. FDA PAFA and the U.S. EPA ToxRefDB have their 
own sets of minimal study inclusion criteria specified for particular study types (chronic, 
subchronic, developmental toxicity, etc.). For instance, the U.S. FDA PAFA classifies the 
studies for “completeness” using regulatory guidelines from the U.S. FDA Redbook (FDA, 
2007) along with its own “core standards” (minimum inclusion criteria). If the study satisfies 
the guideline, it is deemed to “meet the current standards” (PAFA completeness score “A”). 
When the study is not compliant with the guideline but acceptable to the PAFA inclusion 
criteria, it is classified as “not meeting the current standards, but meeting the core 
standards” (PAFA completeness score “B”). When the study does not meet the minimum 
standard of the database, it is considered “unacceptable by not meeting the core standards” 
(PAFA completeness score “C”). For example, the PAFA database allows the entry of a rat 
oral subchronic toxicity study using 5 animals at 2 dose levels without the full scale 
histopathology descriptions, whereas the FDA Redbook requires the use of 20 animals at 
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minimum 3 dose levels in a rat oral study and resulting full scale histopathology. Similarly, 
the U.S. EPA ToxRefDB “data usability score” classifies studies with respect to the U.S. EPA 
OPPT (OCSPP) guidelines and ToxRefDB inclusion criteria. The guideline-compliant studies 
are deemed to be either “Acceptable Guideline (post-1998)” (following the GLP regulations) 
or “Acceptable Guideline (pre-1998)” (pre-dating the GLP regulations). The non-guideline 
studies are classified as “acceptable non-guideline” (when meeting the ToxRefDB standards) 
or “unacceptable, deficient evaluation”. 
The COSMOS database data model has been described in chapter 1.4. At a very high 
level, for each toxicity study recorded for a given compound in COSMOS oRepeatToxDB, a 
particular toxicological effect occurring at a particular dose level and at a particular site is 
represented precisely. The study design captures all the details for species, sex, routes of 
exposure, dose groups (levels and number of animals), control group information and 
references. The effects are described by sets of controlled vocabulary and qualified by the 
time of the findings, severity, statistical significance, and treatment-relatedness. The sites 
are differentiated for organ (system), tissue (segment) and cells (organelles).  
In order to represent the study data at this detailed level, the set of MINImum Study 
inclusion criteria (COSMOS MINIS) have been established for subchronic, chronic, 
reproductive, and developmental toxicity studies. Generally (Table 6.2), the requirements 
for the study parameters included specification of the following elements: study duration, 
animal species, route of exposure, control group, dose groups, dosage regimen, clinical 
signs, water/food consumption, hematology, clinical chemistry, urinalysis, organ weight, 
general necropsy/macro pathology and histopathology. Most of the study parameters have 
been represented by the controlled vocabularies. With regard to the COSMOS MINIS 
criteria, the COSMOS MINIS grade can be calculated algorithmically at the time of entering 
data into the database (Table 6.3). 
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Table 6.2 
General overview of the study inclusion criteria established for the COSMOS oRepeatToxDB  
Parameters The Study Inclusion Criteria 
Study type Subchronic, chronic, carcinogenicity (non-neoplastic effects only), reproductive, 
developmental, neurotoxicity, immunotoxicity 
Species Rat and mouse (all studies); monkey and dog (all studies); rabbit 
(reproductive/developmental studies) 
Duration Greater than or equal to 28 days for subacute and subchronic studies; The 
requirement of “duration days” was not applied for reproductive, developmental 
or multi-generation studies 
Route of exposure Oral, including dietary, drinking water, gavage (or intubation) 
Dose levels and range Repeated dosage (the studies with single dose were not included). All studies with 
dose level and regimen information are included. At least one control group was 
required 
Effects All effects were recorded according to controlled vocabulary 
Reference Regulatory submissions, study reports, published literature (traceable citations) 
 
Table 6.3 
The COSMOS MINIS grade specifications 
COSMOS MINIS 
Grade 
Description 
A 
Study meets the current standards of the guidelines: OECD, U.S. FDA, or U.S. EPA 
and the information for all the required COSMOS MINIS criteria is provided 
B Study is non-guideline, but meets all COSMOS MINIS criteria 
F Study does not meet COSMOS MINIS Criteria  
S 
Assigned when the study data have been harvested from a summarised memo or 
opinions. Although the data source claims the guideline- or GLP-compliance, only 
summary data are available, which may lack detailed information 
 
6.2. The aims of chapter 6 
The aims of the present chapter realised in collaboration with the COSMOS 
consortium partners (please refer to Annex 1) are related to the objective 5 of the current 
PhD program (section 1.5) and include: 
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 Harvesting new oral repeated dose toxicity data for cosmetics and related 
compounds from the regulatory and literature sources according to the predefined SOP; 
 Conducting the QC/QA process of the constructed COSMOS oRepeatToxDB. 
6.3. Materials and methods 
6.3.1. Harvesting new oral repeated dose toxicity data for cosmetics-related 
compounds  
The oral repeated dose toxicity data for over 150 cosmetics-related chemicals were 
harvested by Altamira LLC, LJMU and the U.S. FDA (please refer also to Annex 1). The 
following data sources were used: 
 The opinions of the EC SCCS, providing the safety assessments of substances used in 
cosmetics and consumer products. For many cosmetics and related compounds (e.g. hair 
dyes), SCCS is the only publicly available source of the repeated-dose toxicity information; 
 The ECHA Registered Substances database, including the data used in a regulatory 
setting; 
 Other relevant data sources: When the SCCS opinions or ECHA database referenced 
U.S. National Toxicology Program (NTP) studies or published literature as the data origin, 
the full level of detailed toxicity information was captured from the original sources. In 
cases where unpublished and not available study reports were used by ECHA or SCCS, the 
information presented in the Registered Substances database or in the opinion has been 
used. 
6.3.2. Data entry tool and data entry process 
The data harvesting procedure was performed with respect to the established 
COSMOS MINIS criteria, representing the highly detailed data model of the COSMOS 
oRepeatToxDB (please refer to section 6.1.3). Only those studies fully compliant with GLP or 
Guidelines (or ECHA studies with Klimisch score of 2) and with the COSMOS MINIS criteria 
have been harvested (the “unacceptable” ones were not considered).  
Data entry was performed by adapting the U.S. EPA ToxRefDB forms to the COSMOS 
oRepeatToxDB needs. The data entry tool was delivered to each of the harvesters as a 
Microsoft Access (MDB) file, along with an additional XLS file for the treatment group 
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information upload. The data harvesting was conducted according to the Standard 
Operating Procedure document, prepared by Altamira LLC and a toxicologist from the U.S. 
FDA CFSAN. Prior to the actual data entry, the following steps were conducted for each 
harvested compound:  
 Identification of the most recent data source providing the safety assessment for a 
query compound (e.g. SCCS opinion); 
 Identification of the NO(A)EL value used to calculate the safety assessment metric 
(e.g. the Margin of Safety (MoS) from the SCCS opinion) (please refer to chapter 6.1.1); 
 Identification of the original toxicity study with oral repeated dosage regimen 
(“critical study”), from which the NO(A)EL value (used for the safety assessment) was 
derived. 
Subsequently, the relevant information was entered via the data entry tool. The data 
entry procedure is presented in Figures 6.1-6.2, using the example compound, a hair dye, HC 
Yellow No. 10 (CMS-43601, CAS RN: 109023-83-8), for which the SCCS opinion has been 
harvested (SCCP, 2007).  
In general, several categories of toxicological effects have been recorded (with 
respect to the harvested study type) using the available controlled vocabulary lists to specify 
the effects-related details and corresponding target sites (please refer to the Study Effect 
List in Figure 6.2). The harvested studies were mostly for subchronic and chronic toxicity. 
However, several reproductive and/or developmental studies were recorded as well. The 
recorded effect types include: 
 In-Life Observations: Observations recorded at the beginning of the treatment, 
during the treatment period and at the end of the treatment, before necropsy. They 
included clinical signs (any signs of changes in behaviour, locomotion, appearance, 
salivation, lacrimation, etc., that are associated with the treatment), mortality (associated 
with the compound), body weight/body weight gain, food consumption/efficacy, water 
consumption. 
 Pathology (Clinical): Blood and urine test results, corresponding to clinical chemistry 
(biochemical parameters evaluated from the blood tests, e.g. enzyme activities, lipid 
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profile, electrolyte levels, etc.), haematology (all the blood parameters) and urinalysis (all 
urine tests and parameters). 
 Pathology (Gross): Gross examination of all organs after the treatment period 
referring to the changes in their appearance e.g. discoloration, pigmentation, 
enlargement, etc. 
 Organ Weight: Post-treatment observations including absolute organ weight and 
relative (to the body weight and/or to the brain weight) organ weight. 
 Pathology (Non-neoplastic): Post-treatment observations corresponding to the 
plethora of detailed histopathological changes observed in different organs. Each 
histopathological effect was recorded for particular target organ (e.g. liver), and further 
specified target sites (e.g. centrilobular hepatocytes). 
For reproductive/developmental toxicity studies, the effect types refer to: 
 Maternal toxicity, including in-life observations and necropsy findings (gross 
pathology, organ weights (uterine weight, especially), non-neoplastic pathology). 
 Reproductive toxicity, including the information on the oestrus cycle (number of 
corpora lutea), reproductive performance (number of implantations, pre- and post-
implantation losses, resorptions, birth index, gestation index, etc.), offspring survival 
(number of live and dead fetuses; litter size, litter viability), reproductive outcome (sex 
ratio), foetal/litter weight. 
 Developmental toxicity, including skeletal malformations or alterations. 
Newly harvested data underwent a manual curation process (conducted by Altamira 
LLC), prior to being ported into the COSMOS oRepeatToxDB.  
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Figure 6.1 
Screenshots from the COSMOS ToxRefDB data entry tool for oral repeated dose toxicity data 
harvesting (part 1): Main screen and COSMOS Interim Input Form 
  
Main screen of the COSMOS ToxRefDB 
 
  
 
 
Selecting the harvested 
compound from the drop-
down pick list. 
 
 
 
 
COSMOS Interim Input Form 
 
 Entering the information on:  
Data entry status (e.g.: 
complete) and level (e.g.: all 
observations or summary); 
Harvested document 
(number, source, included 
references, etc.); 
Study design: year; 
study/data quality; study 
type; study duration; test 
animals (species, strain); 
dosage regimen (route of 
administration, etc.); 
Test material (purity, 
batch/lot, etc.). 
Treatment Group Upload XLS file template 
Required fields in blue; Non-obligatory ones in orange 
  
 
 
Filling-in the Treatment 
Group Upload template file 
using the drop-down pick 
lists. 
 
Treatment Group List has been uploaded from 
Treatment Group Upload XLS file 
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Figure 6.2 
Screenshots and examples COSMOS ToxRefDB as the data entry tool for oral repeated dose toxicity 
data harvesting (part 2): Study Effect List, Study Effects Input Form, Input Form for Quantitative 
Data, and Show All Effects Form 
Study Effect List 
 
  
Selecting the Effect Type 
Target. 
 
Specifying the Target Site 
(where applicable). 
 
Providing the Effect 
Description. 
 
Specifying the Effect 
Direction. 
 
Applying the entered 
information to the relevant 
treatment groups. 
Study Effects Input Form 
  
  
 
 
Specifying the study 
endpoint, i.e.: LOAEL value. 
 
 
Entering the details for each 
recorded effect: 
Statistical Significance; 
Severity; 
Treatment relatedness; 
Quantitative data. 
Input Form for Quantitative Data 
 
 
Show All Effects Form 
 
  
 
 
 
Reviewing the recorded 
information. 
 
Drop-down pick lists available for each element 
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6.3.3. The QC/QA of the COSMOS oRepeatToxDB content 
During the data harvesting procedure the Klimisch scores and the information on the 
study compliance with GLP or guidelines were captured from original data sources, i.e. from 
the EC ECHA database and from the SCCS opinions. The data record reliability was 
addressed by the COSMOS MINIS grade (please refer to section 6.1.3).  
Prior to the public release of the oRepeatToxDB, the COSMOS ToxRefDB entry form 
tables were queried from the database for review and QC/QA process (Table 6.4). 
Approximately 2% of the toxicity records included in the COSMOS oRepeatToxDB were 
selected randomly. In total, 2722 records were checked for correctness/completeness 
against the original data sources. The outcome was used to calculate the error rates. 
Table 6.4 
The tables, fields, and total number of records subjected to the QC/QA procedure of the 
COSMOS oRepeatToxDB. During the QC/QA the number of incorrect records in particular tables 
have been recorded and used to provide the QA statistics 
Table Fields subjected to the QC/QA procedure Total QC-
ed records 
Studies Test Substance Name; % Purity; % Active; Tested Form; Test 
Substance Comments; Study Type; Duration; Route Of 
Exposure; Species; Strain; Animal Weight Or Age Range; Dose 
Or Conc. Levels; Dosage Regimen; Vehicle; Dose Comments; 
Study Design Comments; Data Record Reliability [Source]; 
Document Source; Document Number; Study Source Type; 
Study Report; Source; Study Report Number; Study Conducted 
Year; Journal Publication Citation; Study/Article Title; Year 
(Report/ Citation) 
104 
Survival 
Sex; # Animals; Concentration Or Dose; Dosing Comments; 
Assay Type; Sites; Effects; Effects Description; Time Of Findings; 
Statistical Significance; Treatment Relatedness; Effects Severity; 
Comments 
102 
Food/Water consumption 238 
Body weight 578 
Clinical signs 578 
Clinical chemistry 204 
Haematology 408 
Organ weight 204 
Gross pathology 0 
Pathology-micro 306 
Total in QA   2722 
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6.4. Results 
6.4.1. COSMOS oRepeatToxDB content 
The final COSMOS oRepeatToxDB contained 340 in vivo oral repeated dose toxicity 
studies for 228 chemicals: 186 cosmetics-related studies (including 100 hair dyes) and 42 for 
impurities (originating from the U.S. FDA CFSAN CERES).  
As far as the experimental data content are concerned, the COSMOS oRepeatToxDB 
was profiled for the species and study types (Figure 6.3). 
  
Figure 6.3 
Number of studies per species per study type included in COSMOS oRepeatToxDB 
The toxicological effects recorded included: clinical parameters (e.g. body weight 
gain, clinical signs, clinical chemistry, mortality, urinalysis), post- sacrifice measurements 
(organ weight, necropsy, histopathology) and parental, reproductive and developmental 
(pre- natal) toxicity. For each effect recorded the “direction” (increase/decrease/no change) 
and “severity” of finding was specified, as well as “treatment-relatedness”, “dose-
dependency”, “statistical significance” and (where applicable) “biological/toxicological 
relevance”.  
As far as the target organ toxicity was concerned, the organ weight, gross pathology 
and/or histopathology effects were recorded for a total number of 41 organs. The ten most 
frequently affected (in these three assays) are presented in Figure 6.4.  
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Figure 6.4 
The ten most frequently affected target organs in organ weight, gross pathology and histopathology 
assays 
The organ weight observations (including “decrease”, “increase” or “no change” of 
absolute organ weight, and/or relative to brain or body weight organ weight) were recorded 
for 18 different organs for the total number of 161 compounds tested in 201 studies. The 
gross pathological findings include macroscopic lesions and changes in appearance (mostly 
discoloration and size alterations) of 28 organs observed in 65 studies performed for 64 
tested compounds. The histopathological lesions were recorded for 36 target organs and 
further profiled for the species. It turned out that the most sensitive organs are liver and 
kidney, whereas the most sensitive species is rat (Figure 6.5).  
The histopathological lesions were recorded with respect to the sites hierarchically 
differentiated to the organs (systems), tissues (segments), and cells (organelles). This way of 
data recording enabled the further development of ontologies for particular target organs 
toxicity (this process is discussed in more depth in chapter 7). Overall, the COSMOS 
oRepeatToxDB includes histopathological data for the total number of 118 “organ (system)-
tissue (segment)-cell” sites. The example of sites available for the most sensitive target 
organ (i.e. liver) are presented in Figure 6.6. 
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Figure 6.5 
The five most sensitive target organs in COSMOS oRepeatToxDB, as indicated by the number of 
recorded histopathological lesions. They are followed by: thyroid, skeletal muscle, lymph node, bone 
marrow, heart, adrenal, pancreas and large intestine (not presented here). COSMOS oRepeatToxDB 
includes histopathological effects for the total number of 36 target organs 
 
Figure 6.6 
The examples of hierarchical “organ (system)-tissue (segment)-cell” sites available for the liver in 
oRepeatToxDB and corresponding total numbers of records with toxicological effects (across all 
species, study types and dose levels) 
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6.4.2. The QC/QA of COSMOS oRepeatToxDB content 
The results of the QA on the COSMOS oRepeatToxDB indicated 0.57% erroneous 
records (e.g. mistake in animal counts or incorrectly inserted effects), and 5.2% missing 
records (e.g. effect descriptions). 
6.5. Discussion 
This chapter outlines the current requirements for publicly available, cosmetics-
enriched, repeated dose toxicity database. In order to fulfil this need, the new oral repeated 
dose toxicity data were harvested from a range of scientific literature and regulatory 
sources (including SCCS opinions), and incorporated into novel COSMOS oRepeatToxDB. The 
high quality of the incorporated data was assured by consistent application of the 
established MINImum Study inclusion criteria (COSMOS MINIS) during the data collation, 
and rigorous procedure for the data curation and quality control.  
The COSMOS oRepeatToxDB includes 340 toxicity studies for 228 chemicals (186 
cosmetics-related, including 100 hair dyes and 42 impurities). This is (by far) the largest 
publicly available database in which the toxicological effects occurring at particular dose 
levels and at given sites are precisely represented for each recorded toxicity study. The 
study design captures all of the details for species, sex, routes of exposure, dose groups 
(levels and number of animals), control group information, and references. The effects are 
described by sets of controlled vocabularies and qualified by the time of findings, severity, 
statistical significance, and treatment-relatedness. The sites are hierarchically differentiated 
for organs (system), tissues (segment), and cells (organelles). For each relevant numeric 
endpoint recorded (e.g. LO(A)EL), the detailed information on the critical effects observed is 
included.  
The unique data model of the COSMOS oRepeatToxDB and the level of details of the 
recorded data enable in vivo data mining and development of chemical-toxicological 
ontologies (discussed more in-depth in chapter 7). COSMOS oRepeatToxDB supports the 
development of in silico tools for predicting target organ toxicity. As revealed by the analysis 
of the database content, the most sensitive target organs (for which the highest number of 
toxicological effects was recorded) include liver and kidney, which indicates that future 
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research will be focused on these areas. The COSMOS oRepeatToxDB provided the 
foundation for the analysis described in chapter 7. 
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Chapter 7 
Mechanistic, Ontology-based Liver Toxicity Data Mining in COSMOS oRepeatToxDB 
7.1. Background 
The importance of mechanistic (mode-of-action-based) data mining in predictive 
toxicology was discussed in-depth in chapter 1.2. The fundamental significance of mature 
chemical-toxicological ontologies for the successful application of data mining has been also 
outlined (chapter 1.3 and chapter 6). Briefly, the ontologies identifying the toxic effects 
observed at particular organism levels (organs, tissues, or cells) through precisely 
categorised terms can provide the rationale for the MoA-based toxicity prediction. 
In general, chemicals exhibiting systemic toxicity do not cause a similar degree of 
effects in all organs, but elicit the major toxicity in one or two of them, which are termed 
“the target organ(s) for toxicity” (UNL, 2002). The analysis of the COSMOS oRepeatToxDB 
content presented in chapter 6.4.1 identified the liver as the most sensitive target organ for 
which the highest number of histopathological lesions has been recorded. The liver, as the 
largest internal organ and gland in the human body, is highly exposed to a range of 
potentially toxic substances entering an organism. Therefore, with regard to the prediction 
of repeated-dose toxicity, hepatotoxicity and the mode(s) of action of its potential chemical 
inducers are of particular interest. 
7.1.1. Overview of the structure and functions of the liver 
The liver is located in the right upper quadrant of the abdominal cavity, right of the 
stomach and overlying the gallbladder. Gross anatomy divides it into the two lobes, left and 
right, separated by the falciform ligament and visible from the parietal surface. The two 
additional lobes, the caudate lobe and the quadrate lobe, are visible between the right and 
left lobes from the visceral surface (Abdel-Misih & Bloomston, 2010). 
The liver is a metabolically active organ associated with multiple functions. It 
regulates the levels of most chemicals in the blood and produces and excretes bile. 
Physiological functions of the liver cells (hepatocytes) also include synthesis and storage of 
protein, synthesis of cholesterol and phospholipids, transformation of carbohydrates, 
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storage of glycogen and detoxification. Hepatocytes are the primary target of many liver 
injuries, including excessive fat accumulation and drug induced liver damage. In order to 
understand the hepatotoxic effects, it is necessary to understand the distinctive features of 
hepatic vascular and biliary systems and their associations with liver cells’ architecture 
(Bowen, 2003; Abdel-Misih & Bloomston, 2010; Krishna, 2013). 
The liver vascular system is based on a dual blood supply: hepatic artery providing 
arterial oxygenated blood (approx. 25% of liver blood supply), and portal vein, directing the 
nutrient-rich venous blood from the stomach, small intestine, pancreas and spleen (75% of 
liver blood supply). Terminal branches of the hepatic artery and portal vein mix and drain as 
they enter liver sinusoids, i.e. vascular capillaries which are lined with endothelial cells 
separating the hepatocytes from the blood flowing through the sinusoids. Sinusoidal 
endothelial cells play an important role in hepatic microcirculation. The space between 
hepatocytes and sinusoidal endothelial cells contains hepatic stellate (Ito) cells, playing an 
essential role in liver regeneration. Stellate cells secrete growth factors and the main 
constituent materials of the matrix (e.g. collagen and reticulin) to replace the damaged 
hepatocytes and form scar tissue. The sinusoidal lumen contains liver-specific macrophages 
(Kupffer cell), which remove debris or aged/damaged erythrocytes in the blood flow and 
stimulate the immune system through the secretion of numerous factors and cytokines. The 
blood from the sinusoids reaches the central vein of each hepatic lobule (structural unit of 
the liver, please see below). Central veins fuse into hepatic veins, which leave the liver and 
drain into the vena cava (Bowen, 2003). 
The biliary system (biliary tree) of the liver consists of canaliculi (intercellular spaces 
between adjacent hepatocytes surrounding the sinusoids) and ducts which transfer the bile 
from the liver into the small intestine. Hepatocytes secrete bile into the canaliculi. The bile 
flows parallel to the sinusoids, but in the opposite direction to the blood flow. Canaliculi 
coalesce into bile ducts lined with epithelial cells, ultimately draining into the common 
hepatic duct. It fuses with the cystic duct from the gallbladder and forms the common bile 
duct, running to the duodenum, the first section of the small intestine. The distinctive 
arrangement of the bile duct, hepatic artery and portal venule in the liver is called a portal 
triad (Bowen, 2003). 
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The liver is covered with a connective tissue (septae), dividing the parenchyma into 
very small, structural units – lobules. The hepatic lobule consists of hexagonal plates of 
hepatocytes with a central vein (hepatic venule) located in the middle and portal triads 
located peripherally. The lobule is divided into the following parts: centrilobular, midzonal, 
and periportal. The functional unit of the liver is hepatic acinus, roughly oval mass of 
hepatocytes around the hepatic arterioles and portal venules. The hepatic acinus is divided 
into the three zones reflecting the distance from the arterial blood supply. Zone 1 
(corresponding to the periportal part of the hepatic lobule; surrounding the portal tract and 
located closest to the arterioles) consists of the best oxygenated hepatocytes. Acinar zone 2 
(corresponding to the midzonal part of the hepatic lobule) and zone 3 (corresponding to the 
centrilobular part of the hepatic lobule; surrounding the hepatic venule) contain the poorer 
oxygenated hepatocytes, as blood from the portal tract flows though the acinar zones to the 
venule being deoxygenated (Bowen, 2003; Abdel-Misih & Bloomston, 2010; Krishna, 2013).  
The toxic effect of many drugs on the liver has been linked to the circulatory 
dysfunction (Lautt, 2009), and the lesions caused by a range of pathologic processes are 
frequently reflected in the acinar structure (Bowen, 2003). 
7.1.2. Toxicity categories of liver injury: steatosis, steatohepatitis and fibrosis 
Liver steatosis, i.e. excessive accumulation of fatty acids in hepatocytes due to the 
impairment of the process of synthesis and elimination of triglycerides, may be a cause of a 
chronic liver injury. The pathological changes associated with steatosis include formation of 
lipid droplets in the cytoplasm of hepatocytes, lipid vacuolisation, hepatomegaly 
(hypertrophy, enlargement of the liver) and lipid deposition (Vitcheva et al., 2013).  
When associated with inflammation, the fatty liver progresses to steatohepatitis. 
The pathological changes characterising steatohepatitis mostly involve the acinar zone 3 and 
include hepatocellular injury and inflammation in the lobular parenchyma. Hepatocellular 
injury is manifested by ballooning degeneration of hepatocytes, associated with formation 
of Mallory’s hyalines (clumps of damaged material in the hepatocyte cytoplasm), 
apoptosis/necrosis, associated with increased hepatocellular expression of the membrane 
receptor Fas and megamitochondria in hepatocytes. The cell necrosis evokes an 
inflammatory reaction morphologically manifested by the appearance of inflammatory cells 
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(neutrophils, lymphocytes, macrophages), oedema and congestion around parenchymal 
cells (Vitcheva et al., 2013).  
The chronic inflammation leads to liver fibrosis, associated with tissue destruction 
and simultaneous repair processes, resulting in a lack of balance between the deposition 
and degradation of extracellular matrix (ECM) and a change of ECM composition. It can be 
characterised by thickening of the liver capsule (due to the excessive accumulation of ECM 
proteins, including collagen) and hyperplasia (due to the increased nuclear diameter and 
volume and cytoplasmic volume of the hepatocytes) (Bataller & Brenner, 2005; Vitcheva et 
al., 2013, Landesmann, 2016). The Adverse Outcome Pathway (Figure 7.1) for liver fibrosis 
has been recently proposed (Landesmann, 2016).  
 
Figure 7.1 
Schematic representation of the Adverse Outcome Pathway for liver fibrosis (from Landesmann, 
2016). The Molecular Initiating Event (MIE) of this AOP is protein alkylation, leading to the following 
Key Events (KEs): 
 Cell injury and death; 
 Activation of Kupffer cells, due to engulfment of apoptotic bodies, i.e. fragmented DNA from 
apoptotic hepatocytes; 
 Expression of fibrogenic cytokines, Transforming Growth Factor-β (TGF-β1); 
 Activation of hepatic stellate cells (HSC), which change from vitamin A-rich phenotype to a 
myofibroblastic phenotype, exhibiting fibrogenic properties (secretion of pro-inflammatory 
cytokines and chemokines, synthesis of matrix proteins and of inhibitors of matrix 
degeneration); 
 Progressive collagen accumulation and changes in Extracellular Matrix (ECM) composition. 
The excessive accumulation of ECM proteins progressively affects the whole organ and alters its 
normal functioning, which corresponds to liver fibrosis, the adverse outcome (AO). The scheme does 
not include two Key Events, namely inflammation and oxidative stress, which are considered to be 
present throughout the entire AOP  
 Liver fibrosis occurring in the majority of types of chronic liver diseases results in 
derangement of the liver architecture, portal hypertension and may produce irreversible 
circulation changes leading to cirrhosis and, eventually, liver failure and death.  
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7.2. The aims of chapter 7 
The aims of the present chapter realised in collaboration with the COSMOS 
consortium partners (please refer to Annex 1) are related to the objective 6 of the current 
PhD program (section 1.5), and include: 
 Validation of the liver toxicity ontology developed on the basis of the data collated at 
the stage of the construction of COSMOS oRepeatToxDB; 
 Ontology-based liver toxicity (steatosis) data mining of COSMOS oRepeatToxDB; 
 Structural (ToxPrint chemotype) analysis of the chemical compounds obtained as a 
result of data mining and identification of the structural fragments associated with the 
endpoint investigated; 
 Formulating the mechanistic reasoning for the selected compounds on the basis of 
the literature search and results of molecular modelling analysis delivered by collaborating 
COSMOS consortium partners from BAS and S-IN. 
7.3. Materials and methods 
7.3.1. The development and validation of target organ toxicity ontologies 
As mentioned in chapter 6.1.2, mature chemical-toxicological ontologies for target 
organ toxicity are lacking in the existing databases. The currently available resources are 
limited to the taxonomies, e.g. OpenTox (An Open Source Predictive Toxicology Framework, 
available at: http://www.opentox.net/) project dictionaries, describing the relations 
between chemical and toxicological data and experiments, or the taxonomy of biologically 
relevant chemical entities and their activities proposed in the ChEBI dictionary (Smith et al., 
2007; Hardy et al., 2012). 
As discussed in chapter 6, observed toxicity effects have been recorded in COSMOS 
oRepeatToxDB with respect to the corresponding target sites structured hierarchically (as 
organs/tissues/cells). Thus, it was possible to link the phenotypic effects occurring at very 
high (whole organism) level, with the pathological changes observed at various lower levels: 
organs, tissues and finally cells. The conceptual scheme representing this hierarchy is shown 
in Figure 7.2 (Vitcheva et al., 2013). 
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Figure 7.2 
Conceptual scheme of the COSMOS oRepeatToxDB hierarchical ontology, enabling mapping of the 
observed pathological changes with high-level phenotypic effects (Vitcheva et al., 2013) 
Within this concept, the cell, in which the majority of the biological and chemical 
processes occur, can be regarded as the bottom-level intersection where biology, chemistry 
and toxicity meet. It is in the information for the cell that interactions can be investigated by 
accounting for the proteins and genes involved on one hand and the chemical and biological 
roles of the chemical compounds (determined by their physicochemical, electronic, etc., 
properties) on the other. In order to enable linkage of the biological effects with chemicals 
involved in toxicity pathways, such ontologies (along with related controlled vocabularies) 
have been designed within COSMOS oRepeatToxDB.  
The dynamic and iterative process of the development of ontologies actually began 
at the data harvesting stage, when the detailed domains and scopes of the ontologies were 
defined. The simultaneous inspection and mining of the data collated has led to the 
formulation of the initial ontologies. Subsequently, a range of iterative steps were 
performed, including:  
 Further data mining; 
 Consultations with trained toxicologists; 
 Enumeration of the important terms in the ontologies; 
 Re-defining the classes and hierarchies; 
 Validation and updating of the ontologies. 
The focus of the present chapter was placed on the validation of the ontology 
developed for liver toxicity. With respect to the molecular mechanisms involved in the 
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development of chronic liver disease (steatosis, steatohepatitis and fibrosis, discussed in 
section 7.1.2), the formulation of the reasoning can be presented schematically as shown in 
Figure 7.3 (Vitcheva et al., 2013; Mostrag-Szlichtyng et al., 2014). The liver toxicity ontology 
developed may be perceived as the computer science representation of this concept. 
 
Figure 7.3 
The molecular mechanisms involved in the development of chronic liver disease (Vitcheva et al., 
2013) 
7.3.2. Ontology-based liver toxicity data mining of the COSMOS oRepeatToxDB 
The final COSMOS oRepeatToxDB was queried for compounds associated with liver 
toxicity. The extracted dataset was subjected to ontology-based data mining in order to 
identify the chemicals associated with the liver steatosis/steatohepatitis/fibrosis endpoints. 
7.3.3. Structural analysis 
The chemicals identified which were associated with the endpoints investigated 
were subjected to the chemotype analysis. The ToxPrint chemotypes library 
(www.toxprint.org) and the ChemoTyper software tool (www.chemotyper.org) were utilised 
(this methodology was described in-depth in chapter 3). 
7.3.4. Mechanistic reasoning formulation 
For the compounds selected the mechanism of toxic action was proposed on the 
basis of a literature search (NIH PubMed, http://www.ncbi.nlm.nih.gov/pubmed) and the 
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results of a molecular modelling analysis delivered by collaborating COSMOS consortium 
partners from BAS and S-IN. 
7.4. Results 
7.4.1. Ontology-based liver toxicity data mining 
The ontology developed for liver toxicity covers a range of hierarchical sites and over 
30 effects/pathological changes, giving the total number of 53 unique “site-effect” pairs 
(Table 7.1). 
Querying COSMOS oRepeatToxDB for all histopathological effects recorded for the 
liver resulted in the retrieval of a total of 70 compounds with such effects. The terms related 
to liver steatosis/steatohepatitis/fibrosis were used to extract the final set of compounds of 
interest (please refer to section 7.1.2 for the description of the associated pathological 
changes). This analysis led to the identification of 13 relevant combinations of “tissue-cell” 
sites and effects (Figure 7.4) covered by 59 chemicals (Table 7.2) (Mostrag-Szlichtyng et al., 
2014).  
As an example of the type of compound identified, for allyl hexanoate (CMS-13529, 
compound #17 in Table 7.2), oRepeatToxDB contains information on a subchronic study in 
rat with the observed effect “fibrosis” and associated site “liver – general”, for 
tetrakis(hydroxymethyl)phosphonium sulfate (CMS-1349, compound #8 in Table 7.2) 
“cytoplasmic vacuolisation” has been recorded for “lobule – periportal – hepatocyte” in 
subchronic studies in rat, etc.  
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Table 7.1 
The “liver-tissue-cell” sites with corresponding effects covered by the ontology in the COSMOS 
oRepeatToxDB (Vitcheva et al., 2013) 
TISSUE 
CELLS/ 
ORGANELLES 
EFFECT NAMES 
LIVER GENERAL 
 
Congestion; Cytological Alterations; Fatty Change; Fibrosis; 
Firm Areas; Focal Cellular Change; Granuloma; 
Haematopoiesis; Hepatitis; Hypertrophy; Inflammation; 
Lesions (Nos); Lipid Deposition; Necrosis; Pigmentation; 
Proliferation 
BILIARY SYSTEM – 
BILE CANALICULI 
 Pigmentation 
BILIARY SYSTEM - BILE 
DUCT  
Hyperplasia; Proliferation; Vacuolisation 
ACINUS – PERIACINAR 
ZONE 
ACINAR CELLS Fibrosis; Hypertrophy; Necrosis 
CYTOPLASM Vacuolisation 
LOBULE – 
CENTRILOBULAR 
HEPATOCYTES 
Cytoplasmic Alteration; Distention; Enlargement; Glycogen 
Loss; Hypertrophy; Necrosis; Vacuolisation 
LOBULE – MIDZONAL HEPATOCYTES Hypertrophy; Hyperplasia 
LOBULE – 
PERIPORTAL 
HEPATOCYTES Cellular Infiltration; Hypertrophy 
MESENCHYMA 
STELLATE CELLS Hypertrophy; Lipid Accumulation 
KUPFFER CELLS Distention; Hyperplasia; Discoloration; Pigmentation 
CYTOPLASM Vacuolisation 
PARENCHYMA HEPATOCYTES 
Cellular Infiltration; Degeneration; Fatty Changes; 
Hypertrophy; Inflammation; Necrosis; Pigmentation; 
Proliferation; Vacuolisation 
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Table 7.2 
The 59 compounds for which the histopathological changes related to the liver steatosis/steatohepatitis/fibrosis have been found in COSMOS 
oRepeatToxDB (Mostrag-Szlichtyng et al., 2014) 
# CMS ID CAS RN PREFERRED NAME # CMS ID CAS RN PREFERRED NAME 
1 365 108-94-1 CYCLOHEXANONE  16 11422 106990-43-6 
N,N'''-1,2-ETHANEDIYLBIS[N-[3-[[4,6-BIS[BUTYL(1,2,2,6,6-PENTAMETHYL-4-
PIPERIDINYL)AMINO]-1,3,5-TRIAZIN-2-YL]AMINO]PROPYL]-N',N''-DIBUTYL-N',N''-
BIS(1,2,2,6,6-PENTAMETHYL-4-PIPERIDINYL)-1,3,5-TRIAZINE-2,4,6-DIAMINE 
2 609 107-21-1 ETHYLENE GLYCOL  17 13529 123-68-2 ALLYL HEXANOATE  
3 618 104-76-7 2-ETHYL-1-HEXANOL  18 13782 70624-18-9 
POLY(CYANURIC CHLORIDE-CO-TERT-OCTYLAMINE-CO-1,6-BIS(2,2,6,6-
TETRAMETHYL-4-PIPERIDYLAMINO)HEXANE)  
4 663 98-01-1 FURFURAL  19 14793 7128-64-5 2,2'-(2,5-THIOPHENEDIYL)-BIS (5-TERT-BUTYLBENZOXAZOLE)  
5 780 67-63-0 ISOPROPYL ALCOHOL  20 15009 135861-56-2 DIMETHYLDIBENZYLIDENE SORBITOL  
6 887 75-09-2 METHYLENE CHLORIDE  21 15014 134701-20-5 2,4-DIMETHYL-6-(1-METHYLPENTADECYL)PHENOL  
7 1178 51-03-6 PIPERONYL BUTOXIDE  22 15070 161717-32-4 
PHOSPHOROUS ACID, CYCLIC BUTYLETHYL PROPANEDIOL, 2,4,6-TRI-TERT-
BUTYLPHENYL ESTER  
8 1349 55566-30-8 
TETRAKIS(HYDROXYMETHYL)PHOS
PHONIUM SULFATE  
23 25576 56216-28-5 3,5-DIAMINO-2,6-DIMETHOXYPYRIDINE DIHYDROCHLORIDE  
9 2321 131-57-7 OXYBENZONE  24 26324 68391-30-0 C.I. BASIC RED 76  
10 3598 108-91-8 CYCLOHEXYLAMINE  25 26325 68391-31-1 C.I. BASIC YELLOW 57  
11 3639 111-76-2 
ETHYLENE GLYCOL MONOBUTYL 
ETHER  
26 26704 74578-10-2 2,6-XYLIDINE, 4-(2,6-DICHLORO-ALPHA-(4-IMINO-3,5-DIMETHYL-2,5-  
12 3681 108-31-6 MALEIC ANHYDRIDE  27 26998 81892-72-0 1,3-BIS-(2,4-DIAMINOPHENOXY)PROPANE  
13 3855 96-91-3 PICRAMIC ACID  28 27489 94158-13-1 2,2'-((4-AMINO-3-NITROPHENYL)IMINO)BISETHANOL HYDROCHLORIDE  
14 4141 111-77-3 
DIETHYLENE GLYCOL 
MONOMETHYL ETHER  
29 27490 94158-14-2 2-(1,3-BENZODIOXOL-5-YLAMINO)ETHANOL HYDROCHLORIDE  
15 4291 6197-30-4 OCTOCRYLENE  30 27591 97404-02-9 2-((4-AMINOPHENYL)AZO)-1,3-DIMETHYL-1H-IMIDAZOLIUM CHLORIDE  
Continued on the following page 
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Table 7.2, continued 
The 59 compounds for which the histopathological changes related to the liver steatosis/steatohepatitis/fibrosis have been found in COSMOS 
oRepeatToxDB (Mostrag-Szlichtyng et al., 2014) 
# CMS ID CAS RN PREFERRED NAME # CMS ID CAS RN PREFERRED NAME 
31 4464 93-15-2 EUGENYL METHYL ETHER  46 28451 149591-38-8 BISHYDROXYETHYL BISCETYL MALONAMIDE  
32 4878 77-90-7 TRIBUTYL ACETYLCITRATE  47 34877 71786-60-2 N,N-BIS(2-HYDROXYETHYL)ALKYL(C12-C18)AMIDE  
33 4879 77-99-6 TRIMETHYLOLPROPANE  48 42308 26125-40-6 POLY(P-DICHLOROBENZENE-CO-SODIUM SULFIDE)  
34 4997 107-88-0 1,3-BUTYLENE GLYCOL  49 44734 128729-28-2 
HYDROXYPROPYL BIS(N-HYDROXYETHYL-P-PHENYLENEDIAMINE) 
HYDROCHLORIDE  
35 5629 16470-24-9 
C.I. FLUORESCENT BRIGHTENER 
220  
50 46977 16867-03-1 2-AMINO-3-HYDROXYPYRIDINE  
36 5805 32687-78-8 
1,2-BIS(3,5-DI-TERT-BUTYL-4-
HYDROXYHYDROCINNAMOYL)HYD
RAZINE  
51 50942 3248-91-7 C.I. BASIC VIOLET 2  
37 5856 52829-07-9 
BIS(2,2,6,6-TETRAMETHYL-4-
PIPERIDINYL) SEBACATE  
52 56289 59820-63-2 3-METHYLAMINO-4-NITROPHENOXYETHANOL  
38 7013 2682-20-4 2-METHYL-4-ISOTHIAZOLIN-3-ONE  53 56847 61693-43-4 3-AMINO-2,4-DICHLOROPHENOL HYDROCHLORIDE  
39 8572 128-95-0 C.I. DISPERSE VIOLET 1  54 59879 77061-58-6 
2-((4-(DIMETHYLAMINO)PHENYL)AZO)-1,3-DIMETHYL-1H-IMIDAZOLIUM 
CHLORIDE  
40 8676 1777-82-8 2,4-DICHLOROBENZYL ALCOHOL  55 60520 82576-75-8 2-((4-AMINO-2-METHYL-5-NITROPHENYL)AMINO)ETHANOL  
41 8750 75-85-4 AMYLENE HYDRATE  56 60750 84540-50-1 5-AMINO-6-CHLORO-O-CRESOL  
42 9026 846-70-8 EXT. D&C YELLOW NO. 7  57 67443 78301-43-6 
POLY(2,2,4,4-TETRAMETHYL-20-(OXIRANYLMETHYL)-7-OXA-3,20-
DIAZADISPIRO(5.1.11.2)HENEICOSAN-21-ONE)  
43 10280 125643-61-0 
ALKYL(C7-9-BRANCHED) 3,5-DI-
TERT-BUTYL-4-
HYDROXYHYDROCINNAMATE  
58 72013 68391-32-2 BASIC BROWN 17  
44 10707 4368-56-3 C.I. ACID BLUE 62  59 72054 23920-15-2 HC BLUE NO. 11  
45 10786 142-19-8 ALLYL HEPTANOATE          
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Figure 7.4 
Example of liver “site-phenotypic effect” pairs related to the steatosis/steatohepatitis/fibrosis in 
COSMOS oRepeatToxDB 
7.4.2. Structural analysis 
The ToxPrint chemotypes analysis of 59 compounds obtained as a result of data 
mining revealed that the most abundant structural classes included alcohols (aliphatic and 
aromatic), amines (aromatic and aliphatic), ethanolamines, oxy- alkanes, ethers and 
compounds with azo- and nitro- aromatic groups (Figure 7.5) (Mostrag-Szlichtyng et al., 
2014). The example compounds representing identified distinctive structural features are 
presented in Table 7.3 
 
Figure 7.5 
The structural profile of 59 compounds associated with liver steatosis/steatohepatitis/fibrosis 
expressed as the frequency of ToxPrint features (the actual counts were provided on the plot’s bars) 
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Table 7.3 
Distinct structural features identified in the set of 59 compounds associated with liver 
steatosis/steatohepatitis/fibrosis 
Structural characteristics Example compounds 
Aliphatic alcohols/glycols, glycol 
ethers 
 
(Di)Ethanolamines, long aliphatic 
chains 
 
Aromatic nitro- groups, aromatic 
amines, (di)ethanolamines 
 
Aromatic halides, compounds 
with azo- aromatic groups, 
anthraquinones 
 
Furans, thiazoles, cyclohexane 
derivatives 
 
Rigid rings/cyclic fragments and 
long flexible chains 
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7.4.3. Mechanistic reasoning formulation 
As outlined in 1.2, mode-of-action-based predictive toxicology approaches support 
the Adverse Outcome Pathway (AOP) framework (OECD, 2013). In order to facilitate the 
understanding and formulation of the MoA/AOPs involved in the development of chronic 
liver disease, ontology based data mining and subsequent structural analysis was combined 
with the results of molecular modelling (MM), as performed by the collaborating COSMOS 
partners from BAS and S-IN (Mostrag-Szlichtyng et al., 2014; Al Sharif et al., 2016). The 
conceptual scheme summarising this approach is shown in Figure 7.6 (Mostrag-Szlichtyng et 
al., 2014). 
 
Figure 7.6 
Conceptual scheme demonstrating the process of “knowledge discovery from data” (KDD) applied to 
liver steatosis. The possible associations between phenotypic effects, structural features and 
molecular mechanisms were identified through in vivo data and existing knowledge mining, 
combined with molecular modelling 
The AOP leading to the liver steatosis was recently proposed (Al Sharif et al., 2014; Al 
Sharif et al., 2016), and the Peroxisome Proliferator-Activated Receptor gamma (PPAR𝛾) has 
been suggested as one of the receptors involved in the MIE. PPAR𝛾 is responsible for the 
regulation of adipogenesis (adipocyte proliferation and differentiation), lipid and glucose 
homeostasis, inflammatory responses, vascular functions and placental development. The 
MoA/AOP proposed by Al Sharif and co-workers, leading from tissue-specific ligand-
dependent PPAR𝛾 dysregulation to liver steatosis, is shown in Figure 7.7. Within this AOP 
the MIE induces up-regulation of target genes for lipid transport/binding proteins, fatty acid 
and triglyceride synthesizing enzymes, and lipid droplet-associated proteins (LD proteins). 
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This AOP covers the entire cascade of key molecular events and the subsequent cytological 
and histopathological manifestations of liver steatosis, namely increased number or size of 
lipid droplets, deposition of triglycerides in hepatic tissue (instead of in adipose one) and 
hepatomegaly (Al Sharif et al., 2014; Al Sharif et al., 2016). 
 
Figure 7.7 
Proposed MoA/AOP from tissue-specific ligand-dependent PPAR𝛾 dysregulation to liver steatosis 
(from Al Sharif et al., 2014) 
A pharmacophore model for full PPARγ agonists (Figure 7.8), indicating that 
hydrogen bonding and hydrophobic and aromatic structural elements are the most 
significant aspects, has also been proposed recently, as a result of a molecular modelling 
procedure (Al Sharif et al., 2016). 
The structural analysis revealed that the set of chemicals identified contained 
potential PPARγ agonists, i.e. compounds with rigid hydrophobic structural fragments and 
flexible aliphatic chains (refer to Table 7.3). In order to verify the hypothesis arising from the 
in vivo toxicity data mining/structural analysis, the virtual screening procedure developed by 
the COSMOS partners (Al Sharif et al., 2016) was applied to the set of 59 compounds with 
liver steatosis-associated phenotypic effects (Mostrag-Szlichtyng et al., 2014; Al Sharif et al., 
2016). This procedure involved docking query structures in the binding pocket of PPARγ. As 
a result, CMS-26998 (1,3-bis-(2,4-diaminophenoxy)propane; Compound #27 from Table 7.2) 
was identified as a partial PPARγ agonist and CMS-1178 (piperonyl butoxide; Compound #7 
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from Table 7.2) as a full PPARγ agonist (Figure 7.9) (Mostrag-Szlichtyng et al., 2014; Al Sharif 
et al., 2016). 
 
Figure 7.8 
Pharmacophore model of full PPARγ agonists: Rosiglitazone (in magenta), Compound 544 (in green) 
and Farglitazar (in gray) – extracted from the PDB database (PDB, 2015). Obligatory pharmacophore 
points (F1 or F2 and F3), and optional pharmacophore points (F4-F7) are related to the hydrogen 
bonding properties (Don|Acc) and hydrophobicity/aromaticity (Hyd|Aro) (from Al Sharif et al., 2016; 
Mostrag-Szlichtyng et al., 2014) 
CMS-26998 (1,3-bis-(2,4-diaminophenoxy)-propane), in form of the hydrochloride 
salt, is used as a precursor for hair colouring, reacting with primary intermediates to form 
the final hair dye. The findings of a subchronic oral (gavage) repeated dose toxicity study in 
rat, with dose levels of 0, 40, 120 and 360 mg/kg bw/day, are recorded for this compound in 
COSMOS oRepeatToxDB (original data source: SCCP, 2007a). The SCCS concluded that the 
effects observed in this study may be indicators for organ toxicity (especially for the kidney). 
With regard to the liver, several observations related to the test substance were reported 
for the 120 mg/kg and the 360 mg/kg dose groups, including changes in clinical chemistry 
parameters (higher albumin, lower total protein levels, increased cholesterol and alkaline 
phosphatase activity) and higher liver weights in combination with increased incidence of 
inflammatory cell foci in the liver and intimal proliferation of the large veins. This compound 
was included in the list of potential steatosis inducers published by Vinken et al. (2012). 
Further insights regarding its possible mechanism of action are, however, not available in 
the scientific literature. In the present study, 1,3-bis-(2,4-diaminophenoxy)-propane was 
identified as a partial PPARγ agonist, whereas the indications exist that the prosteatotic 
activity of PPARγ is triggered specifically by full, and not partial, agonists (Chigurupati et al., 
2015; Al Sharif et al., 2016). Further investigation would be, therefore, required. 
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Figure 7.9 
The structures, mapping onto the pharmacophore and ToxPrint chemotypes of two compounds 
identified in the virtual screening procedure involving docking the structures in the binding pocket of 
PPARγ (Mostrag-Szlichtyng et al., 2014): 
(A) Partial PPARγ agonist: CMS-26998 (1,3-bis-(2,4-diaminophenoxy)propane) with two 
obligatory pharmacophore points: F1 (Don/Acc) and F3 (Hyd/Aro) and one additional 
pharmacophore point: F6 (Don/Acc);  
(B) Full PPARγ agonist: CMS-1178 (piperonyl butoxide) with two obligatory pharmacophore 
points: F1 (Don/Acc) and F3 (Hyd/Aro) and two additional points: F4 (Don/Acc) and F5 
(Hyd/Aro) 
CMS-1178 (piperonyl butoxide, PBO) is an insecticide synergist co-applied with 
pyrethrins and pyrethroids-like pesticides. It is used as an ingredient in anti-lice shampoos 
and is also classified as a skin protectant according to EU COSING use functions. The toxicity 
of PBO has been investigated in animal studies and liver was identified as the main target 
organ. Two studies for this compound are available in oRepeatToxDB: a 1-year oral (feed) 
study in dog (dose levels tested up to 53 mg/kg for males and 71 mg/kg for females), in 
which mild changes including liver steatosis and enlargement (hepatocyte hypertrophy) 
were observed, and a 90-day oral (feed) study in mouse (high dose levels tested of 10, 30, 
100, 300, 1000 mg/kg bw/day), in which more severe effects, including necrosis and liver 
cancer, were recorded. The available toxicity studies indicated that severity and type of 
hepatotoxic effects depend on the duration of exposure to PBO and/or on the dose levels 
tested. 
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PBO was predicted to be a PPARγ full agonist by the molecular modelling analysis 
and PPARγ activation by PBO binding has been suggested as a possible MIE leading to the 
liver steatosis upon short-term (low dosage) exposure (observed in the dog study). This has 
been attributed specifically to the structural characteristics of the glycol side chain of PBO. 
Noteworthy in our research regarding the hepatocarcinogenic effect of PBO 
observed in rodents (the mode of action of which remains unclear), was the suggestion that 
the mechanism is based on the potential of PBO to generate reactive oxygen species via 
metabolic pathways (opening of the methylenedioxy ring) and to induce oxidative stress, 
including oxidative DNA damage (Vitcheva et al., 2015). 
The integrated application of ontology-based in vivo toxicity data mining and 
structural analysis enabled the identification of the set of chemicals associated with liver 
steatosis, steatohepatitis, and fibrosis phenotypic effects and containing specific ToxPrint 
chemotypes. The molecular modelling provided insights into possible modes of toxic action, 
creating the basis for further investigations. 
7.5. Discussion 
The importance of, and the need for, mature chemical-toxicological ontologies (still 
lacking in the current databases) were demonstrated throughout the present thesis (chapter 
1.3, 6 and present chapter). This chapter describes the novel ontology developed for liver 
toxicity, including 53 unique “site-effect” pairs linking the phenotypic effects observed at 
the whole organism level with pathological changes occurring at lower levels (organs, 
tissues, cells).  
The ontology developed was applied for mechanistic in vivo data mining, which 
demonstrated its utility for identifying the chemical compounds associated with liver 
steatosis, steatohepatitis, and fibrosis phenotypic effects; 13 relevant combinations of 
“tissue-cell” sites and effects from the ontology led to the determination of 59 
hepatotoxicants. Their structural characteristics were investigated and the features 
associated with liver toxicity were found.  
The mechanistic reasoning was discussed for two identified compounds, 1,3-bis-(2,4-
diaminophenoxy)propane and piperonyl butoxide, and the activation of Peroxisome 
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Proliferator-Activated Receptor gamma (PPAR𝛾) was suggested as a mechanism involved in 
the MIE. The studies on the hepatocarcinogenic effect of PBO observed in rodents (the 
mode of action of which remains unclear), suggested the mechanism based on the potential 
of PBO to generate reactive oxygen species via metabolic pathways (opening of the 
methylenedioxy ring) and to induce oxidative stress, including oxidative DNA damage. 
It is envisaged that the knowledge developed in this analysis will be further 
elaborated and will contribute to the development of structural alerts for liver 
steatosis/steatohepatitis/fibrosis. In the present research it was demonstrated that: 
 Grouping of chemicals according to the precisely described phenotypic effects and 
structural analysis can be applied successfully to the discovery of associated chemotypes; 
 Interactive application of molecular modelling methods can be used to support the 
outcome of ontology-based data mining and to provide insights into possible underlying 
molecular mechanisms; 
 Combined approaches of the phenotype classification and molecular mechanisms 
investigation can successfully facilitate the process of MoA/AOP development. 
Chapter 8 
136 
 
Chapter 8 
Discussion 
8.1. Summary of work with respect to the objectives 
As outlined in chapter 1, the three essential building blocks of the COSMOS database 
include: the Cosmetics Inventory, Skin Permeability Database and oRepeatToxDB (oral 
repeated dose toxicity database). In this thesis, undertaken in collaboration with COSMOS 
partners, the entire process of knowledge development has been conducted within each of 
these data domains. It covered:  
 Harvesting, curating and integrating the data into a new relational chemical-
toxicological database; 
 Realising the scientific objectives formulated through data selection, exploration and 
pattern recognition; 
 Evaluating and presenting the knowledge developed. 
Each part of the work described has resulted in measurable outcomes and 
knowledge (the curated content of the database, Standard Operating Procedures, skin 
permeability potential classification rules, validated liver toxicity ontology, structural 
features associated with liver steatosis), supporting the development of computational 
methods for toxicity prediction and creating a solid foundation for further improvements in 
this area. The achievements of the realised PhD program are particularly significant in light 
of the current 21st Century Toxicology approaches (NRC, 2007) and the principles of the 
“3Rs” (Replacement, Reduction and Refinement) in toxicology (Russell & Burch, 1959), 
aiming to reduce the use of animals in toxicity testing. 
8.1.1. COSMOS Cosmetics Inventory 
Chapter 2 describes the current demand for a publicly available chemical inventory 
containing accurately identified cosmetics ingredients and related compounds and 
populated with good quality chemical structures. The need for a strategy addressing 
concerns over the quality of chemical information and structures was also highlighted. In 
order to satisfy these requirements, the collation of the COSMOS database and COSMOS 
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Cosmetics Inventory was associated with the establishment of a consistent procedure for 
chemical records’ curation and quality control. It resulted in the development of novel 
controlled vocabularies for the compounds and structure annotation (stereochemistry, 
double bond geometry, material type and composition type) and the SOP document (Annex 
2) describing the systematic QC approach (as applied during the collation of the COSMOS 
database content). The procedure designed with respect to the characteristic features of 
cosmetics-related compounds provided the standardised terminology to organise the 
complex relationships within this domain and the framework to deal with a range of non-
structurable substances. The annotation schemes were constructed to enable convenient 
identification of chemicals not handled well by cheminformatics methods (inorganics, 
compounds containing metal or metalloid atoms, botanicals, biological macromolecules, 
polymers, and mixtures), thus facilitating the compilation of computational datasets and 
enhancing the development of in silico predictive toxicology tools. The precisely identified 
compounds allowed accurate referencing of the associated biological data.  
The resulting publicly available (at: https://cosmosdb.eu/cosmosdb.v2) COSMOS 
database (81,406 chemical records) includes the largest (by far), quality-controlled inventory 
of cosmetics-related compounds (COSMOS Cosmetics Inventory with 17,100 records), which 
was necessary for conducting the novel analysis described in the chapter 3 of the present 
thesis, as well as for realising the objectives of chapters 4-7.  
The chemical space of the collated Cosmetics Inventory was analysed and compared 
with the chemical space occupied by food-related compounds from the U.S. FDA CFSAN 
PAFA database (chapter 3). The novel approach, combining the ToxPrint chemotypes 
structural features and physicochemical properties analysis was successfully applied to 
identify the structural classes better represented by cosmetics- and food- related 
compounds, and demonstrated their relation to the physicochemical properties and specific 
use functions within the cosmetics domain. For instance, COSMOS Cosmetics Inventory was 
richer in polyethylene glycols, quaternary ammonium salts, organosilicons and 
diethanolamines (characteristic for surfactants, emollients and humectants), and aromatic 
amines, nitro- and azo- aromatic groups, specific for cosmetics colorants and hair dyes. The 
physicochemical properties specific for particular cosmetic use categories included “global 
molecular” and “size and shape” descriptors. The structural classes more abundant among 
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PAFA food-related compounds included sufides, disulfides, sulfhydrides, thio- carboxylic 
esters, thiophenes, furans and pyrazines (flavouring agents and food direct additives), and 
phosphites, phosphine oxides, acyl and alkyl halides, isocyanates and acid anhydrides (food 
contact materials). In terms of physicochemical properties space, the cosmetics- and food-
related compounds occupied a very broad region of similar shape. It indicated that 
physicochemical properties utilised alone do not have sufficient power to discriminate 
between large inventories of cosmetics- and food- related compounds, and that structural 
features analysis is necessary to identify the differences between them. The analysis 
conducted may support further computational modelling efforts within the cosmetics 
domain. Large differences in structural and physicochemical features exhibited by different 
use categories of cosmetics indicated that, most probably, they should be investigated 
independently with different models and/or computational approaches.  
The work summarised here achieved the aims of objective 1 (“The quality control of 
the COSMOS database chemical domain, with particular emphasis on cosmetics and related 
compounds”) and objective 2 (“Characterising the chemical space occupied by cosmetics 
and related chemicals”) of this PhD program. 
8.1.2. COSMOS Skin Permeability Database 
The new COSMOS Skin Permeability Database (chapter 4) was developed in order to 
address the need for a database containing high quality skin permeability/absorption data 
for cosmetics and related compounds. The existing data sources (EDETOX and Kent 
databases) were consolidated with newly data harvested from regulatory documents and 
scientific literature according to the specifically developed, and deliberately rigorous, 
procedure. This procedure was documented in an SOP (Annex 4) and can support skin 
permeability/absorption data harvesting efforts in the future. 
The final COSMOS Skin Permeability Database provides in vivo and in vitro skin data 
for over 230 cosmetics-related compounds (484 chemical compounds in total), covering a 
range of use functions and chemical classes. The quality-controlled content of this database, 
along with its unique data structure, enables efficient data mining and supports 
computational modelling activities. This database served as a foundation for the research 
described in chapter 5. Compiling the set of compounds with available human in vitro JMAX 
Chapter 8 
139 
 
data was followed by the exploration of their structural features (ToxPrint chemotypes) and 
molecular properties (global, size and shape). This analysis led to the determination of 
profiles characteristic of compounds exhibiting low and high skin permeability potential. The 
obtained results may be applied for rapid screening and classification of compounds without 
experimental data. 
The work summarised here achieved the aims of objective 3 (“The development of a 
high quality COSMOS Skin Permeability Database enriched in cosmetics and related 
compounds”) and objective 4 (“Classification of skin permeability potential following dermal 
exposure to chemicals to support the safety assessment of cosmetics related chemicals”) of 
this PhD program. 
8.1.3. COSMOS oRepeatToxDB 
The new COSMOS oRepeatToxDB (chapter 6) was compiled after enriching 
(integrated) existing data sources (including the U.S. EPA DSSTox and FDA CFSAN PAFA) with 
newly data harvested for cosmetics from regulatory documents and scientific literature. The 
data harvesting process, conducted with respect to the established MINImum Study 
inclusion criteria (COSMOS MINIS) and combined with a consistent strategy of data curation 
and quality control, minimised concerns over the data accuracy.  
The final COSMOS oRepeatToxDB consists of 340 toxicity studies for 228 chemical 
compounds (186 cosmetics-related compounds, including 100 hair dyes and 42 impurities) 
and can be considered a milestone in terms of fulfilling the database-related needs of the 
21st Century (predictive) Toxicology. Its unique data model enables the recording of the full 
level of details on toxicity studies: the toxicological effects occurring at particular dose levels 
and at specific, hierarchically represented sites (differentiated as organs, tissues, cells), 
NO(A)EL and LO(A)EL values with associated critical effects and target sites, the study design 
details (species, sex, routes of exposure, dose group levels, number of animals, control 
group information) and references. The effects were recorded with the sets of controlled 
vocabulary and qualified by time of findings, severity, statistical significance and treatment-
relatedness. The rigorous curation of the COSMOS database chemistry content (chapter 2) 
ensured accurate identification of tested compounds. 
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The COSMOS oRepeatToxDB is a major improvement in the landscape of the 
currently available public databases, with multiple potential applications in safety/risk 
assessment, computational models development, and read-across. It was essential for 
conducting the research described in chapter 7.  
 The unique and novel design of the COSMOS oRepeatToxDB enabled the 
development of liver toxicity ontology (chapter 7), which was subsequently applied for 
mechanistic in vivo data mining, leading to the identification of compounds associated with 
liver steatosis, steatohepatitis and fibrosis phenotypic effects. The novel ToxPrint 
chemotype-based analysis of these hepatotoxicants led to the identification of associated 
structural classes. The probable mechanistic reasoning for toxicity was formulated for two 
compounds, namely 1,3-bis-(2,4-diaminophenoxy)-propane and piperonyl butoxide, that 
were (respectively) identified as being partial and full agonists of Peroxisome Proliferator-
Activated Receptor gamma (PPAR𝛾) in an interactively applied molecular modelling 
procedure. It was demonstrated that combined approaches of the phenotype- and 
structure-based classification and molecular mechanisms investigation can facilitate the 
process of Mode-of-Action/Adverse Outcome Pathway development. 
The work summarised here achieved the aims of objective 5 (“Construction of a high 
quality database for oral repeated dose toxicity with dose/concentration level information 
for cosmetics and related compounds”) and objective 6 (“Mechanistic (ontology-based) liver 
toxicity data mining of the COSMOS oRepeatToxDB on the basis of the ontology developed 
from the collated data”) of this PhD program. 
8.2. Final conclusions and perspectives 
Realising the particular objectives within the present thesis contributed to the 
development of the content-related part of the COSMOS database: Cosmos Cosmetics 
Inventory (chapter 2), Skin Permeability Database (chapter 4) and oRepeatToxDB (chapter 
6), comprising the largest quality-controlled, publicly available 
(https://cosmosdb.eu/cosmosdb.v2/) resource with chemical information and data for 
cosmetics ingredients and related compounds. The COSMOS database, delivered as a final 
outcome of the collaboration of consortium partners, is fundamental for the development 
of alternative (non-testing) methods for predicting repeated dose toxicity of cosmetics-
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related compounds. It meets the database-related requirements necessary for reaching the 
goals of modern predictive toxicology (common with the goals of the 21st Century 
Toxicology), as it has a relational design, stores high quality, curated chemical structures and 
toxicity information (which can be searched and retrieved), is equipped with controlled 
vocabularies and ontologies, and through utilising open-source technology, addresses the 
lack of cosmetics-related chemical information and biological data in the public domain.  
The particular data domains, constructed within this PhD program as a part of the 
COSMOS database, were used to develop knowledge that can be elaborated to facilitate the 
further development of in silico tools for risk/safety assessment of cosmetics related 
compounds: 
  The chemical space analysis of the Cosmetics Inventory (chapter 3) provides insights 
into the features of cosmetics substances, delivering valuable information that can be 
utilised for the development of computational models within this domain. This knowledge 
can be used, for example, to select the descriptors appropriate for model building or for 
distinguishing structural classes that should be modelled individually; 
 The rules formulated for the classification of compounds into low and high skin 
permeability potential (chapter 5) can support the estimation of bioavailability of 
chemicals after topical exposure (and, thus, their potential ability to exert systemic 
toxicity). This crucial knowledge for the risk and safety assessment of cosmetics related 
compounds can be further implemented into software applications, which can support 
rapid screening of compounds without experimental data and further modelling of their 
dermal permeability potential; 
 The COSMOS oRepeatToxDB (chapter 6) by itself can serve as an excellent predictive 
toxicology tool for further knowledge development, as it provides toxicity effect data for 
“organ-tissue-cell” levels associated with the LO(A)EL values and links this information with 
accurately identified chemical compounds. It can be used for mechanistic data mining and 
development of ontologies for other (than liver) target organs. In the COSMOS project it 
served as a foundation for the compilation of the new non-cancer Threshold of 
Toxicological Concern (TTC) database, addressing the repeated-dose toxicity of cosmetics-
related chemicals; 
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 The formulated knowledge on structural characteristics of compounds associated 
with liver steatosis, steatohepatitis and fibrosis, and on their potential modes-of-action 
(chapter 7), can be elaborated further and used for the development of the liver toxicity 
knowledgebase (including the rules and chemotype alerts). 
The current PhD project is particularly significant in the light of the current European 
Union legislation, i.e. the banning of animal testing for cosmetics purposes, as it contributes 
to providing the necessary alternative (non-animal) tools for the risk and safety assessment 
associated with the repeated dose exposure to cosmetic ingredients. 
Noteworthy, as of March 2016, the COSMOS DataShare Point, a web-based system 
for exchanging safety evaluation and toxicity data, has been launched (https://www.mn-
am.com/projects/cosmosdatasharepoint). The COSMOS database will continue to be 
developed, maintained and made available to the public, creating a resource for 
toxicological data collection and a means to share data with the scientific community. 
In conclusion, the main aim of the present PhD program, namely “the collation of the 
content within relational chemical-toxicological database and its subsequent application for 
development of knowledge to support the prediction of repeated dose toxicity of cosmetics 
and related compounds” has been fully achieved. 
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